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Manganese (Mn2+) and iron (Fe2+) are essential trace elements required for many 
biological functions. Cellular entry of Mn2+ has been shown to be mediated by 
divalent metal transporter 1 (DMT1), which was originally described for the transport 
of Fe2+. Overexposure of manganese may result in neurological dysfunction 
resembling Parkinson’s disease (PD). The accumulation of manganese in chronic 
occupational exposures is associated with damage to the nigrostriatal dopaminergic 
neurons. Yet, the pathomechanism underlying manganese toxicity is not well 
characterized. As emerging evidence suggest a link between manganese overexposure 
and iron deficiency, a better understanding of intracellular interplay between Fe2+ and 
Mn2+ could help in the understanding and management of manganese toxicity. I have 
shown that the cytoplasmic accumulation of Mn2+ via DMT1 disrupted the labile iron 
pool. This consequently resulted in the degradation of ferritin, an iron storage protein. 
While one group showed that Mn2+ could interfere with iron-regulatory protein 2 
(IRP2), I provided evidence that the enhanced proteolysis of ferritin via autophagy 
was to restore iron balance. Although I found that JNK activation was the major MAP 
kinase responsible for Mn2+-mediated cytotoxicity, JNK activation was not associated 
with autophagy activation or ferritin degradation. At closer examination, JNK 
activation was found to be mediated by iron depletion via the ASK1-thioredoxin 
pathway. Subsequently, another group also showed that iron-depletion using iron 
chelators stimulated JNK and apoptosis. In addition, I also found that Mn2+ reduced 
intracellular superoxide levels, which suggested that Mn2+ is an antioxidant. This led 
us to believe that autophagy and JNK stimulation in the presence of Mn2+ proceeds 
independently of ROS. Finally, I also characterized the novel transgenic model 




manganese neurotoxicity studies. Although the expression of DMT1 transgene was 
widespread in the mouse brain, the substantia nigra (SN) showed marked iron 
accumulation and signs of microglial activation. The increase in iNOS-derived nitric 
oxide was associated with increase in nitrosative stress. As DMT1 was previously 
shown to be indirectly modulated by nitric oxide via S-nitrosylation, here we 
demonstrated that DMT1 could be modified directly by S-nitrosylation with 
corresponding increase in iron transport. Taken together, my results offer a 
mechanistic and functional explanation underlying manganese toxicity via DMT1 and 









Divalent metal ions including iron (Fe2+), manganese (Mn2+), copper (Cu2+), 
chromium (Cr2+), zinc (Zn2+), selenium (Se2+) and cobalt (Co2+) are essential trace 
elements which are required for biological functions. The interplay between different 
metal ion fluxes across cellular membranes exists as many of them share similar 
transport mechanisms as well as the potential to bind to related proteins. Even though 
metal ion toxicity is an uncommon condition, with exceptions in acute iron toxicity, 
chronic trace metal ion intoxication could result in morbidity if left unrecognized or 
treatment was inappropriately managed. Particularly, chronic occupational and 
environmental exposures to manganese are widely accepted as potential hazards 
causing the development of Parkinson-like syndrome called manganism. Parkinson’s 
disease (PD), on the other hand, is an age-related neurodegenerative disease which 
displays characteristic motor abnormalities and has been documented to present 
homeostatic imbalances in trace metals. PD and several other basal ganglia diseases 
are observed to show prominent increase in iron content in regions of pathology, 
suggesting a possible role for iron in neurodegeneration. However, the major question 
on whether abnormal iron accumulation is the initiating event in causing 
neurodegeneration or a consequence of the disease progression remains unanswered. 
As both manganism and PD are characterized by motor deficits associated with 
pathology in the basal ganglia, epidemiological studies have shown possible 
correlations between chronic manganese exposure and the risk of developing an 




2001). With the mechanisms underlying competitive transport, metal handling and 
neurotoxicity of iron and manganese still poorly understood, modern day treatments 
for metal intoxication rely primarily on chelation therapies. However, the interaction 
between essential trace metals in many aspects makes chelation therapy complicated 
without having to compromise the physiological balance of other divalent metal ions. 
Hence, the detailed understanding of cellular metal ion metabolism would provide 
better clarification for the development of effective therapeutics, which may also be 
beneficial for PD and other metal ion-related neurodegenerative diseases.   
1.2 Neurodegenerative Diseases 
Neurodegenerative diseases are brain diseases characterized by progressive 
degeneration of neurons with corresponding loss of function. These diseases include 
Parkinson’s disease (PD), Alzheimer’s disease (AD), Huntington’s disease (HD), and 
amyotrophic lateral sclerosis (ALS). Many of these diseases show similar subcellular 
pathological hallmarks which suggest that the degeneration process likely share 
parallel intracellular and extracellular adverse events. While many inherited 
neurodegenerative diseases feature rather selective pathological hallmarks and loss of 
function affecting specific brain regions, these features are also observed amongst 
patients without any underlying genetic mutations. Even as aging is a main 
contributor towards the onset of disease, it is now accepted that environmental 
trigger(s) plays a major risk factor in the development of sporadic neurodegenerative 
diseases (Mattson and Magnus 2006). Increased in cellular protein burden due to 
protein misfolding and impaired clearance, inflammation and oxidative stress are 
common traits observed across all neurodegenerative diseases (Block, Zecca et al. 
2007, Tai and Schuman 2008). While these traits are known to be the underlying 




Nonetheless, there is mounting evidence that suggest brain metal ion dysregulation is 
likely to contribute to the pathomechanisms of these diseases, if not in influencing 
their onset. Notably, iron dysregulation has been associated with HD, PD and AD 
where iron were observed to preferentially accumulate in affected brain regions 
(Mattson and Magnus 2006). Even as iron accumulates in the brain as a natural course 
of aging, whether it is setting the stage for neurodegeneration remains unanswered. 
Importantly, the reason for age-related iron accumulation and the underlying 
mechanisms for selective neuronal deposition of iron in regions of pathology remain 
elusive.  
1.3 Metals in Neurodegenerative Diseases 
The idea of a barrier system to the brain of the central nervous system (CNS) has 
existed for nearly a century. The barrier system is classified into two systems of 
which (i) the blood-brain barrier (BBB) separates the circulatory blood from the 
cerebral interstitial fluid; while (ii) the blood-cerebrospinal fluid barrier (BCB) 
separates the circulatory blood from the cerebrospinal fluid. Many studies have 
pointed out that the brain barriers are vulnerable to neurotoxicants in the blood which 
may compromise the integrity of these barriers. While certain brain pathologies such 
as traumatic brain injury and meningitis (Sharief, Ciardi et al. 1992, Shlosberg, 
Benifla et al. 2010) can result in the breakdown of the BBB and BCB, the normal 
aging process is also suggested to be a main contributor to the disruption of these 
barriers. Even though the association between the leakiness of the brain barriers with 
aging and neurodegenerative diseases remains poorly understood, the abnormal 
deposition of essential trace metals in the diseased brain may suggest such a 




Essential trace metals are acquired through dietary sources and are important for the 
maintenance of many biological functions. These metal ions are associated with 
metalloproteins which are a part of the enzymatic and structural proteins. Even though 
essential metals are likely to have a broad role in many aspects of cellular 
metabolism, unwarranted uptake and bioaccumulation of metal ions can cause a 
number of detrimental effects. Essential metals can become systemic toxins once 
taken beyond the acceptable doses (either through the diet or occupational exposures) 
into the body via oral ingestion, inhalation or dermal routes. Importantly, divalent 
metal ions can enter the brain via cellular transport mechanisms on the BBB and BCB 
or directly into the brain through the breach in these barriers. Once inside the brain, 
metal ions can be deposited for decades and may potentially mediate the earlier onset 
of neurodegenerative diseases (Markesbery, Ehmann et al. 1984, Gaeta and Hider 
2005, Salazar, Mena et al. 2008). The aberrant accumulation of metal ions may also 
suggest that faulty BBB and BCB may be due to their inefficient clearance from the 
brain. Even though the accumulation of metals is evident with aging as well as in 
neurodegenerative diseases, the hypothesis on whether the BBB and BCB are indeed 
leaky requires further study (Quaegebeur, Lange et al. 2011).  
The cytotoxic effect of many of these metal ions could be explained by their 
capability to catalyze the formation of free radicals via redox cycling. Redox cycling 
results in the increase in oxidative stress due to the formation of reactive free radicals. 
Along with aging, free radical and oxidative stress hypotheses are believed to be the 
major contributor in many neurodegenerative diseases and metal-related neurotoxicity 
disorders. Metal ion-catalyzed oxidative stress can cause damage to DNA and 
proteins (Kobayashi, Oikawa et al. 2008, Chew, Ang et al. 2011). Metal ions can form 




aggregation (Ly and Julian 2008). Divalent metal ions such as Fe2+, Mn2+ and Cu2+ 
contain an unpaired electron which allows their participation in redox reactions 
through oxidation (loss on one electron) or reduction (gain of one electron). However, 
the potential of metal ions to undergo oxidation and reduction is dependent on the 
chemical structure as well as the stability of the metal ions in a biological system.  
For example, iron in the ferrous form (Fe2+) is a pro-oxidant and has been shown to 
catalyze the Fenton chemistry in the presence of hydrogen peroxide (H2O2). And as 
iron accumulation in the basal ganglia has long been observed in many 
neurodegenerative diseases, Fe2+-mediated ROS has been hypothesized to be the main 
culprit for the selective loss of neurons. However, concrete evidence is still lacking to 
establish causation for iron as the primary mediator in the neurodegenerative process.  
Copper ion is another example of an essential metal of which uncontrolled redox 
cycling of Cu2+ is a source of free radicals. Both copper accumulation as well as 
deficiency has been implicated in the neurodegeneration process in AD. The 
accumulation of copper in the basal ganglia is observed in Wilson’s disease. 
(Doraiswamy and Finefrock 2004, Lorincz 2010).  
Interestingly, zinc ion (Zn2+) is a biologically stable species and does not readily 
undergo redox cycling. Zinc is important for its function in many enzymatic proteins 
and is especially crucial for its role in maintaining structural stability of many 
proteins, through the formation of zinc-finger motif. Additionally, zinc ion can act as 
an anti-oxidant that could replace other pro-oxidant divalent metal ions (such as, 
Fe2+), and thus halting redox cycling. The displacement of Fe2+ by Zn2+ may have a 
dual role in determining the fate of the cell, depending on the cellular redox status. 
Intuitively, if excessive Fe2+ is catalyzing the formation of ROS, then the 




required for cellular signalling, then the competitive inhibition of Fe2+ by Zn2+ could 
compromise ROS-dependent cellular transduction pathways. Even though the 
competition by Zn2+ for Fe2+ binding sites has been shown to be protective in cultured 
cells against metal ion-catalyzed ROS, the application of such zinc therapy in treating 
iron-mediated toxicity in animal model of neurodegenerative diseases remains 
unexplored (Har-El and Chevion 1991). Although zinc overload and toxicity is 
extremely rare, nonetheless, zinc has received tremendous attention of late due to its 
protective role in many processes involving age-related neurodegenerative diseases 
and in physiological brain aging (Mocchegiani, Bertoni-Freddari et al. 2005, 
Hoogenraad 2011).  
The relevance of Mn2+ in ROS production remains controversial. It is required as an 
important co-factor for mitochondrial superoxide dismutase (SOD2), where SOD2 
functions to dismutate superoxide anion radical (O2·-) into water. Even though the 
critical role of Mn2+ in SOD2 to curtail excessive O2·-, Mn2+ is biologically known to 
be more toxic than Fe2+. It is likely that the toxic effect is mediated via Mn2+ 
accumulation in the mitochondria leading to energy deficiency and ROS formation. 
Unlike iron accumulation in neurodegenerative diseases, manganese accumulation in 
the basal ganglia is associated with SLC30A10 mutations, environmental and 
occupational exposures, long-term parenteral nutrition and well-waters contamination 
(Dickerson 2001, Agusa, Kunito et al. 2006, Hardy 2009, Stamelou, Tuschl et al. 
2012). As the complex interplay between manganese toxicity and brain iron 
homeostasis exist, the association between manganese toxicity and neurodegenerative 
diseases requires further investigation (Fitsanakis, Zhang et al. 2010). 
Given that these trace metal ions are biologically important and may bind to common 




on cellular functions. While many investigations revolve around the study of the 
effects of metal ions individually, the study of the effects of uptake of two or more 
metal ions and their interactions at the point of entry or their signalling pathways are 
still lacking. Specifically, investigations at the intracellular level would shed light on 
how different metal ions would lead to either convergent or divergent responses in the 
hope that one day better tools for diagnostics could be developed and toxicity better 
managed.     
1.4 Basal Ganglia and Movement Disorders  
In order to appreciate movement disorders and pathology related to the basal ganglia, 
the knowledge on the role of dopamine in the basal ganglia and its associated circuitry 
is important. Dopamine-producing neurons, also known as dopaminergic neurons, are 
a group of heterogeneous cells in the brain which contain tyrosine hydroxylase (TH) 
for the production of dopamine. As dopaminergic neurons lack the two downstream 
enzymes for the production of norepinephrine (dopamine β-hydroxylase) and 
epinephrine (phenylethanolamine N-methyltransferase), consequently dopamine is the 
main neurotransmitter utilized by these neurons. Dopamine is synthesized as a 
neurotransmitter in the presynaptic terminal, transported into synaptic vesicles and 
released into the synaptic cleft upon arrival of electrical signals that trigger the 
neurotransmission process. The initial step to its production involves the 
hydroxylation of the amino acid tyrosine into L-3,4-dihydroxyphenylalanine (L-
DOPA) via the enzyme tyrosine hydroxylase. The enzymatic conversion of tyrosine 
into L-DOPA by TH is the rate-limiting step in this biosynthetic pathway. L-DOPA is 
then converted to dopamine by the removal of the carboxyl group from DOPA by 
aromatic amino acid decarboxylase (AADC). Finally, the synthesized dopamine is 




Released dopamine in the extracellular space is taken back into the presynaptic 
terminal by dopamine transporters (DAT), where dopamine can either be recycled 
into synaptic vesicles or degraded into 3,4-dihydroxyphenylacetic acid (DOPAC) by 
monoamine oxidase type B (MAO-B). The flowchart below shows a simplified 
dopamine biosynthesis pathway (Goldstein 1984). 
 
Dopaminergic neurons can be found in several regions of the brain, including the 
ventral tegmental area (VTA), substantia nigra (substantia nigra pars reticulata and 
substantia nigra pars compacta), hypothalamus and olfactory bulb. Even as the basal 
ganglia consist of a constellation of nuclei which are responsible for procedural 
learning, cognitive and emotional functions, it is especially known for the execution 
and coordination of motor movements. The basal ganglia receive important motor 
inputs from the dopaminergic neurons in the substantia nigra and would eventually 
influence the activity of the motor cortex via the thalamus. The role of dopaminergic 
neurons in the control of motor function is more firmly established than other 
functions due to its rather direct correlation of anatomical structures to the observable 
outcome of motor function using pharmacological drugs (such as L-DOPA).  
In addition, the nigrostriatal system is probably the most well-studied dopaminergic 
pathway which has dopaminergic neurons projecting from the SNpc into the striatum 
of the basal ganglia. And this system can undergo pathological degeneration of 
unknown causes in Parkinson’s disease, leading to the removal of dopaminergic 




As shown in Figure 1.1, the caudate nucleus and putamen, collectively known as 
striatum, are identified to receive motor inputs from the motor cortex and thalamus 
(cortical-thalamic pathway). The motor information are then processed and 
channelled to its two output nuclei, the internal segment of the globus pallidus (GPi) 
and substantia nigra reticulata (SNr). Interestingly, the striatum make connections 
with its output nuclei by two pathways; 
(i) Neurons in the direct pathway makes monosynaptic connections with the 
GPi and to a lesser extent SNr, mediated by neurons containing Ɣ-
aminobutyric acid (GABA) and substance P as neurotransmitters. 
GABAergic neurons are inhibitory neurons.  
(ii) Neurons in the indirect pathway, as the name implies, also influence the 
GPi and SNr, but only after going through several other nuclei. In this 
pathway, the neurons from the striatum use GABA and enkephalins as 
neurotransmitters. The neurons from the striatum projects to the external 
segment of the globus pallidus (GPe), followed by connections from the 
GPe to the subthalamic nucleus (STN) and finally reaching the GPi and 
SNr output nuclei. Neuronal connections between the striatum, GPe and 
STN are all mediated by GABAergic neurons while the final connections 
between STN and the two output nuclei are mediated by glutaminergic 






Figure 1.1. The nigrostriatal system and basal ganglia pathologies. A simplified schematic 
presentation of the basal ganglia circuitry involving the nigrostriatal system (A) normal, (B) 
Parkinson’s disease and (C) Huntington’s disease patients. The modulation of the cortical-thalamic 
pathway is controlled by the direct or indirect pathways via the striatal control of the globus pallidus 
(GP). The direct pathway involves striatal contact with the GPi (internal) and substantia nigra reticulata 
(SNr) while the indirect pathway connects to the GPe (external), the subthalamic nucleus (STN) and 
subsequently the GPi and SNr. Excitatory and inhibitory activities are represented by grey and black 
arrows respectively. White arrow represents modulatory activity of SNpc on the striatum. Dashed lines 
represent loss of dopaminergic neurons in the SNpc or GABAergic neurons in the striatum (Wichmann 
and DeLong 1999, Gatev, Darbin et al. 2006). 
 
Depending on the nature of the incoming motor input, the output nuclei (GPi and 
SNr) would in turn influence the motor nucleus of the thalamus. The direct and 
indirect pathways have antagonistic functions on the thalamus, where the activation of 
the direct pathway is excitatory while the activation of the indirect pathway is 




fine-tuning signals from the dopaminergic innervations of the SNpc to the striatum 
(Alexander and Crutcher 1990).   
There are two unique sets of dopamine receptors found in the basal ganglia. 
Dopamine released from the striatal dopaminergic neurons of the SNpc result in the 
activation of direct pathway via D1 receptors and at the same time exerting an 
inhibitory effect on the indirect pathway through D2 receptors. Thus, in PD, the loss 
of SNpc neurons is observed as a dysregulation to the balance of these two pathways. 
The reduction in activity to the direct pathway with concordant increase in indirect 
pathway activity leads to the hyperstimulation of the GPi and SNr. As these two 
nuclei projects into the thalamus via GABAergic innervations, their hyperactivity 
results in the enhanced inhibition to the motor nucleus of the thalamus. Consequently, 
the lack of stimulation from the thalamus leads to the inhibition of cortically-initiated 
movement and hence producing hypokinesia seen in PD patients.  
Unlike hypokinesia observed in PD patients, an example of hyperkinesia due to the 
reduced inhibition to the cortical-thalamic pathway is seen in HD patients. In HD, 
early pathology is often associated with damage to the neurons in the striatum, 
resulting in a set of rather characteristic motor symptoms such as jerky and random 
movements and uncontrolled involuntary movements called chorea (Walker 2007). 
These abnormalities are a consequence of degeneration in the striatal neurons leading 
to the GPe. As a result, the disinhibition of the indirect pathway leads to the enhanced 
inhibition to the STN and a net reduction in basal ganglia inhibitory output to the 
cortical-thalamic pathway, leading to hyperactivity (Wichmann and DeLong 1996, 





1.5 Basal Ganglia and Metal Ion Toxicity  
Over the past decade, there has been a rising interest in understanding the 
pathological mechanisms of essential transition metals and their influence on 
neurodegenerative diseases. These metal ions, in particular iron and manganese have 
been associated with the development of an earlier onset of neurodegenerative 
diseases as well as the severity of the diseases. Increased exposures and excessive 
uptake of metal ions into the brain due to dysregulation to transport may result in their 
accumulation. Yet, the understanding of metal ion uptake and metabolism in the brain 
is still largely unknown. The topological accumulation for each metal ion in the brain 
is not uniform. Using various methods, it was found that selective deposition of metal 
ions does reflect selective neuronal vulnerability in specific brain region for some 
metals (such as iron and manganese); while the role of other metal ions (such as 
aluminium, copper and zinc) is still poorly understood. In addition, abnormal metal 
ion accumulation is often found in the nuclei of the basal ganglia, of which pathology 
in the basal ganglia is responsible for a several motor diseases. Basal ganglia diseases 
are a group of motor-associated neurodegenerative diseases exhibiting movement 
disorders due to irregularities in the basal ganglia output into the cortical-thalamic 
circuitry. As discussed, the basal ganglia output generally exert an inhibitory effect on 
the cortical-thalamic pathway to inhibit competing motor pathways and ensure a 
smooth and controlled execution of movement. However, any unwanted increase or 
decrease in the inhibition output to the cortical-thalamic pathway can lead to motor 
disturbances in the form of hyperkinesia and hypokinesia, respectively (Mink 1996). 
With the exception to rare autosomally-transmitted basal ganglia diseases, the 
etiology of most basal ganglia diseases remains elusive. Table 1.1 shows a list of 






































































































































































































































































































































































































































































































































































































































































Interestingly, both idiopathic and familiar basal ganglia diseases show unifying 
pathological traits which may point to common causative factors in the initiation and 
the degeneration process (Kell 2010). Like the neurodegenerative diseases mentioned 
above, neuroinflammation, characterized by increase in microglial and astrocytic 
activation, oxidative stress and protein misfolding are common traits often detected in 
basal ganglia diseases. The abnormal reduction or accumulation of metal ions in the 
basal ganglia such as aluminium, manganese, copper and especially iron is often 
detected in basal ganglia diseases but again a direct causal relationship of such 
changes on disease onset and progression remains controversial. Nonetheless, the 
discovery of mutation in genes responsible for iron metabolism indeed suggested an 
important role for iron and its mismanagement in basal ganglia diseases (Curtis, Fey 
et al. 2001, Zhou, Westaway et al. 2001). For example, insertion mutations to ferritin 
light chain gene are associated with autosomal dominant neuroferritinopathy. The 
disease is characterized by progressive degeneration of neurons leading to motor and 
cognitive impairment. Brain T2-magnetic resonance imaging (MRI) shows 
hypointensity in the basal ganglia suggesting iron deposition. As the mutation results 
in the insufficiency of ferritin to store iron, ferritin inclusions are often found in 
neurons and glia cells, suggesting that neuroferritinopathy results in the impairment in 
cellular iron storage (Barbeito, Garringer et al. 2009, McNeill and Chinnery 2012). In 
addition, inherited autosomal recessive loss of ceruloplasmin function called 
aceruloplasminemia, is characterized by progressive neuronal degeneration in the 
basal ganglia with iron accumulation. As ceruloplasmin is a plasma protein with 
ferroxidase activity important for the conversion of ferrous iron to ferric iron, its role 





Furthermore, many studies have demonstrated the vulnerability of the basal ganglia to 
neurotoxins and to trace elemental metal accumulation as compared to other regions 
of the brain. For example, in PD, basal ganglia iron content is frequently altered with 
prominent deposition observed in the substantia nigra pars compacta (Dexter, 
Carayon et al. 1991, Martin, Wieler et al. 2008). In HD, iron deposition is found in 
the caudate nucleus and putamen of the basal ganglia (Bartzokis, Cummings et al. 
1999). The increased deposition of iron in the pathological regions remains a common 
trait and strongly suggests disturbances to iron homeostasis.  
Even so, the detailed mechanism of iron dysregulation and neurodegeneration is still 
unclear. There are a few possible hypotheses that suggest the vulnerability of the 
basal ganglia to iron-induced degeneration, in particular, regions highly enriched with 
dopaminergic neurons. Dopamine, an important neurotransmitter, has long been 
observed to have the propensity to be oxidized by free iron ions (Fe2+ and Fe3+), 
forming iron-dopamine complex and subsequently oxidized dopamine quinine by-
products. These dopamine-derived  quinines have been demonstrated to inhibit the 
activity of various proteasomes, including chymotrypsin-like, trypsin-like as well as 
caspase-like proteasome, which subsequently led to dopaminergic cell death 
(Pezzella, d'Ischia et al. 1997, Zhou, Lan et al. 2010). However, many of these 
dopamine oxidation studies were performed on cellular models and the actual identity 
and presence of such quinine in pathology remains unanswered. The interaction 
among oxygen tension, pH, the balance between antioxidants and prooxidants and the 
presence of physiological iron chelators are a few considerations which may 
significantly affect the outcome of dopamine oxidation in-vivo. Nonetheless, these 
studies provided great insights into the potential of unbound iron in mediating toxicity 




In addition, manganese is also highly associated with pathology of the basal ganglia. 
Positioned next to iron in the periodic table, manganese is known to show chemical 
similarities but with a rather startling difference biologically. Manganese is known to 
utilize common transporters and proteins as iron, and thus the presence of high 
manganese content may disrupt iron homeostasis. Within the cell, manganese is 
demonstrated to exert toxicity at a lower LD50 (median lethal dose) than iron. While 
manganese is an essential trace element required for many biological functions, 
occupational manganese exposures pose the greatest threat to humans as the globus 
pallidus, striatum and the caudate nucleus are vulnerable targets of manganese 
toxicity (Weiss 2006, Thompson, Molina et al. 2007, Fitsanakis, Zhang et al. 2010).   
1.6 Manganism 
The most debilitating pathology associated with manganese toxicity is evidenced in 
the central nervous system, although cardiovascular, liver, reproductive as well as 
developmental effects have been noted. Accumulation of manganese in the brain 
produces neurotoxicity that may result in the development of Parkinson-like 
syndrome called manganism. The first medical case of manganism was originally 
described by James Couper in year 1837. He observed five patients exposed to high 
atmospheric manganese (among many other metals) in the ore-crushing facility where 
the patients were working at. The patients presented muscle weakness, postural 
abnormality, tremoring limbs, uncontrolled salivation and whispering speech (Olanow 
2004). Just like PD, patients suffering from manganism also exhibit behavioural and 
psychological disturbances, which oftentimes precede motor deficits. These 
neuropsychiatric disorders have been described in 15 different studies amongst people 
exposed to manganese. These neuropsychiatric effects include six mood disorders: (a) 




and lack of vigour with sleep disturbances, (e) impulsive-compulsive behaviour and 
(f) aggression and hostility (Bowler, Mergler et al. 1999). While older men with 
higher manganese levels were associated with disturbances of at least four out of six 
mood disorders, men with higher manganese in general would manifest anxiety, 
nervousness, irritability; emotional disturbance; aggression and hostility as compared 
to those with lower manganese. In addition, the examination of formerly manganese- 
exposed workers from ferro- and silica-manganese plant 14 years after the cessation 
of exposure, these men continued to show lasting neuropsychiatric disturbances 
(Bouchard, Mergler et al. 2007). Consequently, if these neuropsychiatric disturbances 
are not promptly diagnosed, continued manganese exposure could eventually affect 
the motor function of the basal ganglia. Motor deficits associated with the 
extrapyramidal pathway are presented with characteristic gait and postural instability, 
rigidity with bradykinesia (slow in movement), micrographia (writing becomes 
progressively smaller), speech disturbances and face devoid of expression (Olanow 
2004).  
Exposure to manganese through occupational hazards, chronic parenteral nutrition 
and environmental pollutants in well waters could be diagnosed through MRI to 
differentiate it from other parkinsonian disorders. While the globus pallidus is the 
primary structure affected by manganese toxicity, other basal ganglia regions may be 
involved. T1-weighted MRI has been successfully used to examine changes in the 
brain, especially the globus pallidus in relation to manganese accumulation (Criswell, 
Perlmutter et al. 2012). In addition, manganism develops at an earlier onset than with 
Parkinson’s disease and patients are usually not responsive to levodopa therapy due to 





1.7 Parkinson’s Disease 
While manganism manifests to be PD-like, however, there are distinctive criteria that 
could be used to differentiate these two conditions. PD is an age-related motor 
neurodegenerative disease with unknown aetiology. It is characterized by the rather 
selective death of dopaminergic neurons in the SNpc. The loss of at least 60% of 
these neurons is required before the onset of PD symptoms. Characteristic PD 
symptoms include resting tremors, rigidity, bradykinesia and postural instability, 
among many other neuropsychiatric disorders (Bernal-Pacheco, Limotai et al. 2012). 
While PD patients are initially responsive to levodopa therapy, patients will no longer 
be responsive to treatment as death of dopaminergic neurons progresses. At the 
cellular level, the dying neurons contain intracytoplasmic proteinaceous materials 
called Lewy bodies, which is another hallmark of PD. While up to 95% of all PD 
cases are sporadic, the remaining 5% cases are attributed by inheritable genetic 
predispositions. Mutations in several PD-related genes with differential penetrance, 
either dominantly- or recessively-inherited have been consistently noted. These PD-
related genes include PINK1, DJ-1, LRRK2, α-synuclein, parkin and ATP13A2 
(Farrer 2006, Henchcliffe and Beal 2008, Li and Guo 2009, Dehay, Ramirez et al. 
2012). Even though these mutations are implicated in various cellular pathways, 
nonetheless, the study of convergent pathways through these inheritable genes opens 
the window for understanding of the pathogenesis of PD. In particular, protein 
misfolding and aggregation, UPS and autophagy-lysosomal deficiency, mitochondrial 
deficiency and oxidative stress, neuroinflammation and iron deposition are common 





1.8 Iron  
In biological systems, iron exists either in the ferrous (Fe2+) or ferric (Fe3+) species. 
The versatility of iron to shuttle between the reduced and oxidized forms makes it one 
of the most dynamic and abundant essential trace metal ions in the human body. Iron 
is utilized by heme and non-heme proteins as a co-factor for many biochemical 
processes involving energy metabolism, DNA synthesis as well as oxygen transport. 
A large proportion of iron of at least 2.1 g is distributed in the haemoglobin of 
circulating red blood cells in the human body, which serves the important role of 
oxygen transport. Among all the organs in the body, the liver has the most appreciable 
quantities of iron, amounting to about 1 g, occurring mostly as stored iron (Munoz, 
Garcia-Erce et al. 2011a, Munoz, Garcia-Erce et al. 2011b).  
In addition to biological functions, iron is also used in many industrial applications, 
including the production of steel and the manufacturing of tools, machinery, and 
structural fortifications for the construction of buildings and ships (Martinez-Finley, 
Chakraborty et al. 2012). Ferric chloride (FeCl3) is commonly used as a flocculent in 
sewage and water treatment plants and also found in paint, fabric dyes as well as an 
additive in animal feeds. Iron-fortified foods (supplemented in milk, bread and 
cereals) for human consumption are usually added in the form of ferric sulphate 
Fe2(SO4)3, while pharmaceutical iron-tablets for the management of iron-deficiency in 
humans are usually prescribed in the form of carbonyl iron (Gordeuk, Brittenham et 
al. 1987). The dietary reference intake for iron determined by the Institute of 
Medicine, USA, is 6 mg per day for adult man and 8.1 mg per day for adult woman. 
Apart from iron-fortified foods, daily iron requirement can be easily met from iron-
rich sources such as meat and poultry (in the form of heme-iron), fruits and vegetables 




As both iron deficiency and iron overload in humans can bring about unfavourable 
health consequences, the regulation of iron metabolism has evolved to become highly 
complex from its point of entry, storage, handling as well as recycling. Nonetheless, 
iron disorders are still a pressing public health concern with iron deficiency anaemia 
as one of the leading causes of iron disorders. Iron deficiency anaemia can be a result 
of different causes. The most common cause of anaemia is due to the inadequacy of 
iron absorption from the diet, due to scarcity of food or the inability of the 
gastrointestinal tract to absorb iron. In addition, inflammatory conditions which alter 
the regulation of iron via the hepcidin axis are also associated with the development 
of anaemia (Kuo, Yang et al. 2012). Notably, iron-deficiency in the brain has been 
associated with restless legs syndrome characterized by the urge to move the limbs of 
the body to stop the unpleasant sensations (Connor, Boyer et al. 2003, Connor, Wang 
et al. 2009). The pathology is hypothesized to be related to disturbances in dopamine 
metabolism with preceding iron homeostatic imbalance (Jones and Cavanna 2012).  
While approximately 30% of the world population is suffering from non-genetic iron 
deficiency anaemia, conversely, iron overload disorders are usually associated with 
underlying genetic defects to iron-regulatory genes. The major form of hereditary iron 
overload disorder is called hemochromatosis and is associated with mutations to 
genes encoding for hepcidin, ferritin, transferrin receptor, frataxin, ferroportin as well 
as the hereditary hemochromatosis protein (HFE). While much effort has been placed 
in deciphering the metabolism of iron at the systemic level, little is known about brain 
iron homeostasis. This is partly due to the exclusive regulation of brain iron 
homeostasis which is independent of the systemic regulation - a result of brain 
vascular separation from the systemic blood plasma by the BBB and BCB (Burdo and 




displaying highest amounts in regions associated with motor functions as compared to 
non-motor regions. Due to this selective iron deposition in the motor regions, it may 
likely explain the many motor-related disorders with accompanying iron imbalance 
(Brar, Henderson et al. 2009).  
1.8.1 Mechanism of Iron Transport and Cellular Metabolism  
Systemic iron balance is achieved at the level of iron entry at the proximal duodenum. 
The uptake of non-heme iron involves the reduction of Fe3+ by ferric reductases (such 
as the duodenal cytochrome b, Dcytb) in the intestinal wall into Fe2+, which is 
subsequently transported across the apical membrane of the crypt on duodenal walls 
by divalent metal-ion transporter 1 (DMT1, NRAMP2, SLC11A2). On the other hand, 
the mechanism of heme iron entry remains elusive but it is believed that heme 
similarly permeates the apical membrane of enterocytes and is subsequently 
metabolized by heme-oxygenase (HO-1) into Fe2+, bilirubin and carbon monoxide 
(CO). Both heme and non-heme-derived Fe2+ are released into the cytosol and is 
rapidly exported into the bloodstream from the basoloateral membrane of the 
enterocytes by ferroportin (IREG1, SLC11A3). The efflux of Fe2+ mediated by 
ferroportin is accompanied by the re-oxidation of Fe2+ by plasma membrane-
associated ferroxidase hephaestin (luminal enterocytes) or serum ceruloplasmin into 
Fe3+. In the circulation, Fe3+ is scavenged by transferrin (Tf), where Tf keeps the iron 
in the redox inert form (Tf-Fe3+) while being transported across the body. As red 
blood cells (RBC) containing haemoglobin are the major iron-containing cells in the 
body, RBCs constantly undergo bouts of erythropoiesis (erythroid synthesis) and 
eryptosis (erythroid programmed cell death) to recycle the iron in the process of 
RBCs regeneration. Hence, Tf iron pool is maintained by the turnover of RBCs and is 





Figure 1.2. DMT1-mediated transferrin dependent and independent iron uptake. Simplified 
schematic illustrating the uptake of Fe2+ and Fe3+ into the cell. (1) Fe3+-bound transferrin (Tf) at the cell 
surface binds to the transferrin receptor (TfR). (2) Invagination of the complex via clathrin-coated pit 
and endocytosis. (3) The formation of a specialized endosome which is acidified by a proton pump. 
Endosomal acidification results in the release of Fe3+ from Tf followed by the reduction of Fe2+ to Fe3+ 
by ferrireductase (Steap 3). The acidification of the endosomal compartment increases the activity of 
DMT1 to transport Fe2+ out of the endosomal membrane. (4) Once in the cytosol, Fe2+ is converted 
back to Fe3+ by ferritin heavy chain, ferritin (H). As ferritin (H) contains ferroxidase activity, it 
mediates the conversion of Fe2+ to Fe3+ and then stored in ferritin (H+L). (5) The acidic endosome is 
eventually recycled to the cell surface where at neutral pH ,Tf is dissociated from TfR and ready for the 
next round of Fe3+ uptake. (6) Apart from Tf-mediated iron uptake, Fe2+ uptake can also take place via 
DMT1 on the plasma membrane (MacKenzie, Iwasaki et al. 2008).  
 
1.8.2 Transferrin-Mediated Iron Transport 
Currently, the two proposed mechanisms of iron uptake into cells involve transferrin-
bound iron uptake and the non-transferrin bound iron (NTBI) uptake. Most cells 




a high affinity for circulating Tf-Fe3+. In the transferrin cycle, upon the attachment of 
Fe3+-bound Tf to the TfR, the complex will be taken into the cell via clathrin-coated 
endocytosis to form an endosome. Consequently, the acidification of the endosome by 
specific proton pumps to pH 5.5 promotes the dissociation of Fe3+ from the Tf/TfR 
complex. Ferrirr reductase (such as Steap3 and Steap2) would then reduce the iron 
into Fe2+ and is transported out of the endosomal membrane by DMT1 (Knutson 
2007). The acidification of the endosome is important to maintain Fe2+ in the reduced 
form as well as to keep Tf dissociated from TfR. Once Fe2+ is released into the 
cytosol, it is quickly converted to Fe3+ by ferritin, scavenged by cytosolic ligands 
(such as citrate and ascorbate), utilized by heme and non-heme proteins, transported 
into the mitochondria or stored away into ferritin (Figure 1.2).  
The transferrin cycle is also present in the brain as neurons and neuroglia are found to 
express both Tf and TfR. However, the precise mechanism on how iron is delivered 
into the brain from the blood is still unknown. Nonetheless, since endothelial cells at 
the luminal end of the BBB are found to express TfR, it strongly suggests that the 
BBB could take up iron from the circulating plasma (via TfR and DMT1) and may 
undergo the same basolateral iron processing analogous to the crypt of the intestinal 
cells involving IREG1. IREG1, also known ferroportin is expressed in the endothelial 
cells of the BBB, neurons and neuroglia, hence supporting the role of the transferrin 
cycle in iron brain uptake (Wu, Leenders et al. 2004, Zecca, Youdim et al. 2004).  
1.8.3 Transport of Non-Transferrin Bound Iron (NTBI)  
There are several transporters capable of facilitating the entry of NTBI into cells. 
Importantly, DMT1 was the first transporter discovered for NTBI entry as it is 




Subsequently, other divalent cation transporters are also found to mediate NTBI 
transport, especially the zinc transporters, Zip8 and Zip14 (Liuzzi, Aydemir et al. 
2006, Pinilla-Tenas, Sparkman et al. 2011). Zip8 and Zip14 are also plasma 
membrane integral proteins which have been shown to be widely expressed, including 
the brain, important for the uptake of Zn2+. Nonetheless, similar to the selective 
uptake of Fe2+ by DMT1, Zip8 and Zip14 preferentially transport Zn2+, yet allowing 
the entry of other cations with differing affinities (Jenkitkasemwong, Wang et al. 
2012). In addition, L-type and T-type voltage-gated calcium channels have also been 
documented as alternative iron entry routes independent of transferrin (Oudit, Sun et 
al. 2003, Lopin, Gray et al. 2012).  
1.8.4 Divalent Metal Ion Transporter 1 (DMT1) 
The DMT1, also known as NRAMP2, was first characterized in year 1995 and was 
shown to be involved in host defence against several kinds of infections (Gruenheid, 
Cellier et al. 1995, Vidal, Belouchi et al. 1995). It represents a highly conserved 
family of metal ion transporters from bacteria to humans. The human DMT1 is a 12-
transmembrane spanning integral protein with the N-terminal and C-terminal ends 
predicted to reside within the cytoplasm of the cell. The DMT1 is capable of 
transporting cations such as Fe2+, Mn2+, Zn2+, Cd2+, Co2+ and Ni2+. 
Based on several recent electrophysiology studies using Xenopus oocytes, the human 
DMT1 was shown to preferentially transport cations with the highest affinity in the 
following order:  Cd2+ > Fe2+ > Co2+, Mn2+ >> Zn2+, Ni2+, VO2+ (Mackenzie, 
Takanaga et al. 2007, Illing, Shawki et al. 2012) . According to this study, the human 
DMT1 selectively transports Fe2+ over other physiological cations such as Mn2+ and 




contribute to Cu2+ transport and hence disproving previous claims for the involvement 
of DMT1 in copper ion uptake. In addition, the contribution of Zn2+ transport via 
DMT1 was shown to be insignificant likely due to the presence of other dedicated 
physiological transporters for zinc ion (ZIP8 and ZIP14). Nonetheless, the ability of 
DMT1 to transport heavy toxic metals such as Cd2+ and Co2+, and also Mn2+, which 
are likely to accumulate in the brain, renders further investigation in areas of human 
chronic metal exposures.  
The human DMT1 exists in two isoforms (DMT1A and DMT1B) due to the presence 
of two different initiation sites at the promoter region of the 5’ UTR,  of which the 
mRNA of both isoforms can still undergo two alternative splicing events to give rise 
to alternatively spliced mRNA with or without the iron-response element (IRE) at the 
3’ UTR (Mackenzie, Takanaga et al. 2007). The stability of the stem loop structure of 
the 3’ UTR IRE is dependent on intracellular iron status. In particular, iron-regulatory 
protein 1 (IRP1) and iron-regulatory protein 2 (IRP2) are iron responsive proteins 
which respond to cellular iron status and eventually influence the expression of 
DMT1 via the 3’ UTR IRE.  
Even though DMT1 is ubiquitously expressed, DMT1 is most notable at the luminal 
end of the enterocytes of the proximal duodenum. In particular, DMT1A with IRE is 
predominantly found on the plasma membrane of enterocytes and epithelial cells 
which appear to be associated with systemic iron absorption. The presence of IRE on 
DMT1A allows the regulation of its translation depending on cellular iron status of 
these cells. Additionally, while DMT1A is mostly found in the duodenum, DMT1B is 
ubiquitously expressed on the apical membrane and especially endosomes of almost 




primarily via the transferrin-mediated pathway, as it is extensively expressed in 
endosomes (MacKenzie, Iwasaki et al. 2008).  
In the brain, controversies exist about the expression of DMT1. In the rat brain, it is 
found to be higher in the neurons than in astrocytes or oligodendrocytes. Specifically, 
DMT1 immunostaining of the rat brain show increased immunoreactivity in the 
striatum, cerebellum, thalamus, cells lining the third ventricle as well as vascular 
enterocytes as compared to other regions (Burdo, Menzies et al. 2001). However, the 
examination of DMT1 in the brain of non-human primate revealed extensive staining 
in the glial cell bodies of the neocortex, subcortical white matter, as well as the 
hippocampus. Importantly, the expression of DMT1 was also found in the astrocytic 
end feet, suggesting the involvement of DMT1 in iron uptake from the endothelial 
cells lining of the BBB (Wang, Ong et al. 2001). Interestingly, the basal ganglia of 
non-human primate also showed robust DMT1 staining. The regions with extensive 
DMT1 staining were also co-observed with iron staining examined using Turnbull’s 
iron staining assay. These regions include the caudate nucleus, putamen and 
substantia nigra pars reticulata. The staining of DMT1 was predominantly found in 
astrocytic processes. While these regions have high DMT1 in the glial cells, the 
thalamus, subthalamic nucleus and substantia nigra pars compacta revealed some 
staining of DMT1 in the neurons (Huang, Ong et al. 2004). The expression of DMT1 
in the regions of the basal ganglia suggests the vulnerability of the basal ganglia to 
metal ion toxicities. Together, these data gathered from the rat and non-human 
primate on the expression of DMT1, it is presumed that DMT1 is important for the 
uptake of iron and perhaps other divalent metal ions into the brain. Importantly, the 
expression of DMT1 in neurons and glia cells of the basal ganglia structures suggest 




While the entry of metal ions can take place via the BBB, entry of metal ions via the 
olfactory epithelium has also been proposed. It is of high relevance as inhalation of 
manganese and iron fumes are common occupational and environmental toxicants 
known to man. DMT1 was found to be expressed on the lumen microvilli and end feet 
of the sustentacular cells of the olfactory epithelium, suggesting the possible route for 
metal entry and toxicity via inhalation (Thompson, Molina et al. 2007). 
Furthermore, the importance of DMT1 in mediating iron and manganese transport 
was corroborated by the discovery of two rodent species carrying a spontaneous 
mutation in the DMT1. The microcytic (mk) mice and Belgrade (b/b) rats carry 
natural occurring mutation as a result of glycine to arginine substitution at residue 185 
(G185R) in the 4th transmembrane domain of the DMT1 gene (Fleming, Trenor et al. 
1997, Fleming, Romano et al. 1998). Both rodents show severe microcytic anaemia 
associated with iron deficiency as well as manganese homeostatic imbalance (Chua 
and Morgan 1997).  
When injected with transferrin bound iron intravenously, the Belgrade rats showed 
impaired brain iron uptake even though transferrin uptake was normal. Consequently 
brain iron amount was lower in the Belgrade rats as compared to control Wistar rats. 
DMT1 staining was found in neurons and choroid plexus and was comparable 
between Belgrade and control rats. This suggests that the mutation does result in the 
downregulation of the transporter activity. Thus, the G185R mutation in DMT1 shows 
impairment of brain iron metabolism due to reduced iron uptake into neurons, 
presumably via transferrin-mediated iron entry (Moos and Morgan 2004). 
Additionally, the Belgrade rats show differential regional distribution of iron. In the 
pyramidal neurons, there was extensive iron staining in the Belgrade rats as compared 




oligodendrocytes and myelin in the Belgrade rats. Moreover, astrocytes in the 
Belgrade rats also showed reduction in iron staining. As DMT1 is expressed in almost 
every population of cells in the brain, these results indicate the importance of DMT1 
in mediating iron transport in the brain.  
In addition, as an example of DMT1 mutation in human, a report of a single patient 
with both microcytic anaemia and liver iron overload was observed with a glycine to 
cysteine substitution at position 1285 (G1285C) at the last nucleotide of exon-12 of 
DMT1. DMT1G1285C resulted in the impairment of normal mRNA splicing leading to 
the skipping of exon-12 and consequently the production of a truncated 
transmembrane domain 8 of DMT1 (ΔTM-8). While DMT1G1285C resulted in the 
skipping of exon-12 and ΔTM-8 loss-of-function, yet a small proportion of the 
DMT1G1285C gene (<10%) was observed to undergo normal splicing and produced a 
relatively normal DMT1 protein, although with an amino acid polymorphism 
(E399D). The E399D of the DMT1 was further tested in-vitro and was found to be 
completely functional, both in transport efficiency and cellular localization. Together, 
while the patient carrying G1285C showed typical microcytic anaemia with low blood 
haemoglobin, surprisingly, the patient was observed with liver iron overload. This 
indeed suggests that the DMT1G1285C is not a complete loss-of-function as the small 
proportion of active DMT1 with E399D was still produced in the patient and the 
authors speculated that E399D could be responsible for the iron overload in the liver 
(Lam-Yuk-Tseung, Mathieu et al. 2005). Later, three out of four mutations of the 
DMT1 gene was observed in patients presented with microcytic anaemia, 
hypochromic, increased ferritinemia and iron overload (Iolascon and De Falco 2009). 
The iron loading anaemia observed in these patients was proposed as a result of 




peptide hormone produced by the liver which acts as the master iron regulator in the 
gut and liver. Dysfunctional erythropoiesis has been associated with low hepcidin 
expression. Thus, with low hepcidin levels in these patients, there is uncontrolled 
absorption of iron through the gut and liver leading to iron accumulation. While these 
mutations are not complete loss-of-function mutations, nonetheless, absorption of iron 
into other tissues is compromised with overt anaemia (Lam-Yuk-Tseung, Mathieu et 
al. 2005).  
 
 
Figure 1.3 Putative DMT1 topology. DMT1 is a membrane-spanning glycoprotein consisting of 12 
transmembrane domains. The DMT1 exists in four different transcripts as a result of alternative 
splicing both at the 5’- and 3’- region of the gene. A total of 543 amino acids are conserved and thus 
are found in all isoforms. Alternative splicing at the 5’- region gives rise to two distinct transcription 
initiation sites, producing either exon 1A or 1B. The use of exon 1A initiation site results in the 
inclusion of an additional 29 amino acids in the protein. Alternative splicing in the 3’ - region either 
includes or excludes the iron-response element (IRE). Thus, four isoforms have so far been identified: 







1.8.5 DMT1 and Neurodegenerative Diseases 
Several neurodegenerative diseases have been associated with the DMT1 gene. The 
DMT1 gene, which is also known as SLC11A2 is located in the long arm of 
chromosome 12. It was found to be in close proximity to the susceptibility regions 
associated with AD (Jamieson, White et al. 2005) and restless legs syndrome (Xiong, 
Dion et al. 2007). While DMT1 and AD only showed borderline allelic association, 
two DMT1 intronic SNPs showed positive association with restless legs syndrome 
with a history of anaemia, when compared to patients without anaemia. 
In addition, the increase in DMT1/+IRE expression was observed with heightened 
iron accumulation in the SN of PD patients, suggesting a role of DMT1 in 
predisposing the brain to iron imbalance. Moreover, two SNPs (C alleles of 1254T 
and IVS4+44C/A) in the DMT1 gene were observed to occur at higher frequencies in 
PD patients among the Hans Chinese population as compared to control, again 
suggesting a possible risk factor of DMT1 for PD in this population (Salazar, Mena et 
al. 2008, He, Du et al. 2011).  
Iron dysregulation has been associated as possible pathogenic factor involved in 
motor neuron degeneration in sporadic amyotrophic lateral sclerosis (ALS). In the 
French population, C allele of rs407135 in DMT1 gene was associated with shorter 
disease duration in sporadic amyotrophic lateral sclerosis patients with onset in the 
legs, suggesting that the occurrence of this polymorphism alters the duration of the 






1.8.6 Cellular Iron Storage  
As mentioned earlier, both transferrin-dependent and independent pathways, efflux of 
Fe2+ from the endosomal compartment requires the function of DMT1. Once in the 
cytoplasm, iron is rapidly bound to both protein and non-protein materials in the cells. 
Unbound iron is kept to a minimal to prevent redox cycling and the formation of 
ROS. Thus, iron is incorporated into iron-requiring metalloproteins, such as arginase, 
aconitase, heme proteins, iron-sulfur proteins or store away in ferritin.  
Ferritin  
As the demand for iron to maintain metabolic functions is high, every cell in the 
human body contains a very efficient iron-storage protein which acts to detoxify 
reactive iron, store, as well as rapid iron mobilization for metabolic use. In the cell, 
iron is predominantly stored in the nonreactive form within ferritin. Iron is stored as 
Fe3+ in the core of the ferritin cage due to its highly favourable equilibrium towards 
ferritin-bound iron than to remain in the Fe2+ labile form (MacKenzie, Iwasaki et al. 
2008).  
Ferritin is a 24 subunit protein shell made up of ferritin heavy chain (FTH1) and 
ferritin light chain (FTL1) polypeptides at differing ratios depending on cell type. 
Each ferritin shell can contain up to 4500 atoms of Fe3+ in the soluble ferrihydrite 
form, which remains inert yet bioavailable upon ferritin degradation (Koorts and 
Viljoen 2007). FTH1 has ferroxidase activity which mediates the oxidation of Fe2+ to 
Fe3+ for storage, while FTL1 functions to nucleate iron atoms into the ferritin shell 
(Arosio, Yokota et al. 1976). The assembled FTH1 and FTL1 heterodimers are 




While ferritin is important for iron storage, it has been demonstrated using in-vitro 
and in-vivo studies that it is able to bind other metals such as zinc, aluminium, 
beryllium, lead and cadmium. It was suggested that the ability to bind these metals is 
part of the broader protective role of ferritin in cellular metal regulation (Joshi and 
Zimmerman 1988). However, the ability of ferritin to scavenge manganese ion is 
currently unknown.  
FTH1 and FTL1 are encoded by two different genes. The gene of the human FTH1 
consists of four exons has been localized to chromosome 11 (Hentze, Keim et al. 
1986, Percy, Bauer et al. 1995) while the FTL1 is found in chromosome 19, also 
consisting of four exons (Curtis, Fey et al. 2001).  
Even though their expression co-exists at the same time, their protein levels differ and 
are tissue dependent. The ratio between FTH1 and FTL1 is not fixed but the reason 
behind this is not well understood. Nonetheless, it was reasoned that since FTH1 
contains ferroxidase activity and is associated with greater antioxidant capacity, it is 
usually expressed in tissues with greater metabolic demand such as the brain and 
heart. In contrary, FTL1 is associated with its ability to nucleate and store more iron, 
and hence are primarily expressed in tissues responsible for detoxification and iron 
storage. Consequently, the spleen and liver are demonstrated to express higher levels 
of FTL1 (Harrison and Arosio 1996, MacKenzie, Iwasaki et al. 2008).  
Interestingly, apart from being responsive to iron, several other mediators are also 
known to induce the expression of ferritin. These include histone deacetylase 
(HDAC) inhibitors (Wang, Di et al. 2010), TNF-α and other inflammatory cytokines 
(Tsuji, Miller et al. 1991, Recalcati, Taramelli et al. 1998, Jennings-Gee, Tsuji et al. 




Boutten et al. 2010). The responsiveness of ferritin expression to a variety of 
mediators suggests that apart from its importance in iron metabolism, ferritin may 
also play a role in other non-iron related events (Arosio and Levi 2010). While ferritin 
heterodimers are often found in the cytoplasm, FTH1 has been detected in the 
nucleus. It was shown to translocate into the nucleus through the binding of CXC 
receptor 4, a chemokine receptor upon the induction with CXCL12 receptor ligand. 
(Li, Luo et al. 2006). The translocation of FTH1 into the nucleus in this cellular 
model provides a typical example of iron-independent role of ferritin in chemokine 
signalling and cell-to-cell communication.  
In the brain, ferritin is found in neurons, oligodendrocytes and microglia. While 
oligodendrocytes express equal amounts of FTH1 and FTL1, microglia cells are rich 
in FTL1 and neurons express predominantly FTH1 (Zecca, Stroppolo et al. 2004). 
Even though ferritin protein is widespread in the brain, neuronal ferritin shows 
differential regional expression, with certain brain regions containing higher levels of 
FTH1 while others are almost undetectable. To counter the deficiency in ferritin, it 
has been proposed that regions such as the locus coeruleus and the SNpc contain 
neuromelanin to compensate for the reduced expression of ferritin in iron handling 
and storage (Double, Gerlach et al. 2003, Zecca, Stroppolo et al. 2004). Neuromelanin 
is a dark pigment produced by a subset of catecholaminergic neurons exclusively 
found in humans and primates (Berg, Gerlach et al. 2001). The biosynthesis pathway 
of neuromelanin is still undergoing intense debate but two workable pathways 
involving (i) non-enzymatic and (ii) enzymatic reactions have been proposed. The 
non-enzymatic reaction proceeds via the auto-oxidation of dopamine and the 
complexing of the oxidized dopamine to melanin to form neuromelanin. The other 




and subsequently into oxidized dopamine derivatives via the enzymatic reaction of 
tyrosine hydroxylase (Zucca, Bellei et al. 2006). Of importance, the SN is often 
observed as a vulnerable region for brain iron accumulation in PD. While substantia 
nigra pars compacta is the neuromelanin containing region associated with neuronal 
degeneration, iron-enrichment is predominantly found in the neighbouring region 
called substantia nigra pars reticulata. The pars compacta expresses low levels of 
ferritin as compared to the pars reticulata (Snyder and Connor 2009). Hence, it was 
proposed that neuromelanin acts as the iron-sink in managing iron imbalance in the 
pars compacta (Zucca, Bellei et al. 2006, Zecca, Casella et al. 2008). 
Even as ferritin and neuromelanin are considered protective against iron-mediated 
oxidative damage by scavenging reactive iron, however fortuitous release of iron 
from these iron-laden complexes could bring about massive oxidative damage and 
cell death. It was proposed that neuromelanin co-increase with iron content in 
dopaminergic neurons of the SNpc at the early stages of iron accumulation. However, 
once the amount of neuromelanin reaches its limit, the saturability of neuromelanin to 
scavenge iron becomes the next concern. It was hypothesized that as the iron content 
continues to rise, the increase in iron-mediated oxidative stress in the presence of 
H2O2 would damage the protective neuromelanin and consequently the degradation of 
it (Yoshida, Tanaka et al. 1995, Shamoto-Nagai, Maruyama et al. 2006). The 
consequence of neuromelanin breakdown is accelerated neuronal death due to 







1.8.7 Labile Iron Pool and Cellular Iron Regulation by IRP/IRE system 
As mentioned, almost all iron in the cell is bound to a ligand. A small portion (<5%) 
of total cellular iron appears as transitory iron, existing between extracellular iron and 
intracellular iron closely bound to proteins. This transitory iron pool, also called labile 
iron pool (LIP), can be scavenged by cell permeant chelators and likely to participate 
in redox cycling. With the advent of newer approaches to determine LIP, several 
fluorescein conjugated dyes such as Calcein-AM and Phen Green SK (PGSK) have 
been developed to quantify LIP in a more precise way (Kakhlon and Cabantchik 
2002).   
The regulation of cellular iron status is tightly control by a 
transcriptional/translational switch. It is governed by the iron-regulatory proteins/iron-
responsive element (IRP/IRE) system at the expense of LIP. TfR, FTH1 and FTL1, 
FPN1 (ferroportin) and DMT1 are examples of genes with IRE, which are responsive 
to cellular iron status. The IRE of the ferritin and ferroportin is found at the 5’ UTR 
while it is found at the 3’ UTR of TfR and DMT1 transcripts.  
As the IRE of iron-responsive genes are located at either the 5’ or the 3’ end, the 
dissociation of the IRPs from IRE put forth dual control of either promoting or 
suppressing translation of these genes.  Thus, when cellular LIP is high, IRPs (both 
IRP1 and IRP2) are inactivated and thus dissociate from the IRE of mRNA. This 
consequently results in the decrease in expression of TfR and DMT1 while increasing 
the translation of ferritin and ferroportin, which effectively reduce the uptake of iron 
and have excess iron, stored away (Figure 1.4). However, dysregulation to IRPs is a 
hypothetical example to illustrate a scenario of “iron accumulation with cellular iron 




possibly due to enhanced degradation, chemical inhibition or loss-of-function 
mutation may result in the increase in ferritin and ferroportin expression. While 
ferritin is usually observed as cytoprotective, the overexpression of ferritin with 
corresponding increase in iron efflux (through ferroportin) may result in cellular iron 
starvation. Although the cells may seem to accumulate iron but ferritin-bound iron 
may not be freely available for use, resulting in cellular iron starvation. Therefore, the 
determination of factors that affect IRPs is important as ferritin upregulation with 
corresponding increase in iron scavenging activity may be an indication of a more 






Figure 1.4 The IRP/IRE Regulatory System. (A) Under low cellular iron conditions, IRPs (iron-
regulatory proteins) are active and able to bind IRE (iron response element) of target mRNAs. 
Depending on the location of the IRE, IRP binding to the IRE located at the 5’UTR (untranslated 
region) would inhibit the formation of the translation pre-initiation complex. On the contrary, the 
binding of the IRPs at the 3’UTR enhances the stability of the mRNAs (Transferrin receptor, TfR1; 
DMT1) and increases the translation of the targeted proteins. (B) Under high cellular iron condition, 
IRPs are inactivated by excess iron. In the presence of high iron, IRP1 is converted into cytosolic 
aconitase through the formation of an iron-sulfur cluster while IRP2 is degraded. Consequently, the 
exposure of the 5’UTR previously blocked by IRPs now permits the translation of targeted mRNAs 
(ferritin and ferroportin). The IRE on the 3’UTR which is no longer protected by IRPs is now unstable 





1.8.8 Degradation of Iron-Regulatory Proteins 
While much is known about the transcriptional and translational regulation of iron via 
the IRP/IRE system, it is not until recently that the mechanism behind the degradation 
of iron-regulatory proteins such as ferroportin, ferritin, DMT1 and TfR has been 
discovered. As neurons are post-mitotic cells, protein degradation is particularly 
important to get rid of targeted unwanted proteins to maintain cellular homeostasis. In 
addition, protein homeostatic imbalance due to impairment to protein degradative 
pathways has been associated with the development of many motor and non-motor 
neurodegenerative diseases, including PD, AD and HD. 
To date, it is known that proteins can be degraded via the ubiquitin-proteasome 
pathway (UPS) and the autophagy-lysosomal pathway. The UPS involves a series of 
enzymatic reactions which results in the polyubiquitination of proteins for proteolysis 
via the proteasome. On the other hand, the autophagy-lysosomal pathway involves the 
formation of an isolation membrane which engulfs the targeted cargo protein into the 
autophagosome. The autophagosome will then fuse with the lysosome to form the 
autophagolysosome for the terminal proteolysis of proteins by acidic proteases in the 
lysosomes. Autophagy is no longer considered to be an unspecific cargo engulfment 
process. It has been shown recently that autophagy is a highly orchestrated process, 
involving recognition of target proteins and recruitment of auxiliary proteins for the 
execution of autophagy. The formation of the autophagy core complex consisting of a 
family of ATG proteins is essential from the initiation to the fusion with lysosomes 
(Meijer, van der Klei et al. 2007, Olzmann and Chin 2008).  
In addition, non-canonical polyubiquitination involving lysine residue 63 (K63) could 




been documented (Olzmann and Chin 2008). Furthermore, p62, which is an adaptor 
protein for autophagic clearance, has been shown to mediate the recognition and 
targeting of both ubiquitinated and non-ubiquitinated proteins for clearance via 
autophagy (Matsumoto, Wada et al. 2011, Watanabe and Tanaka 2011). Generally, 
while polyubiquitination is needed for targeting of proteins towards proteasomal 
degradation, one study showed that monoubiquitination of ferritin functions to 
dismantle the iron-containing nanocage and eventually degradation via proteasomal or 
lysosomal degradation (De Domenico, Vaughn et al. 2006).  
In addition to the regulation at the transcriptional level, the control of protein level is 
equally important to elicit an immediate response towards iron availability. Thus, the 
cellular gatekeepers of iron availability such as DMT1, ferroportin and TfR similarly 
undergo degradation either via UPS or autophagy-lysosomal pathway or both, under 
the influence of intracellular iron status.  
The targeted proteolysis of IRPs, which are the master regulators of iron metabolism, 
is mediated by FBXL5 protein. FBXL5 is an iron-sensing protein with an 
evolutionary conversed hemerythrin domain. This domain likely contains an oxygen-
bridge di-iron binding site. The presence of excess iron stabilizes FBXL5 which in 
turn functions as an adaptor to mediate the ubiquitination of IRP by SKP1-CUL1 E3 
ligase. This leads to the degradation of IRP by proteasome. However, in the event of 
low cellular iron, FBXL5 is destabilized and undergoes degradation by the 
proteasome, allowing IRPs to associate with IREs. (Moroishi, Nishiyama et al. 2011, 
Chollangi, Thompson et al. 2012). While, the mechanism underlying iron-controlled 
degradation of IRPs is known, however, the identity of iron-sensitive adaptor proteins 
responsible for the targeting of iron-related proteins (DMT1, ferritin, TfR and 




Nonetheless, isoform-specific degradation of DMT1B (not DMT1A) has been 
recently shown to be mediated by two different E3 ubiquitin ligases, parkin and 
Nedd4 (neuronal precursor cell-expressed developmentally downregulated 4) (Foot, 
Dalton et al. 2008, Howitt, Putz et al. 2009, Garrick, Zhao et al. 2012). Furthermore, 
two independent studies discovered two GTPases which are involved in the 
internalization and degradation of transferrin receptor (TfR). The internalization of 
TfR via clathrin-coated pits involves Rab12 while Rab5 is responsible for the 
targeting of TfR from the recycling endosomes to the lysosomes. The terminal 
degradation of TfR takes place in the lysosomes (Rabeno (Matsui, Itoh et al. 2011, 
Navaroli, Bellve et al. 2012).  
Ferroportin degradation is influenced by hepcidin levels. Hepcidin is a hormone 
produced in the liver and is known to bind to and result in the degradation of 
ferroportin (Yeh, Yeh et al. 2004, Qiao, Sugianto et al. 2012). Even though hepcidin 
is produced in the liver, there is evidence to suggest that it is also important for brain 
metabolism as hepcidin is extensively expressed in the mouse brain (Wang, Fu et al. 
2010). The degradation of ferroportin likely involves the ubiquitination of ferroportin 
upon the internalization induced by hepcidin (Ross, Tran et al. 2012).  
Ferritin has been demonstrated to be degraded by both proteasomal and autophagy-
lysosomal pathway (De Domenico, Vaughn et al. 2006, Zhang, Mikhael et al. 2010, 
Asano, Komatsu et al. 2011). It was proposed that lysosomal proteolysis is required 
for the extraction of iron from ferritin during cellular iron depletion (Zhang, Mikhael 
et al. 2010). While lysosomal proteolysis is the predominant pathway, one study 
showed the possibility of iron extraction from ferritin independent of lysosomal 
proteolysis. In that study, the overexpression of ferroportin resulted in the reduction in 




ferritin degradation. Interestingly, ferritin mono-ubiquitination was observed as a 
mechanism to dismantle iron-depleted ferritin nanocage for proteolysis via the 
proteasome. And the mono-ubiquitination was demonstrated to be not essential for 
proteasomal degradation of ferritin. In addition, the expression of mammalian ferritin 
into Saccharomyces cerevisiae, which is void of endogenous ferritin, also displayed 
iron extraction from ferritin. This elegant proof of concept suggests that iron 
extraction from ferritin does not require any specific mammalian machinery (De 
Domenico, Vaughn et al. 2006). Together, ferritin degradation and iron mobilization 
seemed to involve several proteolytic pathways. Yet, the mechanism for iron 
extraction preceding ferritin degradation requires further investigation.   
1.8.9 Mechanism of Cellular Iron Toxicity 
Derailment of iron balance has also been observed in certain gene mutations not 
directly related to iron regulation. Majority of these patients with the mutations 
display neurodegeneration with brain iron accumulation and thus the abbreviated 
name ‘NBIA’. The classical NBIA genes include the pathothenate kinase type 2 
(PANK2)-associated neurodegeneration (PKAN) and phospholipase A2, group VI 
(PLA2G6S) genes, which are commonly called NBIA 1 and NBIA 2, respectively. 
Both of the genes in NBIA 1 and 2 are responsible in phospholipid metabolism and 
are involved in myelin formation, thus suggesting that myelin dysfunction is 
associated with iron accumulation. In addition, another gene called ATP13A2 has 
been associated with NBIA. It was first discovered as Kufor–Rakeb disease, and 
designated as PARK9. ATP13A2 is a lysosomal ATPase transport protein with its 
function not fully characterized. And since iron metabolism heavily involves 
lysosomes for iron recycling, mutation and the complete loss-of-function to ATP13A2 




et al. 2009, Schneider, Paisan-Ruiz et al. 2010, Dusek, Jankovic et al. 2012, Paisan-
Ruiz, Li et al. 2012). Excessive unbound iron in the form of Fe2+ is most deleterious 
when in contact with H2O2. The major producer of cellular H2O2 is the mitochondria 
(Cortes-Rojo, Estrada-Villagomez et al. 2011). Mitochondrial impairment induced by 
toxins or merely through the aging process show increase in H2O2 production (Kurz, 
Terman et al. 2008). This could catalyze the formation of reactive oxygen species 
(•OH, hydroxyl radical) in the presence of Fe2+ and Fe3+ via the Fenton and Haber-
Weiss reaction, respectively.  
Fe2+ + H2O2 → Fe3+ + OH- + •OH (Fenton reaction)...1 
Fe3+ + •O2− → Fe2+ + O2• (Haber-Weiss reaction)...2 
O2- + H2O2 → •OH + OH- + O2 (Net reaction from redox cycling of 1 and 2)  
The short-lived •OH could result in the formation of 8-hydroxyguanine DNA adduct 
which may lead to point mutations, single and double DNA strand breaks (Pra, Franke 
et al. 2012). Cell viability loss and cell death are usually observed with excessive 
DNA damage induced by iron toxicity (Lee, Son et al. 2006). In addition, iron could 
also mediate the misfolding of proteins especially α-synuclein, leading to impairment 
in the autophagy pathway in cellular models of PD (Uversky 2008, Arreguin, Nelson 
et al. 2009). Furthermore, patient brain samples of hereditary neuroferrinopathy 
showed increase in protein carbonylation as a consequence of iron-catalyzed ROS, 
which may impair function of proteins (Baraibar, Barbeito et al. 2012). Additionally, 
lipid peroxidation induced by iron is also another hallmark often observed in many 
cellular and animal models of neurodegenerative diseases, suggesting the eminence of 
iron-mediated oxidative damage in these diseases (Castelnau, Garrett et al. 1998, 
Chakraborty, Ray et al. 2001, Takadera, Koriyama et al. 2011). If indeed iron in 




corresponding reduction in ferritin or neuromelanin levels; this could indeed mediate 
the formation of ROS and cascading a series of oxidative damage to proteins, lipids 
and DNA.  
1.9 Manganese  
Manganese is an essential trace element required for the formation of bones and is 
involved in the metabolism of amino acids, lipids as well as carbohydrates. At the 
cellular level, manganese ion is required in many enzymes including mitochondrial 
superoxide dismutase (SOD2), glutamine synthetase, arginase and is involved in 
several hydrolases, carboxylases and transferases. 
Naturally occurring organic manganese can be found in the environment in the form 
of carbonates, oxides and silicates. The antiknock gasoline additive called 
methylcyclopentadienyl manganese tricarbonyl (MMT) is a major environmental 
contributor of organic manganese. In addition, inorganic manganese is also used in 
many industrial applications such as for the production of dry-cell batteries, textile, 
ceramics and leather. The recommended daily reference value for manganese is 2.3 
mg/day for male and 1.8 mg/kg for female, with an upper limit of 11 mg/day (Fraga 
2005).   
Manganese is primarily acquired through the diet which is mostly found in 
wholegrain (for example, rice bran and oat bran), nuts (for example, hazelnut and 
pecans), beans (for example, soybeans and edamame) and seeds (for example, 
flaxseed and sesame seed). Manganese toxicity via normal dietary consumption is 
extremely rare with exceptions to patients with chronic liver failure or on long-term 
parenteral feeding. In patients with chronic liver failure, they are encouraged to limit 
the intake of foods high in manganese. As metabolism and excretion of manganese 




circulating plasma manganese, which consequently result in the selective 
accumulation of manganese in the brain. In addition, patients on long-term parenteral 
feeding with supplemented manganese showed increase in brain manganese, which 
suggests that manganese uptake via oral route may end up in the brain (Fell, Reynolds 
et al. 1996, Iinuma, Kubota et al. 2003, Abdalian, Saqui et al. 2012). 
 In the human brain, manganese has a wide topographical distribution where it is most 
abundant in structures of the basal ganglia (for example, globus pallidus, caudate and 
putamen) and the least in the cortical regions (Burton and Guilarte 2009). The 
accumulation as well as sensitivity of the brain to manganese toxicity has garnered 
immense research effort for the reason that it can cause a highly debilitating disorder 
that exhibits extrapyramidal symptoms (manganism). Similar to PD, manganism is 
characterized by a rather selective motoric impairment including bradykinesia, 
dystonia, and akinetic rigidity (Sadek, Rauch et al. 2003). However, the motoric 
symptoms are usually irreversible and often times present with preceding 
neuropsychological disorders such as impairment in working memory, spatial 
orientation, agitation and several other behavioural manifestations such as 
hallucination and psychoses  (Klos, Chandler et al. 2006, Bouchard, Mergler et al. 
2007, Bowman, Kwakye et al. 2011).  
Importantly, inhalation of manganese fumes amongst welders and workers in the 
smelting and ship-yard industry are at higher risk of developing manganism, 
characterized by basal ganglia manganese accumulation and pathology (Criswell, 
Perlmutter et al. 2012). In addition, an epidemiological study performed in the Unites 
States reported a higher incidence of PD in counties with greater release of 
manganese, suggesting that manganese exposure as a risk factor for the development 




1.9.1 Mechanism of Manganese Transport and Cellular Metabolism  
To date, a dedicated transport protein for manganese has not been discovered. It has 
long been proposed that manganese from dietary sources is absorbed in the intestine 
via the same transport mechanism for iron. However, given the toxicity of this 
essential element at low doses, it is believed that a delicate transport and regulatory 
mechanism should exist to prevent any unwanted toxicity. In addition, during the past 
20 years, many transport mechanisms which were first identified for other divalent 
metal ions are now discovered to transport manganese. For example, the DMT1 
remains the major transporter for manganese uptake for several reasons. Apart from 
iron deficiency, the microcytic (mk) mice and Belgrade (b/b) rats which carry a 
spontaneous mutation in the DMT1 showed manganese disturbances in several tissues 
in the body including the brain (Chua and Morgan 1997). In addition, while 
intranasal-acquired manganese radioisotope was reduced in Belgrade rats, control rats 
showed significant acquisition of manganese. Manganese uptake was further 
enhanced in iron-deficient rats, confirming the role of olfactory DMT1 in mediating 
manganese transport and the influence of iron status on manganese toxicity 
(Thompson, Molina et al. 2007). Additionally, manganese is shown to complex with 
transferrin, further corroborating the role of the DMT1/transferrin pathway in 
manganese transport. Apart from DMT1, manganese transport can also proceed via 
zinc transporters such as ZIP8 and ZIP14. (Fujishiro, Yano et al. 2012). Furthermore, 
SLC30A10 has recently been proposed as a putative manganese transporter since it 
has a higher affinity for manganese than zinc (Quadri, Federico et al. 2012, Stamelou, 






1.9.2 Mechanism of Cellular Manganese Toxicity 
Several studies have addressed the cytotoxic potential of manganese in cultured cell 
lines. One study reported that manganese ion accumulates in several compartments of 
the cell including the mitochondria and nucleus (Kalia, Jiang et al. 2008). Following 
that, it was reasoned that cellular toxicity mediated by manganese ion was associated 
with mitochondria dysfunction as well as DNA damage (Malecki 2001). While the 
effect of manganese ion on the electron transport chain (ETC) of the mitochondria is 
nonspecific, nonetheless the impairment to the ETC was observed to increase ROS 
following manganese ion treatment using functional isolated mitochondria (Zhang, Fu 
et al. 2004).  
The understanding of cell death mechanism mediated by manganese ion has been a 
challenging one due to numerous contradictory studies. Indeed, mitochondria 
impairment, the increase in ROS and the activation of the intrinsic mitochondria cell 
death pathway have been the mainstream pathway involved in manganese toxicity. In 
particular, activation of caspase 9 of the intrinsic pathway using gasoline anti-knock 
agent methylcyclopentadienyl manganese tricarbonyl (MMT) on PC12 dopaminergic 
cells has been demonstrated, showing the potential of this gasoline additive to cause 
dopaminergic neurodegeneration  (Anantharam, Kitazawa et al. 2002). The activation 
of caspase 9 with MMT led to the induction of executioner caspase 3 and eventually 
apoptotic cell death. Moreover, there is also evidence for the activation of caspase 12 
(ER stress pathway) using NIH3T3 cells and caspase 8 (extrinsic death pathway) 
using human B-cells in manganese-mediated cell death (Oubrahim, Chock et al. 2002, 
El Mchichi, Hadji et al. 2007). Indeed, the activation of these caspases was further 




Moreover, the discovery of a core promoter and a manganese-responsive region 
containing three putative Sp1 binding sites on the caspase 3 gene provided the 
elucidation for the increase in caspase 3 protein and activity upon manganese ion 
toxicity. Sp1 is a C2H2-type zinc finger-containing DNA binding transcription factor 
that can activate or repress transcription in response to physiological and pathological 
stimuli (Tan and Khachigian 2009). Manganese ion was shown to increase the 
phosphorylation of Sp1 and subsequently the enhanced transcription and translation 
of caspase 3. The transactivation of caspase 3 mediated by manganese ion was 
observed to stimulate cell death.  
On the contrary,  another study employing the use of selective caspase 3 inhibitor 
(DEVD-CHO) as well as pan caspase inhibitor (Z-VAD-FMK) failed to rescue PC12 
cells from manganese ion toxicity even though caspase 3 activation was observed 
(Roth, Feng et al. 2000). This study suggested that cell death may have proceeded via 
a caspase-independent pathway, which requires further experimentation to confirm. In 
addition, inhibitors towards p38 MAP kinase (SKF86002 and SB203580) also failed 
to prevent cell death (Roth, Feng et al. 2000). Therefore, with the confusion 
underlying the cell death mechanism mediated by manganese ion, it is likely that cell 
death may not involve a distinct pathway, but rather is multifaceted.  
In addition, the heterogeneity in cell population within the brain makes the study of 
manganese toxicity rather complicated. Non-neuronal cells such as microglia and 
astrocytes have been shown to be activated in response to manganese treatment in-
vivo and in-vitro (Filipov and Dodd 2012, Santos, Milatovic et al. 2012). As these 
cells are inflammatory in nature, upon the exposure to manganese ion, they secrete 
pro-inflammatory factors similar to the responses after lipopolysaccharide (LPS) 




inflammatory mediators such as interleukins, cytokines and nitric oxide have been 
shown to be harmful to neurons in-vitro, which has been hypothesized to be one of 
the death-initiating factors in manganese toxicity (Zhang, Lokuta et al. 2010, Sidoryk-
Wegrzynowicz and Aschner 2013). Importantly, airborne manganese through 
inhalation is considered to be the most hazardous form of toxicity as compared to 
absorption and adsorption. This is due to the enrichment of DMT1 on the olfactory 
epithelium of the nasal cavity and BBB. Thus, airborne manganese entry into the 
human brain has been hypothesized to be via DMT1 and the BBB (Au, Benedetto et 
al. 2008). Indeed, astrocytes which form the protective barrier between systemic 
blood and neurons have been shown to be the initial target for manganese-mediated 
toxicity (Henriksson and Tjalve 2000). Moreover, the preferential activation of 
microglia and astrocytes with the parallel accumulation of manganese in the striatum 
and substantia nigra corroborates the involvement neuroinflammation in the 
pathology of manganese toxicity (Ponzoni, Gaziri et al. 2002, Tomas-Camardiel, 
Herrera et al. 2002). 
1.10 c-jun-N-Terminal Kinase (JNK) and Cell Death  
The mammalian mitogen activation protein kinase (MAP kinase) family of proteins 
consist of c-jun-N-terminal kinase (JNK), p38, and extracellular signal-regulated 
kinase (ERK). Each of these MAP kinase signalling pathways involves at least three 
upstream kinases (i) MAPK kinase kinase (MAP3K), (ii) MAPK kinase (MAP2K), 
and (iii) MAPK. The MAP kinases are important protein transducers associated with 
many aspects of cellular regulation including gene regulation, cell proliferation and 
programmed cell death. The c-jun-N-terminal kinase (JNK) is crucial for programmed 
cell death occurring during development as well as pathological death. Similar to the 




JNK pathway. ASK1, apoptosis signal-regulating kinase 1, is activated by many 
stressors including ROS, ER stress, induction by LPS and abrupt calcium influx 
(Borsello and Forloni 2007, Nagai, Noguchi et al. 2007).  
The ASK1-JNK pathway has been implicated in neurodegenerative diseases. For 
example, in cellular as well as animal models of PD, L-DOPA, 6-hydroxydopamine 
(6-OHDA), and paraquat were found to mediate cell death via ASK1 activation (Hu, 
Weng et al. 2011, Liedhegner, Steller et al. 2011, Niso-Santano, Bravo-San Pedro et 
al. 2011). Similarly, in AD, amyloid-β which is the pathogenic protein implicated in 
AD was found to activate ASK1-JNK pathway via ER stress and ROS (Galvan, 
Banwait et al. 2007). Even as the effects of these classical inducers are known, 
however, the role of metal ion toxicity on the thiol antioxidant systems in relation to 
JNK pathway is not well understood. ASK1 kinase activity is regulated by 
thioredoxin (Trx), which is a thiol-containing redox protein. The oxidation of Trx 
leads to the disassociation of it from ASK1, resulting in the activation of ASK1. It 
was shown that metal ions may have differing effects on thioredoxin and 
subsequently the activation status of ASK1. For example, even though iron undergoes 
redox cycling via the Fenton reaction to produce ROS, iron-derived ROS and 
oxidative stress are not known to oxidize Trx (Hansen, Zhang et al. 2006). On the 
contrary, while arsenic and mercury do not readily undergo Fenton reaction, these 
metal ions are known to react with free thiols on Trx. This makes Trx less accessible 
to inhibit ASK1 function leading to the increase in JNK phosphorylation with these 
metal ions (Hansen, Zhang et al. 2006). In addition, arsenic was also shown to 
suppress thioredoxin reductase (TrxR) function. TrxR functions to reduce oxidized 
Trx into the reduced form which allows Trx to inhibit ASK1 function. Deficiency in 




excessive activation of ASK1 and JNK is mainly related to cell death (Lin, Del Razo 
et al. 2001, Karunakaran, Diwakar et al. 2007). Given the potential of metals to exert 
profound effects on the Trx-ASK1-JNK pathway, the relevance of this pathway in 
iron and manganese-mediated toxicity should be important.  
1.11 Neuroprotection and Management of Iron and Manganese Toxicity 
The conventional treatment for acute metal toxicity revolves around the use of metal 
chelators. In the event of arsenic, lead and mercury heavy metal contamination, metal 
chelators such as calcium disodium ethylenediamine tetra acetic acid (CaNa2EDTA) 
and sodium 2,3-dimercaptopropane 1-sulfonate (DMPS) are often used as first line 
therapy (Flora, Mittal et al. 2008). In addition, iron chelators such as desferroxamine, 
deferiprone, and deferasirox are commonly used for iron overload disorders such as 
thalassaemia and aceruloplasminemia. Thalassaemia is an autosomal recessive blood 
disorder pathologically characterized by weakened red blood cells prone to 
destruction leading to anaemia with iron accumulation (Kontoghiorghes 2008). The 
use of deferasirox is limited in aceruloplasminemia as brain iron content was not 
changed even though liver iron content was reduced (Finkenstedt, Wolf et al. 2010). 
Additionally, a phase II clinical trial on the effect of iron chelator deferiprone on 
patients with NBIA 1 (with PKAN mutation) showed no significant reduction in brain 
iron content examined using MRI or any clinical improvement associated with iron 
toxicity (Zorzi, Zibordi et al. 2011). Hence, even as modern day iron chelators may be 
beneficial for systemic iron accumulation, their effectiveness in the brain is still 
limited. This is likely due the permeability of the BBB of either restricting entry of 
the chelators or the possibility of iron-chelator complex retention in the brain. 




toxicity in both cellular and animal models of PD and AD upon neurotoxin treatments 
of either MPTP or 6-OHDA  (Li, Jankovic et al. 2011).  
In manganese toxicity, the use of chelation therapy is limited. With the recent 
discovery of SLC30A10 mutations with patients exhibiting signs of manganism, a 
study described of a patient who benefited from long-term CaNa2EDTA given 
intravenously (Stamelou, Tuschl et al. 2012). The 10-year follow up chelation therapy 
showed significant reduction in T1- MRI hyperintensity after 9 years with 5 – 8 days 
of chelation therapy per month. To decrease absorption of manganese at the enteric 
level, the patient was also supplemented with dietary iron, to out-compete manganese 
at the entry level, especially via DMT1. In addition to CaNa2EDTA, 
dimercaptosuccinic acid (DMSA) which is used for lead poisoning, has also been 
observed with some chelating success in patients with SLC30A10 mutations (Tuschl, 
Clayton et al. 2012). Unlike patients with SLC30A10 mutations, patients with 
environmental manganese exposures were only successfully treated with sodium para-
aminosalicylic acid (PAS) and trientine. PAS is an antibiotic used for tuberculosis 
treatment while trientine is a hydrochloride salt which is used for chelating copper in 
Wilson’s disease (Jiang, Mo et al. 2006, Park, Kim et al. 2008).  
Since the major role of DMT1 in Fe2+ and Mn2+ toxicity, several groups have taken 
the effort to determine specific compounds that could inhibit the function of DMT1. 
By performing screening on heterologous overexpression system of DMT1, small 
molecule inhibitors have been identified. Ebselen, which is a selenium-containing 
compound, is currently undergoing clinical trials to be used as a protective agent 
against iron toxicity in ischemic stroke. Another unrelated compound called 
pyrrolidine dithiobarbamate (PDTC) which has antioxidant properties was shown to 




centres were identified to be inhibitors of DMT1 in a competitive and reversible 
fashion (Wetli, Buckett et al. 2006, Buckett and Wessling-Resnick 2009, Zhang, 
Kodumuru et al. 2012). While these compounds may be useful in the event of acute 
toxicity, the relevance of such DMT1 inhibitors for the treatment of chronic iron 
diseases remains unknown.  
Although the direct removal of iron via chelation or the inhibition of metal ion 
transport using inhibitors maybe helpful, extensive research is investigating the 
possibility of genetic manipulation of IRPs and their associated proteins to influence 
cellular iron status. In a hemorrhagic stroke model, cortical cultures prepared from 
IRP2 knock-out mice expressed high levels of ferritin heavy chain in both neurons 
and astrocytes, which showed resistance towards haemoglobin toxicity.  In addition, 
the overexpression of ferritin heavy chain has been proven to be protective against 
neurotoxin-mediated iron toxicity, such as paraquat, lactacystin (proteasomal 
inhibition) and MPTP (Kaur, Yantiri et al. 2003, Regan, Chen et al. 2008, Chen, Awe 
et al. 2010, Zhu, Li et al. 2010). Even as the idea of chelation therapy maybe the best 
option for acute toxicity, the use of these chelators and other inhibitors to transporters 
for patients with chronic iron and manganese intoxication requires further 
understanding on the interplay of these highly chemically-related metals (Fitsanakis, 
Zhang et al. 2010).  
1.12 Rationale and Objectives 
Given the importance of iron and manganese ions to sustain cellular functions, 
dysregulation in the transport and handling in any of these metal ions is highly 




overload has been associated with iron deficiency. This provided the impetus for us to 
investigate the interplay between Fe2+ and Mn2+ in influencing cell fate via DMT1. 
We hypothesized that DMT1 facilitates Mn2+ entry during Mn2+ overload, influencing 
the uptake and intracellular signalling pathways of Fe2+ in mediating deleterious 
effects. In addition, we hypothesized that DMT1 overexpression in the brain leads to 
iron accumulation and inflammatory-associated nitric oxide production which could 
modulate the function of DMT1 and that NO-modified DMT1 could underlie the 
mechanism for increased iron accumulation.   
To test these hypotheses, I pursued the following objectives:  
Part One  
(i) To determine the accumulation of Fe2+ and Mn2+ in DMT1 overexpressing 
cells. 
(ii) To clarify the interplay between Fe2+ and Mn2+ in relation to the MAP 
kinase pathway and autophagy in mediating cytotoxic effects.  
(iii) To elucidate the mechanism underlying Mn2+ cytotoxicity associated with 
iron depletion. 
To extend the study of iron and manganese neurotoxicity to animal model, the novel 
transgenic mouse overexpressing DMT1 was characterized by pursuing the following 
objectives:  
Part Two  
(i) To determine DMT1 overexpression in the brain of the transgenic model 




(ii) To examine the TH neurons and the motor performance in the DMT1 
transgenic model.  
(iii) To examine for brain microglial activation and nitrosative stress. 
As the results in part two (iii) of my thesis showed marked increase in SN microglial-
derived nitrosative stress, we extended the study by investigating the role of nitric 
oxide (NO) on DMT1 function in-vitro. As we hypothesized that NO influences 
DMT1 function, the following objectives were pursued: 
Part Three 
(i) To determine the functional effect of S-nitrosylation on DMT1-mediated 
Fe2+ entry. 
(ii) To elucidate the molecular mechanism underlying changes in DMT1 
function. 
At the start of my thesis in 2008, we were investigating the effect of Fe2+ on DMT1-
overexpressing cells. Interestingly, the cells were rather resistant to Fe2+-mediated 
toxicity and only displayed significant cell death at high Fe2+ concentrations. Since 
then, we were convinced that low Fe2+ accumulation alone might not be sufficient to 
result in cell death or trigger cell death in neurodegenerative diseases such as PD. 
Therefore, we extended the study by investigating gene-environmental interaction, by 
factoring in a genetic component. Indeed, we found that the overexpression of the 
mutant A53T α-synuclein showed significant cell death in the presence of Fe2+, and 
the involvement of autophagy in mediating cell death. This provided evidence that the 
effect of Fe2+ toxicity is indeed aggravated in the presence of other pathogenic factors, 
such as increase in H2O2 due to mitochondrial dysfunction, often observed in many 




of DMT1 in mediating toxicity, but involving another highly chemically-related metal 
ion, Mn2+. Thus began my work featured in part one, Chapter 3 of my thesis, which 
sought to clarify the effect of Mn2+ entry via DMT1. As DMT1 and the transferrin 
cycle is considered the primary mechanism for Fe2+ entry, my results provided robust 
evidence that Mn2+-mediated cytotoxicity involves Fe2+ depletion associated with 
JNK and autophagy stimulation. Interestingly, although Mn2+ was found to reduce 
intracellular ROS, it resulted in JNK-mediated reduction in cell viability. As loss of 
ferritin is prominent in the presence of Mn2+, this provided clear evidence that Mn2+ 
toxicity involves Fe2+ imbalance. Unlike Fe2+, Mn2+ accumulation is highly 
detrimental and thus supporting the evidence of the development of highly 
debilitating motor disorders associated with manganese occupational exposures.    
Finally in part two and part three of Chapter 3, I have discussed my findings on the 
characterization of the novel transgenic mouse model overexpressing DMT1. The 
increase in nitrosative stress associated with DMT1 functional modulation may 
potentially underlie the mechanism of iron accumulation found in neurodegenerative 
diseases.    
Taken together, the results presented in this thesis have shed light on the mechanisms 
underlying the interplay of Fe2+ and Mn2+ via DMT1 and the potential role of NO on 
DMT1 function.  
  




MATERIALS AND METHODS 
2.1 Materials  
2.1.1 cDNAs 
cDNA of the monkey DMT1B (Accession: AF153279) without the iron-response 
element (IRE) at the 3’ UTR, previously described in (Chew, Ang et al. 2011) was 
subcloned into the pEGFP-N3 expression vector (Invitrogen) to generate pEGFP-
DMT1 using sequential digestion with Xho1 followed by Apa1. The FLAG-tagged 
ferritin heavy chain (FTH1-FLAG) plasmid was generated by cloning the human 
FTH1 (Accession: NM_002032) without the IRE at the 5’ UTR into pCDNA3-Flag 
expression vector. Human cDNA was isolated from SH-SY5Y cells using TRIzol® 
reagent (Invitrogen) and reverse-transcribed using Superscript III Reverse 
Transcriptase (Invitrogen). FTH1 cloning insert was amplified using PfuTurbo DNA 
Polymerase (Agilent Technologies) with the following EcoR1 site-flanked upstream 
and Xba1 site-flanked downstream primers: FTH1 (F) (5’-
ATGCGAATTCATGACGACCGCGTCC-3’) and FTH1 (R) (5’-
GATAATGAAAGCTAATCTAGACGTA-3’). The resultant PCR product was 
sequentially digested with Xba1 (NEB), followed by EcoR1 (NEB) to obtain the 
desired fragment. The digested fragment was subcloned into EcoR1/Xba1 pCDNA3-
Flag vector using T4 Ligase (Promega) and the successful insertion of the fragment 
was validated by sequencing. The TRX1-Flag plasmid was obtained from Addgene 
(plasmid: 21283) and was previously described (Liu and Min 2002). The FLAG-
tagged parkin plasmid was a kind gift from Dr. Lim Kah Leong (NUS).  




The following antibodies were used in part one of the thesis: rabbit polyclonal anti-
phospho-JNK, anti-JNK, rabbit polyclonal anti-phospho p38, anti-p38, rabbit 
polyclonal anti-phospho-ERK, anti-ERK, rabbit polyclonal anti-FTH1 (Cell 
Signalling Technology), rabbit polyclonal anti-TRX (Santa Cruz), rabbit polyclonal 
anti-LC3B (Abgent), mouse monoclonal anti-actin, and HRP-conjugated anti-rabbit 
and anti-mouse (Sigma). In part two and part three of the thesis, the following 
antibodies were used: mouse monoclonal anti-DMT1B (Abnova), rabbit polyclonal 
anti-parkin, rabbit polyclonal anti-3-nitrotyrosine, mouse monoclonal anti-TH, rabbit 
polyclonal anti-iNOS, rat polyclonal anti-CD11b (Millipore), Alexafluor (594 and 
488) fluorescein-conjugated anti-rabbit and anti-mouse secondary antibody 
(Molecular Probes), and biotin-conjugated anti-rabbit and anti-mouse secondary 
antibody (Sigma). Typically, antibodies were used at a concentration of 0.2 μg/ml for 
immunoblotting and 0.1 μg/ml for immunocytochemistry.   
2.1.3 Reagents 
3-methyladenine (3-MA) and wortmannin (WM) (Sigma) dissolved in distilled water 
were pharmacological agents used to inhibit autophagy. NH4Cl (Sigma) and 
chloroquine (CQ) (Sigma) in dissolved in distilled water were used as pH-neutralizing 
lysosomotropic agents. Amino acid-free Earl’s balanced salt solution (EBSS; Sigma) 
was used to induce the upregulation of autophagy as a positive control. SP600125 and 
anisomysin (Sigma) in DMSO was used to inhibit and induce the phosphorylation of 
JNK, respectively. MnCl2 and FeCl2 (Sigma) were prepared fresh daily in 0.1 M HCl 
in distilled water to prevent oxidation. NOC-18, SNAP, SIN-1 and GSH were 
purchased from Sigma. Other reagents were from Sigma Aldrich, otherwise stated. 




2.2.1 Cell Culture and Western Blot 
The DMT1 stable cell line (S-DMT1) was maintained in 200 µg/ml G418 (Gibco) -
supplemented DMEM (Gibco) containing 10% FBS (v/v) (Gibco) and 1% Pen/Strep 
(v/v) (Gibco) in 5% CO2 atmosphere at 37 °C. The immortalized autophagy-deficient 
MEF cells ATG5-/- and ATG7-/- with their corresponding WT cells were kind gifts 
from Dr. Noboru Mizushima from Tokyo Medical and Dental University. The MEFs 
were maintained in DMEM containing 10% FBS and 1% Pen/Strep in 5% CO2 
atmosphere at 37 °C. Cell transfection was performed using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s instructions. Protein extraction was 
carried out by disrupting the cells in PBS buffer containing 1% Triton X-100 (v/v) 
with added cocktail protease and phosphatase inhibitors (Roche). Cells were rotated 
for 15 min, and then the supernatant was collected after centrifuging at 13 500 rpm at 
4 °C. Subcellular fractionation was performed using a buffer containing 250 mM 
sucrose, 20 mM HEPES (pH7.4), 10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM 
EGTA and added with cocktail protease inhibitor. Subcellular fractionation protocol 
was from Abcam developed by Dr. Richard Patten of Molecular Cardiology Research 
Centre, Boston. Protein content was determined using Bradford assay (Pierce).  Total 
protein of between 25 μg and 70 µg were resolved on 8-12% SDS-PAGE gel before 
transferring on PVDF membrane (Millipore) and detection using ECL reagents 
(Pierce).  
2.2.2 Calcein-Am Quenching Assay 
Calcein acetoxymethylester (calcein-AM; 4 mM stock solution in DMSO) was 
obtained from Sigma Aldrich. The use of calcein-AM to measure the transport and 
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accumulation of divalent metals has previously been described (Picard, Govoni et al. 
2000). Briefly, cells were grown in 24-well plate up to 70% confluency before 
treatment with either MnCl2 or FeCl2 for 30 min. The cells were rinsed with PBS and 
incubated with calcein-AM at a final concentration of 0.25 µM in DMEM for 20 min 
at 37 °C, 5% CO2.  The cells were rinse in PBS twice and lysed in RIPA buffer 
containing 1% Triton-X 100 (v/v) for 5 min. The lysates were centrifuged at 13500 
rpm at 20 °C. 100 µL of the supernatant was transferred to a 96-well flat-bottom plate 
for fluorescence analysis at 488/518 nm (Tecan Infinite 200 PRO multimode reader). 
The fluorescence of the lysates was normalized to protein concentration determined 
using BCA method (Thermo Scientific). 
2.2.3 MTT Cell Viability Assay 
Cell viability was determined using MTT Cell Proliferation Kit (Roche) as per 
manufacturer’s instruction. Cells were seeded in 96-well plate to reach a confluency 
of 70%. The cells were then treated with MnCl2 or FeCl2 or with other chemical 
inhibitors for 24 hr before analysis using MTT. The absorbance was read at 590 nm 
and reference at 690 nm using a 96-well plate reader (Tecan Infinite 200 PRO 
multimode reader).  
2.2.4 RNA Extraction and RT-PCR 
Total RNA was isolated using TRIzol® reagent and reverse transcribed using 
Superscript III (Invitrogen). The isolation of RNA and reverse transcription were 
performed according to manufacturer’s instructions. Standard PCR was performed 
and GAPDH was used as loading control. Primer sequences for FTH1, IRP1 and IRP2 
are as follow: FTH1 (F) TGC GCC AGA ACT ACC ACC AG, (R) GAG ATA TTC 
CGC CAA GCC AGA TTC; IRP1 (F) GCT GAG CGG TAC CAG CAG GC, (R) 
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AGC ACC CCT CCC AGA GGC AG; IRP2 (F) AGG TAC TGA CCC CAC CGG 
CA, (R) GAG ATA TTC CGC CAA GCC AGA TTC.  
2.2.5 Immunocytochemistry and Confocal Microscopy for Lysosomal and LC3 
Puncta Staining 
Lysotracker Red DND-99 is a red-fluorescent dye which stains for acidic organelles 
was obtained from Invitrogen. A working concentration of 0.1 µM was diluted in 
DMEM from a stock of 1 mM in DMSO. Cells on coverslips were incubated with 
lysotracker in DMEM for 30 min at 5% CO2 atmosphere at 37 °C. The cells were then 
rinsed once with PBS and fixed with 2.5% PFA (w/v) for 4 hr before viewing under 
the confocal microscope. The tf-LC3 plasmid was previously described in our work 
(Chew, Ang et al.). Transfection of tf-LC3 was performed using Lipofectamine 2000 
(Invitrogen) on SH-SY5Y cells seeded in 3.5 cm plate. Post 24 hr transfection, the 
cells were trypsinized and seeded onto coverslips. After 24 hr, the cells were treated 
with various metals and chemical inhibitors for 6 hr before fixation with 2.5% PFA 
and viewing under the confocal microscope. 
2.2.6 Intracellular ROS and Flow Cytometry 
Intracellular ROS was measured using H2DCFDA (Invitrogen) by flow cytometry. 
Briefly, confluent cells (70%) were grown in 6 cm dish. After treatment, the cells 
were trypsinized and incubated in DMEM containing H2DCFDA (10 µM) for 15 min 
at 37 °C, 5% CO2. The cells were then centrifuged down and resuspended in PBS 
containing 50 mM EDTA. The cells were subjected to flow analysis at 488 nm 
excitation and 585 nm emission wavelength using FACS Calibur System (BD 
Sciences, USA). 20,000 cells per experiment were used for analysis.  
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2.2.7 Densitometric and Statistical Analysis 
Western blotting and RT-PCR band intensities were analyzed using densitometric 
analysis tool from Quantity One (Biorad). The intensities of the specified bands were 
normalized in relative to β-actin or GAPDH loading control. Data were expressed as 
standard error of mean (S.E.M) of at least three experiments. Statistical analysis was 
performed using Microsoft Office Excel Student’s t-test (two-tailed distribution with 
non-equal variance) and statistical significance was considered when p<0.05.  
2.2.8 Tail Digestion, DNA Purification and PCR 
The genotype of the transgenic mice was determined using clipped tail of day 21 
weanlings. The tails were digested in digestion buffer containing 0.1 M NaCl, 50 mM 
Tris-HCl (pH 7.6), 1 mM EDTA, 0.5% SDS (w/v) and 0.2 mg/ml Proteinase K. 
Briefly, the tails were digested in digestion buffer for overnight at 55 °C. 1 M NaCl 
was added to the digestion mix and centrifuged at 13500 rpm for 15 min at 4°C. 
Isopropanol was added in 1:1 ratio to the supernatant and centrifuged again. 70% 
alcohol was added to the pellet and centrifuged for 15 min before reconstituting the 
DNA in ultrapure water for standard genotyping PCR. Primers used were: PrP Exon 2 
(F) CCA TTT CAA CCG AGC TGA AGC ATT CTG CCT, DMT1B (F) CCC TTT 
GCC CTC ATA CCC ATC CTC AC, and PrP Exon 3 (R) GTG GAT ACC CCC 
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2.2.9 Brain Digestion and Western Blot 
Mouse brains were harvested and protein lysates were prepared using 1% SDS (w/v) 
lysis buffer in PBS. Cocktail protease inhibitor (Roche) was added fresh before use. 
Brain lysates were homogenized using a handheld Teflon glass homogeniser for 15 
strokes on ice. Thereafter, the lysates were sonicated for a continuous 15 sec at 40 
amps. The lysates were then rotated for 15 min before centrifugation at 13500 rpm for 
15 min at 4 °C. The supernatants were collected and protein concentration determined 
using Bradford assay. Protein concentrations of between 55 μg and 100 μg were 
revolved using 10-15% SDS polyacrylamide gel.   
2.2.10 T2-Weighted Magnetic Resonance Imaging (MRI) 
Two-dimensional T2-weighted images were performed in collaboration with 
Singapore BioImaging Consortium (SBIC), A*STAR, Singapore. Briefly, mice were 
anaesthetized with ketamine/xylazine (10 mg/kg) and transcardially perfused with 
saline (0.9% NaCl, w/v) and thereafter with 4% PFA (w/v). The brains were 
harvested and embedded in 1% agarose.  
The T2-weighted multislice fast spin echo 3D was performed with the following 
parameters: Resolution - 100 µM (isotropic) ; matrix size – 256 x 192 x 192; RO x 
PE1 x PE2 - 25.6 mm x 19.2 mm x 19.2 mm; TR – 2000 ms; ETL – 8.00; ESP – 9.79 
ms; Effective TE – 39.15 ms; Signal Averages – 1.  
2.2.11 Proton-Induced X-ray Emission (PIXE) and Nuclear Magnetic Resonance  
PIXE was performed in collaboration with Department of Physics, NUS. Briefly, 
brain sections were sectioned with thickness of 200 μM using a vibratome and freeze-
dried. Then, the substantia nigra was scanned using the nuclear microscope operating 
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a 2-MeV proton beam. The particle induced X-ray emission (PIXE) and Rutherford 
backscattering (RBS) were simultaneously employed in the analysis, as described 
earlier (Ren, Ong et al. 2003). PIXE was used for multi-elemental analysis in the 
samples expressed in parts per million (ppm). RBS was used to determine the matrix 
composition, thickness and density for the normalization of elemental concentrations.  
2.2.12 Prussian Perls Iron Staining 
Fixed brain tissue sections containing the SN were immersed into Perls solution 
containing 2% HCl (v/v) and 2% potassium ferrocyanide (w/v) in 1:1 ratio for 30 min 
at room temperature. Sections were washed 3 times in distilled water before 
counterstaining with Nuclear Fast Red solution (Sigma) for 5 min. The counterstain 
was rinsed off twice using distilled water before the mounting process. The sections 
were dehydrated in 75%, 90% and 100% gradient alcohol before 2 changes of xylene, 
3 min each step. The sections were finally mounted using DPX mounting medium and 
viewed under light microscope.   
2.2.13 Immunohistochemistry and Immunofluorescence of Brain Sections 
Anaesthetized mice were perfused with saline followed by 4% PFA (w/v). The brains 
were removed and post-fixed for another 24 hr before putting them into 
cryoprotectant containing 15% sucrose (w/v) in PBS for 24 hr followed by 30% 
sucrose for another 24 hr. Brains were sectioned coronally at 20 µm thick and 
mounted onto adhesive-coated histology grade slides (Marienfeld, Germany). The 
sections were dried before short-term storage in -80 °C. Before staining, the slides 
were rehydrated using blocking buffer containing 0.5% BSA (w/v) and 0.5% FBS 
(v/v) in PBS with added 0.1% Tween-20 (v/v). Primary and secondary antibodies 
were diluted in blocking buffer. Primary antibody incubations (dilutions of between 
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1:200 and 1:400) were done overnight at 4 °C. Secondary antibodies (dilution of 
1:400) were incubated for 30 min at room temperature. Sections were washed after 
primary and secondary antibodies for 3 times, 3 min each using TNT Wash Buffer 
containing 0.1 M Tris-HCl (pH7.5), 0.15 M NaCl and 0.05% Tween-20 (v/v). For 
immunohistochemitry, the antibody signal was further amplified using VectorElite 
ABC Kit (Vector Laboratories) for 30 min and washed thrice with TNT buffer and 
developed using DAB (Vector), 2 min. Amplification and DAB staining protocol as 
per manufacturer’s instruction was performed. The sections were dehydrated under 
gradient alcohol (75%, 90% and 100%) and subsequently 2 changes of xylene, 3 min 
each. Finally, the stained sections were mounted using DPX mounting medium. For 
immunofluorescence, Alexafluor (594 and 488) fluorophore-containing secondary 
antibodies (dilutions of 1:400) were incubated for one hour in the dark before 
mounting them with coverslip using FluorSave Reagent (Calbiochem). Peroxidase 
immunohistochemical slides were viewed using Olympus Microscope while 
immunofluorescence slides were viewed using confocal microscope (Olympus).  
2.2.14 Rotarod Test 
The rotarod was used to assess motor coordination and balance as recommended 
(Carter, Morton et al. 2001). Mice were tested using a 240 sec accelerating protocol. 
Briefly, mice were acclimatized to the procedural room for 30 min. Before the start of 
the test, mice were made to move at 4 rpm for a brief 30 sec to inform the mice of the 
motor task as well as to stabilize the mice on the rotating beam. Thereafter, the 
rotation was ramped up from 4 rpm to 40 rpm in 240 sec. The latency to fall in sec 
was noted for each mouse. Each mouse was given 3 trials with at least 15 min rest in 
between trials. The average of 3 trials was taken for the analysis.  
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2.2.15 Fe55 Uptake Assay 
55Fe uptake assays were performed as previously described (Chew, Ang et al. 2011). 
Briefly, cells were incubated with serum-free DMEM for 1 hr to deplete cells of 
transferrin. Cells were then washed with PBS followed by washing buffer containing 
50 mM Tris-HCl (pH 5.5), 25 mM MES, 140 mM NaCl, 5.4 mM KCl, 5 mM D-
glucose, 1.8 mM  CaCl2, 800 µM MgSO4. Next, cells were incubated in incubation 
buffer containing 1 µM 55FeCl3 (Perkin Elmer Life Science, Wellesley, MA, USA) 
conjugated with nitriloacetic acid (NTA) in a 1 to 20 molar ratio and 50 µM ascorbic 
acid for 30 min at 37 °C. Cells were then washed with ice-cold washing buffer and 
followed by PBS. Cells were then trypsinized and collected by centrifugation before 
solubilised with scintillation cocktail (Perkin Elmer Life Science). Iron uptake was 
assessed using Beckman LS6000 scintillation counter. An aliquot of the resuspended 
cells were used for protein determination using Bradford method.  
2.2.16 Biotin-Switch Assay 
Cells were grown in 10 cm plate to 80% confluency before subjected to lysis using 
HEN buffer containing 250 mM HEPES-NaOH (pH 7.7), 1 mM EDTA and 0.1 mM 
neocuproine. Cells were mechanically sheered using a 21G needle and syringed for 10 
strokes. The lysates were centrifuged at 13500 rpm for 5 min at 4 °C. Protein 
concentration was determined using Bradford assay. A total of 500 μg protein was 
used for the assay. 200 μM of NOC18 was added to the lysates and rotated for 1 hr in 
the dark at room temperature. 200 μM of GSH was also used as a control. Four times 
volume of blocking buffer containing HEN buffer and 20 mM MMTS was added to 
the lysates. The blocking was done at 50°C for 20 min with intermittent vortexing. 
Protein precipitation was performed to remove MMTS by adding 2.5 times volume of 
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iced-cold acetone and left at -20 °C for 20 min before centrifuging at 830 g for 5 min 
in a spin-bucket centrifuge. The pellet was washed using 70% acetone at room 
temperature and centrifuged down again. This was repeated twice before the addition 
of resuspension buffer containing HEN buffer, 1% Triton-X 100 (v/v) and protease 
inhibitor. 20 mM sodium ascorbate and 0.8 mM biotin-HPDP was further added to the 
lysates and rotated for 1 hr in the dark at 37 °C. Proteins were precipitated using iced-
cold acetone for 20 min at -20 °C. Wash was repeated twice using 70% acetone 
before final resuspension in HENS buffer containing HEN buffer and 1% SDS (w/v). 
Neutralization buffer containing 20 mM HEPES-NaOH pH 7.7, 100 mM NaCl, 1 mM 
EDTA and 0.5% Triton-X 100 (v/v) was added together with avidin beads. The 
lysates were rotated overnight at 4 °C. Washes were done using neutralization buffer 
6 times with 200 g centrifugation for 30 sec. Proteins were eluted using elution buffer 
containing HEN buffer and 100 mM β-mercapthaethanol at 37 °C for 25 min. Finally, 
loading buffer was added and lysates were boiled for 5 min before loading into 
polyacrylamide gel. Blocking of PVDF membranes was done using 1% BSA (w/v) in 








Epidemiological studies over the past several decades have greatly                                                                                                      
garnered awareness and improved understanding of the health risk associated with the 
exposure to manganese. As mentioned in the Introductory Chapter 1, DMT1 was 
originally discovered for the uptake of Fe2+ via the transferrin dependent and 
independent pathways. Presently, the DMT1 was also found to transport other 
divalent metal ions with different affinities. As DMT1 is ubiquitously expressed as an 
iron-regulatory glycoprotein, DMT1 may facilitate the transport of Mn2+ during times 
of Mn2+ overexposure. This is highly relevant to workers in the welding and steel 
mining industries as they are regularly exposed to high airborne manganese levels. In 
addition, the use of methylcyclopentadienyl manganese tricarbonyl (MMT) as an 
antiknock additive in gasolines may be a potential public health concern.  While the 
direct accumulation of manganese in the brain of manganism patients is certain, 
however, the status of iron in the specific brain regions remains unknown. 
Nevertheless, there are evidence to associate systemic iron imbalance in manganese 
intoxicated humans, suggesting a delicate physiological interaction between iron and 
manganese (Boojar, Goodarzi et al. 2002, Ellingsen, Haug et al. 2003, Li, Zhang et al. 
2004).  
Since Fe2+ and Mn2+ compete for entry via DMT1, disruption in cellular iron 
homeostasis during Mn2+ toxicity may be another pathway for cell death. As iron is 
essential for many biological functions, iron depletion has been shown to result in 




al. 1998, Jiang, Wang et al. 2002, Sun, Ge et al. 2009). More importantly, recently it 
was demonstrated that iron depletion using iron chelator, desferroxamine resulted in 
MAP kinase pathway activation, in particular JNK and p38 pathways. As the MAP 
kinase pathway is conventionally known to be activated by heavy metals and ROS, 
the activation of JNK and p38 due to iron depletion is paradoxical. As JNK activation 
is primarily associated with apoptotic cell death, its activation may explain iron 
depletion-mediated apoptotic cell death. 
Hence, using a cellular as well as a mouse model overexpressing DMT1, the present 
study is aimed to further clarify the role of DMT1 and closely examine cellular iron 
homeostatic imbalance mediated by Mn2+ toxicity. Here, the toxic effect of Mn2+ was 
established to occur primarily via JNK activation in SH-SY5Y cells overexpressing 
DMT1. The effect of Mn2+ on iron homeostasis was investigated in a more 
physiological condition by observing the levels of ferritin, an important cellular iron-
storage protein upon Mn2+ exposure. We found that ferritin was significantly 
degraded in the presence of Mn2+ with enhanced autophagy activation.  
While we previously reported that DMT1 co-expression with mutant α-synuclein 
promoted autophagic cell death during Fe2+ toxicity (Chew, Ang et al. 2011), in my 
current work, we found that Mn2+  toxicity does not involve autophagic cell death. On 
the contrary, upon Mn2+ treatment, autophagic activation and lysosomal degradation 
of ferritin were observed to be essential for the maintenance of iron homeostasis 
through iron extraction from ferritin. In addition, cells treated with lysosomal 
inhibitor exhibited enhanced JNK activation and reduction in cell viability in the 
presence of Mn2+. Interestingly, by overexpressing thioredoxin, which is an inhibitor 
of ASK1-JNK upstream kinase, Mn2+-mediated JNK activation was suppressed, 




together, part one of my thesis demonstrates a cellular model of iron homeostatic 
imbalance mediated by Mn2+ toxicity, which redefines the mechanism underlying 
Mn2+  toxicity.   
In part two, I attempted to characterize a novel transgenic mouse overexpressing 
DMT1 as a model for iron and manganese accumulation. The DMT1B/-IRE splice 
variant was chosen and was sub-cloned into an expression vector downstream of the 
mouse prion promoter. DMT1B/-IRE was found to be extensively expressed in the 
brain of the transgenic mouse. In addition, the transgenic mice also showed 
substantial accumulation of iron specifically in the substantia nigra using several 
methods of iron detection. While these mice did not exhibit overt motor deficits or TH 
neuron loss, nonetheless there were signs of neuroinflammation characterized by 
microglia activation and iNOS expression. The iNOS-derived NO also increased 
nitration reactivity, suggesting nitrosative stress. And, in part three, in the effort to 
further understand the role of NO, we question whether NO could modulate DMT1 
function. Indeed, we found that NO could augment the function of DMT1 by 
increasing the influx of Fe2+. Importantly, we found that DMT1 could be S-
nitrosylated in-vitro by using a long-lived NO donor and by performing the S-
nitrosylation biotin-switch assay. Hence, part two and part three of this thesis 
confirms the role of DMT1 in mediating Fe2+ uptake. In addition, the increase in 
iNOS-derived NO from microglia cells activation and S-nitrosylation of DMT1 
maybe a possible mechanism underlying selective uptake and accumulation of iron in 
vulnerable regions such as the substantia nigra.   




3.2 Enhanced JNK Activation and Cellular Iron Depletion Mediated by Mn2+ 
Toxicity via DMT1 
The figure below shows the systematic investigation into the interplay between Mn2+ 
(red lines) and Fe2+ (green lines) on cellular events. The black lines indicate the 
possible interactions among cellular events in Mn2+ toxicity. The results are presented 
in subsequent headings in this chapter.  
 
1. The cellular uptake and 
accumulation of Fe2+ and Mn2+  
2. The effect of Fe2+ and Mn2+ on 
JNK pathway 
3. The effect of Mn2+ on 
autophagy 
4. The effect of Mn2+ on iron-
storage protein ferritin    
5. The interplay between Mn2+-
mediated autophagy and 
ferritin protein expression 
6. The interplay between Mn2+-
mediated JNK activation and 
ferritin protein expression 
7. The interplay between Mn2+-
mediated JNK activation and 
autophagy stimulation 
8. The redox status of Mn2+-
treated cells 
9. The effect of lysosomal 
inhibition on Mn2+-mediated 
JNK activation  
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3.2.1 Expression of DMT1 and Fe2+ uptake in DMT1 overexpressing cells  
 
FIGURE 3.1. Expression of DMT1 and Fe2+ uptake. (A) Expression of stable vector (SGFP) and 
DMT1 (S-DMT1) transfected SH-SY5Y cells (20X objective). (B) Western analysis of DMT1B 
expression using Triton-X lysis with upper band above 250 kDa (glycosylated species of DMT1B) and 
a lower 90 kDa band using DMT1B monoclonal antibody (GFP = 25 kDa; DMT1 = 65 kDa). The 
lower band shows endogenous DMT1B. Actin is used as a loading control. (C) Fe2+ uptake assay 
performed using Fe55 radioisotope. S-DMT1 cells were treated with Fe55 for 30 min at pH 5.5 and 
quantified using scintillation counter showed robust uptake of Fe55 up to 350-fold as compared to 
control cells. Data shown are representative of at least three independent experiments. Error bars 
represent standard error of mean (S.E.) with *, p<0.05.  
 
The DMT1B isoform without iron response element (DMT1B/-IRE) of the Macaca 
fascicularis (GenBank: AF153279.1) was previously cloned into pEGFP-N3 
expression vector. The sequence was verified using DNA sequencing and western 
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analysis. The DMT1B/-IRE gene will be written in short as DMT1 throughout the 
thesis.  
As an initial characterization of the DMT1 overexpressing stable SH-SY5Y cell line 
(S-DMT1) established using selective antibiotic geneticin (G418), the growing cells 
were viewed under fluorescence microscope. Punctated green fluorescence was 
observed in the GFP-DMT1 overexpressing cells, while the GFP-expressing cells 
showed diffuse cytoplasmic GFP protein expression (Figure 3.1A). Using a 
monoclonal antibody against DMT1B, the expression of the fusion GFP-DMT1 
protein was confirmed by western analysis with a size of approximately 90 kDa, 
corresponding to the size of DMT1 protein at 65 kDa and GFP protein at 25 kDa 
(Figure 3.1B). In order to determine the ability of the transfected DMT1 to transport 
iron, Fe2+ uptake assay was performed by my colleague using radioisotope iron, Fe55. 
Fe55 was found to be increased significantly by 350-fold in the S-DMT1 as compared 
to control cells.  
The DMT1B/-IRE is known to localize to the plasma membrane and internalized to 
form early endosomes, late endosomes and acidic lysosomes (Lam-Yuk-Tseung, 
Touret et al. 2005). To verify that our neuronal cells overexpressing GFP-DMT1 
similarly exhibited such cellular localization, we determined the localization of the 
protein using fluorescence imaging studies. The S-DMT1 cells were stained with 
lysotracker red, a lysosomal marker, and viewed under confocal microscopy without 
any membrane permeabilization. GFP-DMT1 expression was observed to overlay 
with lysotracker red, confirming the expression of a fraction of GFP-DMT1 on 
lysosomal membrane (Figure 3.2A). As lysotracker red is known to only stain for 
intracellular acidic vesicles, the remaining puncta are likely to be early and recycling 
endosomes. In addition, GFP-DMT1 was also found on the peripheral outline of the 
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cells, indicating its localization to the plasma membrane. Taken together, the 
expression and localization of GFP-DMT1 to the plasma membrane allows the intake 
of divalent metals from the extracellular media into the cell. In addition, other cellular 
studies on transfected DMT1 into two non-neuronal cells such as Hep2 and CHO 
cells, also confirmed DMT1 plasma membrane and lysosomal localization (Picard, 
Govoni et al. 2000, Tabuchi, Yoshimori et al. 2000). These results clearly suggest that 
our DMT1 overexpression in the dopaminergic neuronal-like cell line was a feasible 
model for Fe2+ and Mn2+ toxicity study. Data from Figure 3.1C has been published in 
Journal of Biological Chemistry (Chew, Ang et al. 2011).  
 
FIGURE 3.2. Expression of exogenous GFP-DMT1 localized to the plasma and acidic lysosomal 
membrane. A. S-DMT1 cells treated with lysotracker red (acidic lysosomal marker) for 20 min and 
fixed onto viewing microscope slide without any membrane permeabilization. Cells were viewed using 
confocal microscope. S-DMT1 cells with the GFP-DMT1 fusion protein were observed on the plasma 
membrane with typical peripheral membrane localization. In addition, GFP-DMT1 also showed co-
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3.2.2 DMT1-mediated Fe2+ and Mn2+ uptake, cytoplasmic accumulation and 
reduction in cell viability 
S-DMT1 cells have previously been shown in our work to mediate robust transport of 
Fe2+ into the cell as compared to vector-transfected cells using Fe55 uptake assay 
(Chew, Ang et al.). As Fe55 uptake assay measures the absolute cellular accumulation 
of Fe55, the distinction between labile and non-labile Fe55 in the cytoplasm and 
subcellular compartments could not be distinguished. Here, the determination of 
cytoplasmic accumulation of Fe2+ and Mn2+ was essential to investigate the interplay 
of labile Mn2+ on labile Fe2+ pool via DMT1. Labile Fe2+ is a pool of transitory iron 
usually bound to cytoplasmic ligands for immediate use by iron-requiring metabolic 
processes. This Fe2+ pool is often referred to as the chelatable labile Fe2+ pool. 
Therefore, to determine the specific accumulation of labile Fe2+ and Mn2+ in the 
cytoplasm, cell-permeant calcein-AM was used as an indicator of cytoplasmic Fe2+ 
and Mn2+ accumulation. Calcein-AM has been shown to permeate the plasma 
membrane and is not known to enter into subcellular organelles (Tenopoulou, Kurz et 
al. 2007). In the cytoplasm, calcein-AM is readily processed through hydrolysis by 
unspecific esterases into detectable green calcein fluorescence (Picard, Govoni et al. 
2000). The fluorescing calcein is easily quenched by chelatable cytoplasmic Fe2+ and 
Mn2+. Thus, based on the understanding of the specific retention of fluorescing 
calcein in the cytoplasm, the percentage of calcein quenching exclusively in the 
cytoplasm in the presence of increasing concentrations of Mn2+ and Fe2+ could be 
determined in this study.  
For all the experiments performed throughout the study, both iron chloride (FeCl2) 
and manganese chloride (MnCl2) were both dissolved in 0.1 M hydrochloric acid 
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(HCl) and were made fresh daily to ensure that the metal ions remained in their ionic 
state upon addition to the culture medium of the cells.  
 
FIGURE 3.3. Cytoplasmic accumulation of labile Mn2+. The accumulations of 
Fe2+ and Mn2+ ions were assayed using calcein-AM, a cell-membrane permeant dye 
which is exclusively quenched by cytoplasmic labile Fe2+ and Mn2+. Cells were 
treated with either Fe2+ or Mn2+ for 30 min at pH 7.4 and thereafter with calcein-AM 
for 20 min. Fluorescence was detected at excitation/emission of 488/517 nm. (A) An 
average quenching of calcein of 26.5% was observed with S-DMT1 cells treated with 
Fe2+ albeit with increasing concentrations of Fe2+. There was no observable 
quenching of calcein even with higher concentrations of Fe2+ up to 1 mM, suggesting 
inherent protective effect of S-DMT1 cells to scavenge iron. (B) Mn2+-treated S-
DMT1 cells showed observable increase in calcein quenching with increasing 
concentrations of Mn2+, suggesting accumulation of cytoplasmic Mn2+ in S-DMT1 
cells. All data shown are representative of four independent experiments performed 
in triplicates. Error bars represent standard error of mean (S.E.) with *, p<0.05.  
Cellular Iron Depletion Mediated by Mn2+ Toxicity 
76 
 
The cytoplasmic accumulation of Fe2+ in S-DMT1 cells was determined using 
calcein-AM by first treating the cells with Fe2+ from a low dose of 62.5 µM to 1.0 
mM for 30 min in an incubation buffer of pH 7.4. The experiment was not performed 
at longer Fe2+ incubation periods (even up to 24 hr) due to the possible reduction in 
cell proliferation and number, which may interfere with the calcein-AM study. 
Interestingly, the Fe2+-treated cells exhibited a consistent calcein quenching with an 
average of 26.5±5.9% loss in signal, across all the different concentrations (Figure 
3.3A). This observation was in contrary to our initial prediction that Fe2+ treatment on 
DMT1-overexpressing cells with increasing concentrations would similarly increase 
cytoplasmic labile Fe2+ pool. To further validate this observation, we set to study 
whether Mn2+ would also display such consistent accumulation given the increasing 
concentration of the metal ion in the extracellular medium. 
Upon treatment of S-DMT1 cells with Mn2+ ranging from 62.5 µM to 1.0 mM, the 
cells indeed exhibited a robust cytoplasmic accumulation of Mn2+ in a concentration 
dependent manner (Figure 3.3B). By comparing the calcein quenching status of Fe2+ 
and Mn2+ as shown in Figure 3.3, we deciphered that Fe2+ could be readily re-
compartmentalized from the cytoplasm, or it could be scavenged by iron-storage 
proteins and was beyond reach by calcein. While the cytoplasmic accumulation of 
Fe2+ was insignificant, the robust accumulation of Mn2+ may be detrimental to cells.  
Therefore, to clarify the consequence of such accumulation of Fe2+ and Mn2+ on the 
cells, experiments examining cell viability were carried out following treatment with 
Fe2+ and Mn2+ in increasing concentrations for 24 hr. As shown in Figure 3.4A, SGFP 
and S-DMT1 cells both showed a similar concentration-dependent reduction in cell 
viability, suggesting that Fe2+-treated S-DMT1 cells were no more vulnerable to Fe2+ 
overload and toxicity.  
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In Figure 3.4B, cell viability was also determined following Mn2+ treatment for 24 hr 
and was found to be more sensitive towards Mn2+ toxicity as compared to SGFP cells. 
Indeed, this supports the role of DMT1 for Mn2+ transport. Nonetheless, the 
vulnerability of SGFP cells to Mn2+ could be explained by the presence of other 
plasma membrane bound transporters which are permissive towards Mn2+ (Au, 
Benedetto et al. 2008). These transporters include zinc transporters, ZIP-8 and ZIP-14 
(Fujishiro, Yano et al. , Frigerio, Mela et al. 1984) and ionotropic NMDA glutamate 
receptor (Kannurpatti, Joshi et al. 2000). 
In addition, by comparing the viability of cells between S-DMT1 treated with Fe2+ 
and Mn2+, S-DMT1 cells were shown to be more resistant towards Fe2+-mediated 
toxicity as compared to Mn2+, with LC50 of Fe2+ and Mn2+ approximately 2000 µM 
and 250 µM, respectively (Figure 3.4C). Furthermore, cells treated with Fe2+ between 
concentrations of 0.0625 µM and 1 mM displayed resistance towards Fe2+-mediated 
cell viability reduction, correlating well with the uptake and resisted accumulation of 
cytoplasmic labile Fe2+, measured using calcein-AM (Figure 3.3A).   
Increase in labile iron in the Fe2+ form is known to mediate the formation of ROS as 
Fe2+ catalyses the generation of ·OH from H2O2 via the Fenton chemistry. The 
homeostatic balance of cellular labile Fe2+ pool (LIP) is tightly regulated within the 
cell by ferritin (Wang and Pantopoulos 2011). Ferritin is a Fe3+ storage protein which 
is made up of ferritin heavy chain (FTH1) and ferritin light chain (FTL1), dimerized 
at different ratios depending on cell type (Rosenstock, Simons et al. 1971). Since 
ferritin heavy chain is predominantly expressed in neurons, we sought to examine the 
levels of ferritin heavy chain, henceforth called ferritin throughout the thesis. 
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To address the mechanism of protection against Fe2+ cytotoxicity in our cellular 
model, we determined the upregulation of ferritin in S-DMT1 cells exposed to Fe2+. 
S-DMT1 cells treated with Fe2+ for 24 hr upregulated the expression of ferritin in a 
concentration-dependent manner as shown in Figure 3.4D. As ferritin heavy chain 
contains ferroxidase activity which mediates the oxidation of reactive Fe2+ into the 
non-reactive Fe3+, the upregulation of ferritin heavy chain will reduce the expansion 
of LIP and ROS production (Zhang, Tian et al. 2009). On the contrary, the quenching 
of calcein by Mn2+ suggests that Mn2+ is not preferentially sequestered by any storage 
protein and mediates cytotoxic effect through its cytosolic accumulation. In addition, 
Mn2+ treatment is not known to induce ferritin upregulation.  
Taken together, my data clearly suggest that DMT1-overexpression facilitated the 
entry of both Fe2+ and Mn2+. The entry of Fe2+ resulted in it being sequestered by iron-
storage protein, ferritin while Mn2+ accumulated in the cytoplasm. The cytoplasmic 
accumulation of Mn2+ resulted in the reduction of cell viability of S-DMT1 cells.  
Fe3+ bound to ferritin does not quench calcein. Hence, the scavenging of Fe3+ by 
ferritin explained the lack of cytoplasmic Fe2+ despite the increasing concentrations of 
it. In addition, the upregulation of ferritin also explained the resistance of S-DMT1 
cells towards DMT1-mediated Fe2+ influx and toxicity. In our previous published data 
with S-DMT1 cells treated with Fe2+, we similarly showed that the cells were resistant 
to Fe2+ toxicity and only displayed reduction in cell viability at concentrations beyond 








FIGURE 3.4. Loss of cell viability in S-DMT1 cells treated with Mn2+, but Fe2+-treated cells 
showed resistance. Cells were treated either with Fe2+ or Mn2+ for 24 hr and viability was quantified 
using commercially available MTT assay. In addition, protein lysates from Fe2+-treated cells were also 
analyzed for ferritin iron-storage protein (FTH1). (A) Increasing concentrations of Fe2+ on S-DMT1 
cells did not show any drastic dose-dependent loss in cell viability, not until 1.0 mM was reached. 
While there was an initial reduction in cell viability (20%) to cells treated with 0.0625 mM of Fe2+, the 
cells were able to maintain its viability at 80% up to 0.5 mM before showing signs of gradual reduction 
in viability. (B) Unlike Fe2+ treatment, Mn2+-treated S-DMT1 cells showed significant cell viability 
loss as compared to SGFP vector cells with increasing concentrations of Mn2+ from 0.25 mM to 2.0 
mM. (C) Comparison between concentration-dependent effect of Fe2+ and Mn2+ on the viability of S-
DMT1 cells. (D) FTH1 was observed to be upregulated in cells treated with Fe2+, suggesting protective 
role of ferritin against Fe2+ accumulation and Fe2+-mediated cytotoxicity. All cell viability data are 
representative of at least three independent experiments performed in triplicates. Error bars represent 
standard error of mean (S.E.) with *, p<0.05.  
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3.2.3 Effect of Mn2+ and Fe2+ on MAP kinase pathway   
The mitogen-activated protein kinase pathway (MAP kinase) plays an important role 
in the regulation of cell proliferation, differentiation, survival and apoptosis (Wang, 
Wang et al. 2008). The MAP kinase pathway (c-Jun-N-terminal kinase, p38 and 
ERK) is known to be responsive to many heavy metals such as cadmium, mercury 
and arsenic examined in cell lines as well as in the lower organism Caenorhabditis 
elegans (Villanueva, Lozano et al. 2001, Goussetis, Altman et al. 2010, Rai, Maurya 
et al. 2010, Son, Lee et al. 2010). While ERK phosphorylation is primarily associated 
with cell proliferation and cell survival, JNK and p38 are closely associated with 
processes leading to inflammation and apoptosis (Kim, Ryu et al. 2006, Lennartsson, 
Burovic et al. 2010, Wijesekara, Krishnamurthy et al. 2010). Even as Mn2+ has been 
shown to activate the MAP kinase pathway in several studies, however the 
mechanism underlying the activation of the MAP kinase pathway is not well 
understood (Hirata, Adachi et al. 1998, Hirata, Adachi et al. 1998). Furthermore, it 
also been suggested that the activation of the MAP kinase pathway may be triggered 
differentially by different divalent metal ions. In addition, investigation into the effect 
of Fe2+ on the MAP kinase pathway is still lacking. Therefore, to further clarify the 
mechanism by which toxicity is mediated by Mn2+ and Fe2+, the MAP kinase pathway 
was investigated in our cellular model. I examined the activation of ERK, p38 and 
JNK in Mn2+ and Fe2+-treated cells.  
Upon Mn2+ treatment (0.5 mM), our initial investigation showed that phosphorylated 
JNK (54 kDa and 46 kDa) was persistently phosphorylated up to 24 hr as compared to 
phosphorylated ERK and phosphorylated p38. As shown in Figure 3.5A, JNK 
phosphorylation occurred as early as 1 hr and continued to increase up to 6 hr and 24 
hr, with non-phosphorylated JNK not significantly altered. In contrast to JNK 
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phosphorylation, even as there was an increase in phosphorylated ERK at 1 hr and 6 
hr, it returned to almost basal levels at 24 hr with no change to non-phosphorylated 
ERK levels. Nonetheless, the increase in phosphorylated ERK was expected as Mn2+ 
has been found to be a potent neuronal differentiation agent, similar to NGF which 
was previously reported in PC12 cells (Lee, Guo et al. 2006). In addition, in this study 
we also did not observe any significant phosphorylated p38 with Mn2+ treatment 
either at 1 hr, 6 hr or 24 hr while non-phosphorylated p38 remained unaltered. Hence, 
these results suggest the importance of JNK signalling pathway in Mn2+-mediated 
toxicity.  
Unlike Mn2+, upon Fe2+ treatment (0.5 mM) on S-DMT1 cells, the MAP kinase 
pathway was suppressed; in particular phosphorylated ERK and phosphorylated p38 
were reduced at 1 hr and 6 hr. While JNK phosphorylation was not affected at 1 hr, 6 
hr or 24 hr, at 24 hr both ERK and p38 phosphorylation were continually suppressed 
and lower than basal phosphorylation levels, without any significant change in non-
phosphorylated proteins. These results likely suggest that the reduction in 
phosphorylated p38, ERK, and possibly JNK in response to Fe2+ treatment were 
protective responses against Fe2+ toxicity.  This is in agreement with our cell viability 
data shown in Figure 3.4A, whereby S-DMT1 cells treated with Fe2+ in the given 
range of concentrations resisted loss in cell viability examined at 24 hr. While it is 
generally accepted that phosphorylation of ERK is responsible for cell differentiation, 
proliferation and survival, the reduction in the phosphorylated ERK with Fe2+ 
treatment in my study is not readily explainable, which indeed requires further 
investigation.  
Furthermore, we also revealed an interesting observation with regards to Fe2+ (0.5 
mM) and Mn2+ (0.5 mM) co-treatment. As observed in Figure 3.5A, co-treatment 
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with equal molar concentration of Fe2+ and Mn2+ on S-DMT1 cells dampened 
phosphorylated JNK in the 6 hr treatment, as compared to Mn2+ treatment alone.  
This observation led us to believe the likely interplay between Fe2+ and Mn2+ at the 
cellular entry as well as intracellular signalling transduction pathway, which were 
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FIGURE 3.5. JNK MAP kinase activation in Mn2+-treated S-DMT1 cells. Activation MAP kinase 
pathways (JNK, p38 and ERK) were analyzed on Mn2+ (0.5 mM) and Fe2+-treated (0.5 mM) cells at 
three time points. (A) Representative western blots showing Mn2+-treated cells with robust 
phosphorylation in JNK at 1 hr, 6 hr and at 24 hr. While phosphorylated p38 and ERK showed changes 
at 1 hr and 6 hr but they returned almost similar to baseline at 24 hr. Interestingly, cells treated with 
Fe2+ did not show any significant increase in phosphorylation, rather exerted inhibitory effect on the 
MAP kinases. In addition, the phosphorylation of JNK by Mn2+ was abolished with Fe2+ co-treatment at 
6 hr. Red dashed lines represent the average basal levels of the phosphorylated protein. (B) 
Representative western blot showing Mn2+-treated (1 mM) S-DMT1 cells with highest JNK 
phosphorylation at 6 hr, but none was observed in Fe2+-treated (1 mM) cells.  JNK phosphorylation 
was similarly observed in control cells treated with Mn2+, but not as robust as with S-DMT1 cells. JNK 
phosphorylation was not observed with Fe2+ treatment. However, a general trend of inhibition to JNK 
phosphorylation was observed with Fe2+ treatment, in both S-DMT1 and control cells. Anisomysin was 
used as a positive control for JNK phosphorylation.  Experiments were repeated at least three times.  
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To further verify the specific activation of the JNK pathway was mediated by the 
influx of Mn2+ via DMT1, Figure 3.5B shows a representative time-dependent 
experiment carried out with Mn2+ treatment on vector (SGFP) and S-DMT1 cells. 
Using anisomysin as a positive control for JNK phosphorylation (54 kDa and 46 
kDa), increase in JNK phosphorylation was observed in S-DMT1 cells treated with 
Mn2+ in a time-dependent manner. The phosphorylation of JNK in the S-DMT1 cells 
peaked at 6 hr and persisted through 20 hr, without any significant change to non-
phosphorylated JNK. In addition, the phosphorylation of JNK was also observed in 
SGFP cells treated with Mn2+ albeit at a lower intensity as compared to S-DMT1 
cells. As shown in Figure 3.5B, once again when the experiment was performed with 
Fe2+ treatment, both S-DMT1 and control cells did not result in the phosphorylation of 
JNK, even up to 20 hr. However, a general trend of JNK phosphorylation suppression 
was observed with Fe2+ treatment, with non-phosphorylated JNK unchanged. This led 
us to believe that Fe2+, in addition to phosphorylated p38 and ERK, has suppressive 
effect on JNK phosphorylation as well. Therefore , based on the results presented thus 
far, these results clarified that JNK activation is the predominant phosphorylated 
kinase in the MAP kinase pathway activated in response to Mn2+ cytotoxicity while 
Fe2+ notably suppressed the MAP kinase pathway.  
Next, we evaluated whether JNK phosphorylation was a major component responsible 
for Mn2+-mediated reduction in cell viability. This was done by using a specific 
chemical inhibitor of JNK phosphorylation called SP600125, which is a highly 
selective small molecule inhibitor of JNK. At concentrations between 25 µM and 50 
µM, it has been shown to inhibit downstream c-jun phosphorylation as well as JNK 
auto-phosphorylation (Bennett, Sasaki et al. 2001).  
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To verify the effectiveness of SP600125 in dampening JNK phosphorylation, as 
shown in Figure 3.6A, treatment of S-DMT1 cells with SP600125 (25 µM) and Mn2+ 
for 24 hr suppressed both 0.5 mM and 1.0 mM Mn2+-mediated JNK phosphorylation. 
Accordingly, all subsequent experiments were carried out using 25 µM of SP600125.  
 Cell viability following co-treatment with SP600125 (25 µM) over several 
concentrations of Mn2+ for 24 hr was determined. As shown in Figure 3.6B, there was 
a significant increase in cell viability detected in S-DMT1 cells treated with 
SP600125 as compared to Mn2+-treated alone, in concentrations of Mn2+ from 0.5 mM 
up to 4 mM. Indeed, as shown in Figure 3.6C, we observed the appearance of white-
halo at the periphery of the cells treated with Mn2+ (0.5 mM) as compared to control 
cells. Moreover, while Mn2+-treated cells appeared stressed, the SP600125-treated 
cells assumed a flatten morphology with less peripheral white halo, similar to control 
cells. These results clearly demonstrate the importance of JNK phosphorylation in 
mediating Mn2+ toxicity and cell viability reduction.  
As mentioned earlier in Figure 3.5A, we observed a reduction in phosphorylated JNK 
when cells were co-treated with Fe2+ for 6 hr as compared to Mn2+-treated cells alone. 
To address this observation whether the reduction in JNK phosphorylation in the 
presence of Fe2+ carried any functional implication, cell viability of co-treated cells 
with Fe2+ and Mn2+ was determined at 24 hr.  




FIGURE 3.6. JNK inhibition and Fe2+ treatment rescued Mn2+-mediated cell viability loss. (A) 
Effect of SP600125 (25 µM) on JNK phosphorylation mediated by Mn2+ (B) JNK inhibition with 
SP600125 significantly rescued viability of S-DMT1 cells against toxicity of Mn2+ ranging from 0.25 
mM to 4.0 mM for 24 hr. Error bars represent standard error of mean (S.E.) with *, p<0.05, with at 
least three independent experiments performed in triplicates. (C) Figures are representative phase 
contrast images of the morphology of control, Mn2+-treated and Mn2+ with SP600125 co-treatment. (D) 
Co-treatment of Fe2+ and Mn2+ in equal molar concentrations showed significant protection against 
Mn2+-mediated cell viability loss from 0.25 mM to 2 mM. However, this protection was no longer 
observed at a higher concentration of Mn2+ from 4 mM onwards. (E) Accompanying figures are 
representative phase contrast images of control, Mn2+-treated and Fe2+ co-treated cells. Cell viability 
assays shown are representative of at least four independent experiments performed in triplicates. * is 
comparisons between Mn2+ and Mn2++ Fe2+ while # is comparison between Fe2+ and Mn2++ Fe2+. Both 
* and # represent p<0.05 and error bars represent standard error of mean (S.E.). 
Cellular Iron Depletion Mediated by Mn2+ Toxicity 
87 
 
Interestingly, the Fe2+ co-treated cells were detected with significantly higher cell 
viability as compared to Mn2+-treated cells alone. As shown in Figure 3.6B, co-
treatment of Fe2+ at equal molar concentrations significantly protected cells against 
Mn2+ toxicity over several treatment concentrations (Figure 3.6D). Indeed, Mn2+ (0.5 
mM) treated cells were observed to have a greater number of cells assuming the 
peripheral white halo, indicative of cell stress, while the Fe2+ (0.5 mM) co-treated 
cells remained comparable to control cells (Figure 3.6E).   
As DMT1 is known to transport both Fe2+ and Mn2+ (Illing, Shawki et al.), the 
competitive uptake of both metals at the cellular entry level may have detrimental 
consequences. Even as Fe2+ and Mn2+ may share similar physical and chemical 
properties (Fitsanakis, Zhang et al.), however their cellular requirement and function 
are highly specific towards their respective metabolic pathways. In the event of 
cellular Mn2+ overexposure, its accumulation may interfere and compromise with the 
metabolic processes of iron-requiring proteins. Hence, in my study, we observed that 
co-treatment of Fe2+ has protective effect against Mn2+ toxicity, which is the first 
cellular evidence demonstrating the disturbance to cellular iron homeostasis mediated 
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3.2.4 Effect of Mn2+ on autophagy pathway 
While there are many adaptive responses which could be activated (or down-
regulated) in response to metal ion intoxications, such as the NfkappaB, Nrf-2, 
metallothioneins and the many heat-shock protein families, we were determined to 
examine the effect of Mn2+ on the autophagic pathway (Lewis, Randol et al. 2003, 
Kobayashi, Kuroda et al. 2007, Li, Wu et al. 2011).  
Experiments were carried out to examine the response of autophagy in Mn2+-treated 
cells using an antibody specific for LC3B and immunoblotted for endogenous LC3-II 
in S-DMT1 cells. LC3-I is a mammalian homologue of the yeast Atg8 protein. It is a 
cytoplasmic protein that is lipidated upon autophagy induction to form LC3-II, which 
is then recruited to the autophagosomes (Gurusamy and Das 2009).  
Accordingly, the levels of LC3-II could be used as an indicator of autophagy. As 
shown in Figure 3.7, treatment of S-DMT1 cells with 0.5 mM and 1.0 mM of Mn2+ 
resulted in a robust increase in LC3-II. However, LC3-II was not detected in Fe2+-
treated as well as in control cells. The increase in LC3-II suggested an enhancement 
in autophagic activity provoked by Mn2+. Next, we verified the effect of Fe2+ co-
treatment on autophagy induction. As shown in Figure 3.7, cells co-treated with 0.5 
mM of Fe2+ and Mn2+ showed a reduction in LC3-II band as compared to Mn2+-
treated alone, with actin showing equal protein loading. However, at higher 
concentration of both Fe2+ and Mn2+ at 1.0 mM, the LC3-II band was comparable to 
Mn2+-treated alone. Autophagy induction mediated by both 0.5mM and 1.0mM of 
Mn2+ could be suppressed by equal molar concentration of Fe2+, suggesting again the 
competitive interaction of Fe2+ and Mn2+. As a further confirmation to the finding of 
Mn2+-mediated autophagy, it was validated using the tandem red fluorescence-tagged 
GFP-LC3 construct (tfGFP-LC3) to monitor autophagic activation and its progression 
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to the lysosomes. The tfGFP-LC3 construct produces a gene product containing a 
tandem pH-stable red (RFP) and a pH-sensitive green fluorescence (GFP) LC3 
protein, and was transfected into naïve SH-SY5Y cells. As the control cells in our 
experiments were shown to be vulnerable to Mn2+ toxicity, naïve cells were used in 
this experiment to prevent any green GFP fluorescent interference between the DMT1 
and tfGFP-LC3 constructs.  
The increase in autophagic activity due to the recruitment of red LC3 to the 
autophagosomes and autophagolysosomes was determined by quantifying the number 
of red puncta per cell. Along with LC3 recruitment and red puncta formation, the 
acidic autophagolysosomes resulted in the quenching of the green GFP puncta. Thus, 
the appearance of red puncta with the loss of green signal is indicative of autophagy 
induction and its progression to form the autophagolysosomes (Klionsky, Cuervo et 
al. 2007, Chew, Ang et al. 2011). As shown in Figure 3.8A, untreated cells have 
minimal red puncta and the absence of green puncta, indicating basal autophagy with 
these puncta localized to the autophagolysosomes. As a positive control, cells starved 
by amino acid starvation using EBSS, showed a robust increase in red puncta with 
very few green puncta. To test the effect of Mn2+ on this system, following 6 hr of 0.5 
mM Mn2+ treatment, there was a significant (p<0.05) increase in the number of red 
puncta per cell (analysis of at least 50 cells per experiment) as compared to control or 
0.5 mM Fe2+-treated cells (Figure 3.8A). Moreover, cells treated with Mn2+ in the 
presence of ammonium chloride (NH4Cl) similarly showed a significant increase in 
red puncta. Additionally, due to the presence NH4Cl, green puncta were observed 
along with red puncta upon Mn2+ treatment. NH4Cl is recognized to neutralize the 
acidic pH of the lysosomes and thus disinhibiting the quenching of GFP. This resulted 
in the appearance of green GFP puncta due to the lack of quenching when the LC3 
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was recruited to form the autophagolysosomes. The detectable yellow puncta in the 
merged figure was confirmatory of autophagy activation and progression to fuse with 
the lysosomes provoked by Mn2+ (Figure 3.8A). In addition, Mn2+-mediated 
autophagy activation was significantly reduced in the presence of equal molar 
concentration of 0.5 mM Fe2+, again suggestive of the potential of Fe2+ in restoring 
iron balance in Mn2+-treated cells (Fig. 4B). Taken together, my data shows robust 
Mn2+-mediated increase in autophagy which targets the cargo towards the 
autophagolysosome. 
 
FIGURE 3.7. Mn2+-mediated increase in autophagy reversed with Fe2+ treatment. A representative 
blot showing S-DMT1 cells treated with 0.5 mM and 1.0 mM Mn2+ for 24 hr, displayed a concentration 
dependent enhancement in autophagy measured using LC3-II, a specific marker for autophagy 
activation. Autophagy activation was reduced with co-treatment with Fe2+ and autophagy activation 
was not observed with Fe2+ treatment alone. At least three experiments were performed for this 
experiment.     
 













FIGURE 3.8. Mn2+ increased LC3 puncta formation in mRFP-GFP-LC3 transfected cells. (A) 
Representative immunofluoroscent images of SH-SY5Y cells transfected with tfGFP-LC3 (mRFP-
GFP-LC3) and treated with 0.5 mM Mn2+ and 0.5 mM Fe2+ for 6hr. In the Mn2+-treated cells, there was 
an almost complete loss of GFP-LC3 signal with a corresponding increase in red-LC3 puncta. The 
GFP-LC3 signal was lost due to the quenching of the green in the acidic environment of the lysosomes. 
Meanwhile, Fe2+ treatment did not produce any obvious red-LC3 puncta formation. In addition, 
incubation of Mn2+-treated cells with NH4Cl, a lysosomal inhibitor resulted in the appearance of both 
red-LC3 and green-LC3 puncta due to pH neutralization of the lysosomes. As a positive control, EBSS 
treatment similarly showed increase in red LC3 puncta formation confirming that Mn2+ treatment 
resulted in robust autophagy activation. The activation of autophagy by Mn2+ could be reduced when 
treated with equal molar concentration Fe2+. (B) Accompanying bar chart shows the average red puncta 
per cell of at least 50 cells per experiment of three independent experiments with *, p<0.05, **, 
p<0.001. Error bars represent standard error of mean (S.E.) and n.s., denotes that values did not reach 
statistical significance.    
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3.2.5 Role of autophagy in Mn2+ toxicity   
JNK phosphorylation has been associated with several forms of cell death which may 
occur in a combination with apoptotic (Newhouse, Hsuan et al. 2004, Kim, Moon et 
al. 2005), non-apoptotic (Wu, Zhang et al. 2008) or autophagic cell death (Shimizu, 
Konishi et al. , Byun, Yoon et al. 2009, Park, Lee et al. 2009).  
As the mode of cell death mediated by Mn2+ remains controversial, we sought 
evidence on whether Mn2+ could mediate autophagic cell death as Mn2+ stimulated 
robust JNK phosphorylation with accompanying increase in autophagy and reduction 
in cell viability. The phosphatidylinositol 3-kinase class III (PI3K Class III) is an 
important protein for the activation for autophagy. Several chemical inhibitors of PI3 
kinase have been discovered including wortmannin (WM), LY294002 and 3-
methyladenine (3-MA) (Caro, Plomp et al. 1988, Blommaart, Krause et al. 1997, 
Stroikin, Dalen et al. 2004).  
In order to clarify the possible involvement of autophagy in mediating cell death in 
Mn2+ toxicity, we examined the effect of autophagy inhibition on Mn2+-treated cells. 
By determining cell viability of the cells, we found that co-treatment of S-DMT1 cells 
with 3-MA (5 mM) or WM (200 nM) with increasing concentrations of Mn2+ for 24 hr 
did not to produce any significant protective effect on cell viability (Figure 3.9). In 
fact, we observed a non-significant reduction in viability in WM-treated cells in the 









FIGURE 3.9. Chemical inhibition of autophagy using unspecific PI3K Class III inhibitors, 3-MA 
and WM did not rescue Mn2+-mediated cell viability reduction. S-DMT1 cells were treated with 
autophagy inhibitors together with Mn2+ for 24 hr and thereafter assessed for cell viability using MTT 
assay. However, chemical inhibition of autophagy using PI3 kinase inhibitors showed mixed responses 
in the cell viability assay. Data shown is representative of at least three independent experiments 
performed in triplicates. Error bars represent standard error of mean (S.E.).  
 
As we failed to detect major differences with the use of chemical inhibitors towards 
autophagy, we alternatively examined the effect of Mn2+ on autophagy-deficient cell 
lines. Two immortalized mouse embryonic fibroblast (MEF) cells deficient in 
autophagy with their accompanying wild-type cells were acquired from Dr. Shen Han 
Ming, NUS with permission from Dr. Noboru Mizushima from Tokyo Medical and 
Dental University.   
These MEF cells were either ATG5 null (ATG5-/-) or ATG7 null (ATG7-/-) MEF 
cells. ATG5 and ATG7 are important autophagy genes required for the activation of 
autophagy as well as initiation of autophagic cell death (Yu, Alva et al. 2004, Byun, 
Yoon et al. 2009).  
To verify that the ATG5-/- MEF cells were deficient in autophagy, cells were treated 
with NH4Cl to allow the accumulation of LC3-II. To reiterate, as autophagic cargo is 
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eventually degraded in the lysosomes, the use of NH4Cl inhibits the function of 
lysosomes and allows the accumulation of autophagic cargo, including LC3-II. As 
shown in Figure 3.10A, NH4Cl treated control cells showed significant accumulation 
of LC3-II protein while it was absent in the ATG5-/- MEF cells, confirming the 
deficiency in autophagy.   
Finally, cell viability was determined on ATG5-/- MEF cells treated with Mn2+ in 
increasing concentrations. As shown in Figure 3.10B, the ATG5-/- MEF cells were 
observed to be more sensitive to Mn2+ toxicity as compared to control cells. The 
ATG5-/- MEF cells showed significant reduction in cell viability from 0.5 mM up to 2 
mM Mn2+. At 2 mM, a greater number of cells were found to have lifted off the plate 
and appeared smaller than control cells (Figure 3.10C). In addition, we also detected 
similar observations with ATG7-/- MEF cells. As shown in Figure 3.10D, while 
ATG7-/- MEF cells to some extent showed resistance towards low concentrations of 
Mn2+ toxicity, however substantial reduction in cell viability still occurred at higher 
toxic levels of Mn2+. The variability in cell response upon Mn2+ treatment observed 
between ATG5-/- and ATG7-/- MEF cells may be due to the differences in the 
involvement in the autophagic pathway played by these autophagic gene products. 
Nonetheless, my data clearly demonstrates that autophagy induction in the context of 
Mn2+ toxicity is not likely to be involved in the cell death process, rather is associated 










FIGURE 3.10. Cell viability reduction in autophagy-deficient MEF cells treated with Mn2+. ATG5-
/- and ATG7-/- with their accompanying wild type (WT) mouse embryonic fibroblast cells (MEF) were 
treated with Mn2+ for 24 hr and cell viability was assessed using MTT assay. (A) Autophagy deficiency 
was confirmed in ATG5-/- MEF cells by immunoblotting for LC3-II protein in the presence of 
lysosomal inhibition (NH4Cl). (B) MTT assay showing the vulnerability of ATG5-/- MEF cells to Mn2+ 
cytotoxicity as compared to ATG5+/+ MEF cells from a concentration of 0.5 mM onwards. (C) 
Representative images of cell morphology viewed under phase contrast microscope of untreated, Mn2+-
treated (2.0 mM) in both ATG5-/- and ATG5+/+ cells. (D) ATG7-/- MEF cells, another autophagy 
deficient cell line, also displayed vulnerability towards Mn2+ cytotoxicity, with significant cell viability 
reduction from 0.5 mM onwards. All data shown are representative of at least three independent 
experiments, with cell viability assays performed in triplicates. Error bars represent standard error of 
mean (S.E.) with *, p<0.05.  
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3.2.6. Effect of Mn2+ on iron storage ferritin protein   
In view that autophagy was observed to be important for the viability of cells during 
Mn2+ stress; we further investigated the role of Mn2+-mediated autophagy in relation 
to iron homeostasis. As mentioned earlier in Figure 3.3A and 3.4A, Fe2+-treated cells 
exhibited consistent low accumulation of cytoplasmic iron as well as resistance 
towards cell viability loss with increment in Fe2+. The upregulation of ferritin in Fe2+ -
treated cells seemed to protect cells against the cytoplasmic accumulation and toxic 
effect of reactive unbound Fe2+. Similarly, as shown in Figure 3.11, we observed 
Fe2+-treated cells with an increment in ferritin levels corresponding to the increase in 
Fe2+ concentration. While Fe2+ repletion (overload) resulted in ferritin upregulation, 
Fe2+ depletion would result in the downregulation of ferritin. Indeed, studies 
performed by others using Fe2+ chelators such as desferroxamine clearly showed that 
cellular Fe2+ depletion affected the labile Fe2+ pool and resulted in reduction in ferritin 
synthesis through the regulation of the IRP/IRE system (Coccia, Perrotti et al. 1997, 
Konijn, Glickstein et al. 1999).    
Hence, to determine whether Mn2+ treatment similarly affected cellular Fe2+ 
homeostasis, we found that Mn2+-treated cells for 24 hr indeed resulted in a 
significant reduction in ferritin protein (Figure 3.11). Ferritin levels in Mn2+-treated 
cells both at 0.5 mM and 1.0 mM were undetectable as compared to control cells, 
suggesting that Mn2+ promoted the downregulation of basal ferritin levels. In addition, 
co-treatment of Fe2+ at 0.5 mM prevented the complete loss of ferritin as compared to 
Mn2+ treatment alone, suggesting the restoration of iron balance in Mn2+-treated cells.  





FIGURE 3.11. Mn2+-mediated downregulation of cytoplasmic ferritin. Representative western blot 
showing S-DMT1 cells treated with Mn2+ for 24 hr resulted in the loss of ferritin protein. Fe2+ treatment 
resulted in the increase in ferritin protein expression in a concentration dependent manner. In addition, 
co-treatment with Fe2+ at 0.5 mM equal molar concentration led to the recovery of ferritin. As a control 
for Mn2+ transport into the cells, phosphorylated JNK was similarly observed with Mn2+ treatment in a 
concentration-dependent manner. At least three experiments were performed for this study.     
 
3.2.7 Involvement of ubiquitin-proteasome and autophagy-lysosomal pathways 
in Mn2+-mediated ferritin degradation 
Metals are notoriously recognized for the misfolding and aggregation of proteins into 
insoluble proteinaceous materials (Chong and Suh 1995, Breydo and Uversky 2011). 
While the mutant ferritin light chain (MT-FTL) has been demonstrated to have 
increased propensity to aggregate in the presence of Fe2+, the effect of Mn2+ on ferritin 
aggregation is currently unknown. (Baraibar, Barbeito et al. 2012). In addition, the 
use of Triton-X lysis buffer in our western experiments performed hitherto was 
limited to the analysis of cytoplasmic proteins. Thus, it is likely that in Mn2+-treated 
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cells, ferritin loss from the cytoplasmic fraction maybe due to its aggregation and 
cellular translocation into the insoluble fraction. To test this, we performed 
subcellular fractionation on control S-DMT1 cells and cells treated with Mn2+. The 
cell lysates were separated into the nuclear, cytoplasmic (soluble) and pellet 
(insoluble) fractions using a detergent-free, differential centrifugation method. S-
DMT1 cells were first treated with Fe2+ for 12 hr to upregulate the expression of 
ferritin. The cells were then treated with Mn2+ or a washout for another 12 hr before 
subjected to fractionation. If indeed ferritin is aggregated, it would appear in the 
insoluble fraction. As shown in Figure 3.12A, ferritin protein was upregulated in the 
Fe2+-treated cells, and clearly found in the cytoplasmic fraction and some detected in 
the insoluble fraction. Upon treatment with Mn2+, we found that the cytoplasmic 
ferritin protein was not translocated into the nuclear or the insoluble fraction, thus 
indicating that Mn2+ does not result in the aggregation or translocation of ferritin into 
the insoluble fraction. This provides further evidence that ferritin is loss via 
proteolysis.  
Mn2+ has been shown to affect the activity of the IRP2 protein in reducing ferritin 
translation (Crooks, Ghosh et al. 2007). As a validation that the effect of Mn2+ on 
ferritin loss was not due to alteration in ferritin mRNA levels, we investigated the 
mRNA levels of ferritin (FTH1), as well as IRP1 and IRP2 using reverse transcription 
PCR (RT-PCR). As shown in Figure 3.12B, we did not observe any significant 
change to the mRNA levels of these transcripts between control cells and S-DMT1 
cells treated with Mn2+ or Fe2+ for 24 hr. The band intensities were normalized to 
GAPDH and presented in Figure 3.12C. The RT-PCR data suggest that Mn2+ 
treatment has no adverse effect on ferritin, IRP1 or IRP2 transcript levels.  
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As we observed autophagy activation along with ferritin degradation in Mn2+-treated 
cells, therefore it is likely that autophagy induction by Mn2+ is important to restore 
iron homeostatic balance by degrading ferritin. To test this, we determined the 
cellular degradative pathways involved in ferritin degradation using chemical 
inhibitors against UPS (MG132), autophagy (WM) and lysosomal (NH4Cl) pathway. 
The S-DMT1 cells were first treated with Fe2+ (0.5 mM) for 12 hr to upregulate 
ferritin and thereafter with Mn2+ (0.5 mM) along with proteolysis inhibitors for 
another 12 hr. As shown in Figure 3.12D and E, significant loss of ferritin was found 
in the control cells treated with Mn2+ without any inhibitors (lane 3). Upon the 
treatment with MG132 and NH4Cl with Mn2+, Figure 3.12E (lane 6 and 9) clearly 
demonstrates the significant recovery of ferritin protein when the UPS and lysosomal 
pathways were inhibited. While WM-treated cells failed to recover ferritin in Mn2+-
treated cells (lane 12), nonetheless in the autophagy-deficient ATG5-/- MEF cells was 
observed with considerably higher accumulation of ferritin when induced with 
increasing concentrations of Fe2+ as compared to control cells. To verify that the 
accumulation of ferritin was due to deficiency in autophagy in the ATG5-/- MEF cells, 
we also examined the levels of a Fe2+-independent mitochondrial protein as a 
comparison. Superoxide dismutase 2 (SOD2) is a mitochondrial protein and the 
deficiency in mitochondrial autophagy (mitophagy) will promote its accumulation 
(Lee, Giordano et al. 2012). Hence, as shown in Figure 3.12F, while SOD2 levels 
were unaffected with increasing Fe2+ concentrations, the ATG5-/- MEF cells clearly 
showed higher levels of SOD2 as compared to control cells due to autophagy 
deficiency. It also confirmed the increase in Fe2+-dependent accumulation of ferritin 
due to autophagy deficiency as compared to control cells.  
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FIGURE 3.12. Cytoplasmic ferritin loss was due to enhanced protein degradation provoked Mn2+. 
Cells were first treated with Fe2+ (0.5 mM) for 12 hr to upregulate ferritin and thereafter treated with 
Mn2+ (0.5 mM) for another 12 hr. (A) Representative western blot showing subcellular fractionation of 
S-DMT1 cell lysates. Mn2+ treatment resulted in the loss of ferritin protein. Cytoplasmic ferritin loss 
was due to protein degradation and was not translocated into other subcellular fractions. Lamin, is a 
nuclear cytoskeletal protein, was used as a loading control for the nuclear fraction. (B) Representative 
image of RT-PCR on ferritin heavy chain (FTH1), iron-regulatory protein 1 (IRP1) and IRP2 mRNA 
on SGFP and S-DMT1 cells treated with different metal ions for 24 hr. GAPDH was used as loading 
control. (C) Bar chart is the accompanying quantification of the relative density of the PCR products 
normalized to GAPDH. (D) Representative western blot showing the recovery of ferritin protein with 
the use of proteolysis inhibitors upon Mn2+ treatment. (E) Accompanying bar chart is the protein 
density of ferritin protein normalized to actin. All experiments shown were repeated at least three times 
with error bars represent standard error (S.E.) and *, p<0.05. (F) Representative western blot showing 
iron-dependent accumulation of ferritin protein in ATG5-/- MEF cells, treated with Fe2+ for 24 hr. (G) 
Representative western blot showing accumulation of ferritin in Mn2+  (0.5 mM) pre-treated or post-
treated ATG5-/- MEF cells.  
 
Moreover, we also confirmed that ATG5-/- MEF cells were resistant to Mn2+-mediated 
ferritin degradation.  To show this, the cells were either treated with Fe2+ or Mn2+ for 
the first 12 hr followed by a washout, then treatment with Fe2+ or Mn2+ for another 12 
hr. As shown in lane 13 and lane 14 of Figure 3.12G, regardless of (i) Fe2+ pre-
treatment followed by Mn2+ post-treatment, or (ii) Mn2+ pre-treatment followed by 
Fe2+ post-treatment, both conditions resulted in the accumulation of ferritin in the 
ATG5-/- MEF cells as compared to control cells in lane 6 and lane 7, respectively 
(Figure 3.12G). The accumulation of ferritin in ATG5-/- MEF upon Mn2+ exposure 
strongly suggests that ferritin degradation mediated by Mn2+ takes place via 
autophagy.  
Taken together, subcellular fractionation of control and Mn2+-treated cells clearly 
confirms that ferritin was lost due to enhanced protein degradation in S-DMT1 cells. 
Mn2+-mediated ferritin degradation involves several protein degradation pathways, 
including UPS, autophagy and lysosomal pathway, which suggest the importance of 
ferritin degradation in maintaining iron homeostasis during Mn2+ exposure.    
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3.2.8 Effect of Fe2+ repletion (pre-treatment) on Mn2+-mediated JNK 
phosphorylation  
Several studies reported that iron depletion using iron chelators resulted in JNK and 
p38 phosphorylation (Yu, Kovacevic et al. 2007, Yu and Richardson 2011). 
Furthermore, iron chelation is also known to down-regulate ferritin due to the 
disruption in labile Fe2+ pool. (Torti, Torti et al. 1998, Konijn, Glickstein et al. 1999). 
As we detected substantial JNK phosphorylation and down-regulation of ferritin in 
Mn2+-treated cells, we reasoned that these observations were closely associated with 
disturbance to cellular Fe2+ homeostasis, involving the depletion of labile Fe2+ pool. In 
particular, we hypothesized that JNK phosphorylation is an immediate effect of Fe2+ 
depletion upon Mn2+ treatment.  
Hence, we investigated the hypothesis by examining JNK phosphorylation as well as 
ferritin levels by performing experiments involving the effect of Fe2+ repletion (pre-
treatment) followed by Mn2+ treatment (post-treatment). In these studies, S-DMT1 
cells were pre-treated with 0.25 mM Fe2+ for 12 hr followed by 0.25 mM Mn2+ post-
treatment for another 12 hr. And as a comparison, the cellular responses in the reverse 
were also examined according to treatments regime as mentioned above. Finally, the 
effect of each metal ion as well as co-treatment of metal ions on an extended 










FIGURE 3.13. Fe2+ repletion (pre-treatment) and Fe2+ co-incubation diminished Mn2+-mediated 
JNK phosphorylation. 12 hr: 12 hr treatment regime was performed for this study. The concentration 
of Fe2+ and Mn2+ chosen was 0.25 mM. (A) Representative western blot showing the Fe2+ pre-treatment 
followed with Mn2+ post-treatment and other appropriate controls. Bar charts showing (B) ferritin 
protein levels (C) phosphorylated JNK protein levels upon Fe2+ and Mn2+ treatment. Fe2+ treatment 
showed no significant change to phosphorylated JNK. Mn2+ provoked significant JNK phosphorylation 
at different treatment regimes. (D) Fe2+ repletion significantly reduces Mn2+-mediated JNK activation. 
(E) Mn2+ repletion followed by Fe2+ treatment significantly suppressed ferritin upregulation (F) Cells 
treated with equal molar concentration of Fe2+ and Mn2+ displayed significant upregulation of ferritin 
and reduction in phosphorylated JNK, as compared Mn2+ treatment alone. At least four experiments 
were performed for this study. The density of ferritin and phosphorylated JNK was normalized to actin 
and non-phosphorylated JNK, respectively and expressed as fold change increment over untreated. 
Error bars represent standard error of mean (S.E.) with *, p<0.05 and **, p<0.01. 
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As shown in Figure 3.13A, each experiment was performed and analyzed as a single 
western gel for an accurate densitometry analysis. Accompanying bar charts show the 
protein density of phosphorylated JNK normalized to non-phosphorylated JNK, and 
ferritin normalized to actin loading control. In Figure 3.13B, 0.25 mM Fe2+ pre-
treatment followed by a washout and Fe2+ post-treatment resulted in a significant 
(p<0.01, Figure 3.13A lane 2 and 3) 6-fold and 7-fold increase in ferritin expression 
as compared to control cells, respectively. Moreover, ferritin was significantly 
(p<0.05) increased up to 10-fold after incubation with Fe2+ for 24 hr (Figure 3.13A, 
lane 12). While these results confirmed that Fe2+ treatment led to the corresponding 
increase in ferritin, JNK phosphorylation was not significantly altered with Fe2+ 
treatment in these experiments. Unlike Fe2+ treatment, ferritin expression was almost 
undetected with Mn2+ pre-treatment, post-treatment or for 24 hr as compared to 
control cells (Figure 3.13A, lane 4, 5 and 11). However, JNK phosphorylation with 
Mn2+ was significantly increased in the pre-treatment (2-fold), post-treatment (7-fold) 
and 24 hr-treatment (4-fold) as compared to control cells (Figure 3.13C). We next 
examined the hypothesis whether Fe2+ pre-treatment protected cells against Mn2+-
mediated JNK phosphorylation. As shown in Figure 3.13A, upon Mn2+ post-treatment 
on cells pre-treated with Fe2+, phosphorylated JNK was detected to be 1.5 fold 
significantly lower as compared to Mn2+ post-treatment alone (p<0.05, Figure 3.13A 
lane 5 and 6). In Fe2+ pre-treated cells, significant downregulation of ferritin was 
observed in Mn2+ post-treated cells as compared to washout. This led us to believe 
that Fe2+ pre-treatment resulted in a higher expression of ferritin which was quickly 
degraded during Mn2+ treatment. Indeed, this strongly suggests that intracellular Fe2+ 
status has a profound effect on JNK phosphorylation mediated by Mn2+ exposure.  
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Additionally, JNK phosphorylation mediated by Mn2+ pre-treatment was significantly 
attenuated by a washout (Figure 3.13A, lane 4 and Figure 3.13E). The return of 
phosphorylated JNK to basal levels suggested that cellular Fe2+ imbalance could be 
restored upon the removal of Mn2+ treatment. In addition, we also found that cells pre-
treated with Mn2+ were less responsive to post-Fe2+ treatment as ferritin upregulation 
was significantly affected (Figure 3.13A, lane 3, 7 and Figure 3.13E). This is 
suggestive of an intracellular interference to iron-binding proteins responsible for 
cellular iron status provoked by Mn2+.  
Finally, co-treatment of Fe2+ (0.25mM) and Mn2+ (0.25mM) for 24 hr resulted in a 
significant 2.5-fold increase in ferritin as oppose to a robust 7.5-fold ferritin increase 
with Fe2+ treatment alone (Figure 3.13A, lane 10, 12 and Figure 3.13F). Furthermore, 
JNK phosphorylation of Mn2+ treatment in the presence of Fe2+ co-treatment was 
substantially reduced by 2-fold as compared to Mn2+ treatment alone. This suggests 
that Fe2+ co-treatment could restore intracellular Fe2+ imbalance by competing with 
Mn2+ at the entry (DMT1) as well as intracellular level.  
Taken together, these results firmly established that intracellular Fe2+-repletion 
attenuated JNK phosphorylation mediated by Mn2+. This is likely due to increased 
expression of Fe3+-laden ferritin upon Fe2+ repletion which allowed rapid Fe2+ 
extraction via ferritin degradation during Mn2+ exposure. In addition, the increase in 
ferritin levels with Fe2+-repletion made ferritin readily available for Fe2+ release as 
oppose to low ferritin at basal levels. Hence, due to the limited availability of ferritin 
in normal cells, Mn2+ exposure resulted in higher JNK phosphorylation than in Fe2+-
repleted cells. This indeed corroborates our hypothesis that Fe2+-depletion by Mn2+ 
exposure could lead to enhanced JNK activation, which could be attenuated with Fe2+ 
repletion.  
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3.2.9 Effect of JNK inhibition on Mn2+-mediated ferritin degradation  
Since we observed an inverse relationship between JNK phosphorylation and ferritin 
expression upon Mn2+ treatment, we reasoned that there was a possibility of JNK 
phosphorylation in targeting ferritin towards degradation. In addition,  ROS-mediated 
JNK phosphorylation has been demonstrated to result in the specific degradation of 
ferritin provoked by TNF-α, with the accompanying increase in intracellular Fe2+ 
levels (Antosiewicz, Ziolkowski et al. 2007).  
Hence, we specifically examined whether inhibition to JNK phosphorylation 
mediated by Mn2+ could impede degradation of ferritin. If indeed JNK 
phosphorylation preceded and was important for ferritin degradation, then the 
inhibition of JNK would inhibit Mn2+-mediated ferritin degradation. For this purpose, 
we again pre-treated the S-DMT1 cells with Fe2+ (0.5 mM) for 12 hr to upregulate 
ferritin levels. This was followed by treatment with Mn2+ (0.5 mM) for another 12 hr 
in the presence of JNK inhibitor, SP600125 (25 μM).  
As a control for the effectiveness of JNK inhibition, SP600125-treated cells in the 
presence of Mn2+ showed a reduction in phosphorylated JNK as compared to Mn2+-
treated alone (Figure 3.14A, lane 5 and 6), without any significant change to non-
phosphorylated JNK levels. Treatment with Mn2+ resulted in a significant decrease in 
ferritin protein as compared to Fe2+ pre-treated cells (p<0.05, lane 2 and 3). While 
phosphorylated JNK mediated by Mn2+ was substantially reduced in the presence of 
SP600125, we failed to suppress the degradation of ferritin upon JNK inhibition (lane 
4). This provided evidence that the degradation of ferritin mediated by Mn2+ is 
independent of JNK phosphorylation.  
 





FIGURE 3.14. Mn2+-mediated ferritin degradation is independent of JNK phosphorylation. (A) S-
DMT1 cells were pre-treated with Fe2+ (0.5 mM) for 12 hr and thereafter in the presence of (i) Mn2+ 
(0.5 mM) or (ii) Mn2+ with JNK inhibitor (SP600125, 25 µM) for another 12 hr. JNK inhibition did not 
prevent the degradation of ferritin in the presence of Mn2+ even there was an obvious reduction in 
phosphorylated JNK. (B) Accompanying bar chart showing the relative levels of ferritin. Experiments 
were repeated at least three times with error bars representing standard error (S.E.) and *, p<0.05.  
 
3.2.10 Effect of ferritin overexpression on Mn2+-mediated JNK phosphorylation 
Ferritin upregulation, especially ferritin heavy chain via the NfkappaB pathway, has 
been associated as a protective response to reduce TNF-α-induced ROS in cellular 
models involving inflammatory responses. Moreover, the overexpression of ferritin 
heavy chain has also been shown to reduce the phosphorylation of JNK via the 
modulation of ROS, presumably via its Fe2+ scavenging effect (Pham, Bubici et al. 
2004, Antosiewicz, Ziolkowski et al. 2007). These studies led us to wonder if ferritin 
loss was responsible for the heightened JNK phosphorylation in the presence of Mn2+ 
exposure. To test this, we performed a ferritin overexpression study. The human 
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ferritin heavy chain was cloned and placed into a FLAG-tagged mammalian vector 
plasmid and verified using DNA sequencing and western analysis. The ferritin 
plasmid (FLAG-FTH1) was overexpressed using Lipofectamine 2000 for 18 hr before 
treatment with Mn2+ (0.5 mM) for another 12 hr.  
To test the effect of ferritin heavy chain on Mn2+-mediated JNK phosphorylation, S-
DMT1 cells were transfected with both vector plasmid and Flag-FTH1 at a low 0.25 
μg and a high 2.0 μg DNA concentrations. As shown in Figure 3.15A, the levels of 
JNK phosphorylation between vector-transfected and FTH1-transfected cells were 
comparable when treated with Mn2+ (0.5 mM), with no significant change to non-
phosphorylated JNK. In addition, we also did not observe any significant 
concentration-dependent effect of ferritin on JNK phosphorylation.  
Taken together, in contrary to the studies involving TNF-α (Pham, Bubici et al. 2004), 
the specific overexpression of ferritin heavy chain did not reverse JNK 
phosphorylation mediated by Mn2+. As we hypothesized that Mn2+ exposure interferes 
with Fe2+ balance which consequently leads to JNK phosphorylation, thus the 
overexpression of ferritin heavy chain is ineffective against Mn2+-mediated JNK 
phosphorylation.  





FIGURE 3.15. Ferritin overexpression does not affect Mn2+-mediated JNK phosphorylation. (A) 
Ferritin heavy chain was transfected into S-DMT1 cells for at least 18hr before treatment with Mn2+ 
(0.5 mM) for 24 hr. Both high (2.0 µg) and low (0.25 µg) DNA concentration of transfected ferritin did 
not significant reduced JNK phosphorylation in the presence of Mn2+. (B) Bar chart showing relative 
levels of phosphorylated JNK. Experiments were repeated at least four times with error bars 
representing standard error (S.E.).  
 
3.2.11 Effect of JNK inhibition on Mn2+-mediated autophagy activation 
As we have established that (i) JNK phosphorylation was not due to the reduction in 
ferritin level and (ii) ferritin proteolysis was not driven by JNK phosphorylation, next 
we examined the interplay between JNK and autophagy upon Mn2+ exposure. The 
modulatory role of the JNK pathway in the initiation and progression of autophagy 
has been well described in several animal and cellular models. (Park, Lee et al. 2009, 
Li, Luo et al. 2012, Liu, Fang et al. 2012, Trejo-Solis, Jimenez-Farfan et al. 2012). 
Beclin-1 is an essential protein required for the activation of autophagy which is 
associated with its negative regulatory protein, Bcl-2. The activation of JNK promotes 
the phosphorylation of Bcl-2, resulting in the dissociation of the “Beclin1 and Bcl-2 
complex” leading to the activation of autophagy. While the interaction between JNK 
phosphorylation and Beclin1-Bcl-2-dependent autophagy is well studied, nonetheless, 
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there is also evidence for JNK-independent autophagy induced by arsenic trioxide 
(Goussetis, Altman et al. 2010).  In order to clarify the involvement of JNK in the 
activation of autophagy, we conducted an experiment examining the inhibition of 
JNK phosphorylation and its effect on Mn2+-mediated autophagy activation.  
We assessed the levels of LC3-II autophagic protein as a marker of autophagy 
following Mn2+ treatment for 12 hr, in the presence of SP600125 (JNK inhibitor).  As 
shown in Figure 3.16A, S-DMT1 cells treated with Mn2+ (0.25 mM) for 12 hr resulted 
in the activation of autophagy through the detection of LC3-II protein and the increase 
in JNK phosphorylation (lane 2) as compared to control cells. In the presence of 
SP600125 (lane 3), even though there was a reduction in phosphorylated JNK, 
however the level LC3-II remained the same as compared to Mn2+-treated alone. This 
was further corroborated with cells treated with NH4Cl. As LC3-II is easily degraded 
by the lysosomes, the addition of NH4Cl prevented its degradation. Even as there was 
an accumulation of LC3-II in the control cells due to basal autophagy; nevertheless 
we still observed an increased in LC3-II in the Mn2+-treated cells which was not 
significantly different from the SP600126-treated cells. 




FIGURE 3.16. Mn2+-mediated autophagy activation independent of JNK activation. (A) 
Representative western blot showing levels of LC3-II and phosphorylated JNK in the presence of 0.25 
µM Mn2+ and SP600125 (25 µM) for 24 hr. Experiments were performed at least three times. (B) 
Increased phosphorylated JNK (56 kDa) in ATG7-/- MEF cells as compared to ATG7+/+ MEF cells. 
 
This data suggests that the activation of autophagy we observed with Mn2+ treatment 
is independent of JNK phosphorylation. Furthermore, we also discovered that the 
reverse was true in that autophagy inhibition in the presence of Mn2+ treatment 
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resulted in higher JNK phosphorylation. To reiterate, ATG7-/- MEF cells are deficient 
in autophagy and hence these cells were used to test the hypothesis that autophagy 
inhibition increases phosphorylated JNK in the presence of Mn2+. Indeed, Mn2+-
treated (0.5 mM) ATG7-/- MEF cells were observed to have higher JNK 
phosphorylation than control cells. Even though non-phosphorylated JNK was 
marginally higher in the ATG7-/- MEF cells than control cells, nonetheless, the 
increase in the 56 kDa phosphorylated JNK was obvious at 0.5 mM. This indeed 
confirmed that autophagy deficiency resulted in the reduction of ferritin degradation 
and iron availability, which consequently led to the increase in JNK phosphorylation 
under Mn2+ exposure.  
3.2.12 Intracellular ROS formation in Fe2+ and Mn2+-treated cells  
Unlike Fe2+ and Cu2+ which are known to mediate the formation of ROS through 
redox cycling, the redox status of Mn2+ in biological system remains a controversy. 
Mn2+  is capable of acting as a pro-oxidant (Zhang, Wong et al. 2009, Park and Park 
2010) or an anti-oxidant (Chen, Yiin et al. 2002, Worley, Bombick et al. 2002, 
Jomova and Valko 2011), shown in both animal and cellular models of manganese 
toxicity. The dual role of manganese in affecting cellular redox was hypothesized to 
be due to the species and concentration of manganese used (Aguirre and Culotta 
2012). Hence, it is important for us to clarify the levels intracellular ROS mediated by 
Mn2+ in our study.  
To determine the redox status of Mn2+-treated S-DMT1 cells for 24 hr, we measured 
intracellular ROS production using 2’,7’-dichlorofluorescein (H2DCFDA) and 
subjected the cells to flow cytometry analysis. H2DCFDA is a cell-permeant acetate 
dye which is processed by intracellular esterases and captured within the cytoplasm. 
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Upon the oxidation by intracellular ROS, specifically superoxide anion, the 
fluorescence of the dye could be detected and measured.  
As shown Figure 3.17A, Mn2+-treated (0.5 mM) S-DMT1 cells were associated with a 
significant 1.6 fold (p<0.01) reduction in intracellular ROS (24.7%) as compared to 
control cells (42.8%).  While the increase in intracellular ROS upon Fe2+ treatment 
was insignificant (47.5%), co-treatment of Fe2+ and Mn2+ resulted in a 1.7 fold 
decrease in intracellular ROS levels (28.2%) as compared to Fe2+-treated cells 
(47.5%).  
To confirm that the reduction in intracellular ROS with Mn2+ was not due to any 
technical artefacts, we performed a series of treatments involving pre and post metal 
ion treatments. To do this, S-DMT1 cells were pre-treated with Fe2+ (0.5 mM) or 
Mn2+ (0.5 mM) for 12 hr followed by a washout or treatment with another different 
metal ion for another 12 hr. These cells were similarly subjected to H2DCFDA 
treatment and flow cytometry analysis. Expectantly, we observed an increase in 
intracellular ROS levels in Fe2+-treated cells, either with pre-treatment followed by a 
washout or post-treatment alone (Figure 3.17C, lane 2 and 3). Indeed, we similarly 
observed the reduction in intracellular ROS in cells-treated with Mn2+, both in Mn2+ 
pre-treated followed by a washout or Mn2+ post-treated (lane 4 and 5). In addition, 
cells pre-treated with Mn2+ followed by Fe2+ post-treatment or Fe2+ pre-treatment 
followed by Mn2+ post-treatment showed an average of 2-fold and 3-fold reduction in 
intracellular ROS, respectively (lane 6 and 7). Taken together, these data confirms 
that Mn2+ in the form of MnCl2 reduces intracellular ROS, even in the presence of 
Fe2+. 





Figure 3.17. Reduction in intracellular ROS with Mn2+ treatment. Cells were treated with 0.5 mM 
of Mn2+ or Fe2+ for 24 hr. (A) Histogram showing untreated and treated S-DMT1 cells with 2’,7’-
dichlorofluorescein (H2DCFDA) and measured using flow cytometry. (B) Bar chart showing average 
intracellular ROS of Fe2+, Mn2+ and co-treated cells. Experiments were performed at least four times 
with error bars representing standard error (S.E.) and *, p<0.01. (C) Intracellular ROS of cells pre- and 
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3.2.13 Effect of lysosomal inhibition on Mn2+-mediated JNK activation  
As we observed that autophagy inhibition (thus the reduction in ferritin degradation) 
led to the increase in JNK phosphorylation in the presence of Mn2+, we further 
clarified this finding by investigating the involvement of the lysosomal pathway. The 
lysosomal pathway has been shown to be essential for the terminal degradation of 
ferritin and subsequently the extraction of Fe2+ for metabolic use (Radisky and 
Kaplan 1998, Kidane, Sauble et al. 2006, Zhang, Mikhael et al. 2010). Since both 
Mn2+ toxicity and Fe2+ depletion (using iron chelators) have been shown to involve 
robust JNK phosphorylation (Yu and Richardson 2011), we reasoned that inhibition 
of the lysosomal pathway in the presence of Mn2+ would further enhance JNK 
phosphorylation. We hypothesized that the enhancement in JNK phosphorylation is 
due to aggravation of cellular Fe2+ depletion in the presence of Mn2+ and lysosomal 
inhibition.  
To test this hypothesis, western blot analysis was carried out on S-DMT1 cells treated 
with Mn2+ (0.5 mM) in the presence of NH4Cl (30 mM). As shown in the Figure 
3.18A, Mn2+ treatment resulted in a time-dependent phosphorylation of JNK from 
time 2 hr to 6 hr. As predicted, treatment in the presence NH4Cl led to enhancement 
of JNK phosphorylation, which occurred at the 6th hr as compared to the Mn2+-treated 
cells, without any significant change to non-phosphorylated JNK levels (Figure 
3.18A). The effectiveness of NH4Cl was also determined by detecting for LC3 
protein. LC3-II bands were detected in cells treated with NH4Cl, suggesting that 
lysosomal pathway was indeed inhibited. This is in agreement with the use of 
leupeptin, another lysosomal inhibitor which resulted in reduced Fe2+ mobilization 
due to ferritin stabilization (Zhang, Mikhael et al. 2010).  





Cellular Iron Depletion Mediated by Mn2+ Toxicity 
118 
 
FIGURE 3.18. Lysosomal inhibition enhanced disruption to Fe2+ homeostasis mediated by Mn2+. 
(A) Time-dependent Mn2+-mediated (0.5 mM) JNK phosphorylation was enhanced in the presence of 
lysosomal inhibitor, NH4Cl. As a control for lysosomal inhibition, appearance of autophagy related 
LC3-II protein in the NH4Cl treated group confirmed the inhibition of autophagic flux via lysosomes. 
(B) Accompanying bar chart to show the abundance phosphorylated JNK upon Mn2+ treatment in the 
presence of NH4Cl. (C) Representative western blot showing S-DMT1 cells treated with either Fe2+ or 
Mn2+ or vice versa using a 12 hr: 12 hr treatment regime. NH4Cl was added at the last 12 hr. Robust 
JNK phosphorylation was observed in all Mn2+ treatment groups in the presence of NH4Cl as compared 
to the non-NH4Cl treated groups. Recovery of ferritin was observed in the Mn2+-treated cells in the 
presence NH4Cl. Experiments were performed at least three times with error bars representing 
standard error (S.E.) and *, p<0.05.   
 
As the experiments performed above were not primed with Fe2+ for ferritin 
upregulation, ferritin changes could not be examined. To further confirm that the 
inhibition of lysosomal pathway resulted in ferritin stabilization and enhancement in 
JNK phosphorylation in the presence of Mn2+, we performed iron-repletion to induce 
ferritin upregulation. S-DMT1 cells were pre-treated with Fe2+ (0.5 mM) for 12 hr 
followed by Mn2+ (0.5 mM) for another 12 hr. Other treatments involving single Fe2+ 
and single Mn2+ treatments were also performed as comparisons and cells were 
immunoblotted for phosphorylated JNK and ferritin protein. As shown in Figure 
3.18C, Fe2+-repletion resulted in the upregulation of ferritin while treatment with 
Mn2+ after Fe2+ repletion resulted in the loss of ferritin protein (lane 3 and 6). In the 
presence of NH4Cl, ferritin protein was recovered and stabilized even in the presence 
of Mn2+ as compared to Mn2+-treated alone (lane 6 and 12). Even as phosphorylated 
JNK was expectantly increased in Mn2+-treated cells (lane 2, lane 4 and lane 6); 
however in the presence of NH4Cl, phosphorylation of JNK was further enhanced 
(lane 8, 10 and lane 12). Taken together, these data further validates that Mn2+ 
exposure resulted in cellular Fe2+ depletion and JNK activation. Notably, Mn2+-
mediated Fe2+ depletion could be aggravated with lysosomal inhibition leading to 
enhancement in JNK phosphorylation.  
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3.2.14 Effect of thioredoxin overexpression on Mn2+-mediated JNK 
phosphorylation  
JNK activation mediated by cellular Fe2+ depletion using Fe2+ chelators was proposed 
to be arbitrated via the thioredoxin-ASK1-JNK pathway (Yu and Richardson 2011). 
While in our study we have shown that both Mn2+ exposure and lysosomal inhibition 
resulted in cellular Fe2+ depletion, we proposed that the upstream activator of JNK 
could be similarly mediated via the thioredoxin-ASK1-JNK pathway. In the 
unstimulated condition, ASK1 is usually bound to its suppressor, thioredoxin, which 
is a redox protein involved in the reduction of other proteins (Nordberg and Arner 
2001). Upon oxidation, thioredoxin changes its conformation and dissociates itself 
from ASK1, thus allowing ASK1 to phosphorylate its putative substrates. One of this 
substrates is JNK (Laskar, Ghosh et al. 2012). As thioredoxin-ASK1-JNK might be 
the candidate pathway in Mn2+-mediated JNK phosphorylation, we examined the 
status of JNK by over-expressing the negative regulator of ASK1, thioredoxin. The 
overexpression of thioredoxin is expected to stabilize the thioredoxin-ASK1 complex 
resulting in the reduction of JNK phosphorylation by ASK1.  
As an initial characterization of the FLAG-tagged human thioredoxin plasmid (Liu 
and Min 2002), it was overexpressed in S-DMT1 cells with 0.5 μg and 1.0 μg DNA 
concentration using Lipofectamine 2000. After 18 hr post-transfection, the cells were 
treated with Mn2+ (0.5 mM). As shown in Figure 3.19A, the overexpression of 
thioredoxin resulted in the concentration-dependent suppression of JNK 
phosphorylation mediated by Mn2+ treated for 12 hr, without any significant change to 
non-phosphorylated JNK. As 1.0 μg of thioredoxin DNA resulted in a drastic 
suppression in JNK phosphorylation, it was used for subsequent experiments. 
Similarly, we also determined whether thioredoxin overexpression would suppress 
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JNK phosphorylation in cells treated with Mn2+ and lysosomal inhibition. As shown 
in Figure 3.19B, the treatment with Mn2+ resulted in a significant increase in JNK 
phosphorylation as compared to control cells. In addition, cells treated with Mn2+ and 
NH4Cl showed a robust enhancement of JNK phosphorylation. Compared to vector 
control cells, the overexpression of thioredoxin significantly reduced the 
phosphorylation of JNK in Mn2+-treated cells (p<0.05, 1.5-fold) as well as Mn2+-
treated cells in the presence of NH4Cl (p<0.01, 2.3-fold). This finding was further 
corroborated using another lysosomal inhibitor, chloroquine (CQ) which has the same 
pH neutralizing effect on the lysosomes as NH4Cl. The use of chloroquine on Mn2+-
treated cells was similarly observed to further enhanced JNK phosphorylation. And 
the overexpression of thioredoxin substantially reduced the phosphorylation of JNK 
(Figure 3.19C), verifying the specific involvement of the lysosomes in mediating Fe2+ 
depletion in presence of Mn2+. 
Thioredoxin overexpression was also tested on another neuronal-like cholinergic cell 
line, N2A of mouse origin. As thioredoxin is found in almost all organisms with high 
protein homology, the overexpression of human thioredoxin into a mouse cell line 
should similarly reduce JNK phosphorylation in the presence of Mn2+. Indeed, the 
overexpression of thioredoxin significantly (p<0.05) reduced the phosphorylation of 
JNK in both Mn2+-treated and Mn2+-treated in the presence of NH4Cl in N2A cells 
(Figure 3.20A). Finally, we also examined whether thioredoxin overexpression-
mediated JNK suppression could augment viability of cells treated with Mn2+. To test 
this, S-DMT1 cells grown in 96-well plate were transfected with thioredoxin (0.25 
μg) or vector plasmid for 18 hr. Then the cells were treated with 0.25 mM Mn2+ or in 
the presence with NH4Cl for 12 hr. While the cells treated with 0.25 mM Mn2+ for 12 
hr was not sufficient to produce any significant loss in cell viability as opposed to 
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treatment for 24 hr shown previously (Figure 3.4B), nonetheless we used 12 hr to 
limit the toxic effects mediated by NH4Cl. In Figure 3.20B, NH4Cl treatment alone 
produced substantial cell viability loss which was significantly reversed (p<0.05) in 
the presence of thioredoxin overexpression. As predicted, Mn2+ treatment together 
with NH4Cl significantly aggravated cell viability loss as compared to NH4Cl 
treatment alone. And cell viability loss was significantly reversed (p<0.05) in the 
presence of thioredoxin overexpression. Taken together, these results suggest that 
Mn2+-mediated JNK phosphorylation is indeed arbitrated via thioredoxin-ASK1 
pathway. The overexpression of thioredoxin suppresses the synergistic effect of Fe2+ 
depletion mediated by Mn2+ and lysosomal inhibition, and restores cell viability due 
to excessive JNK activation.  






FIGURE 3.19. Effect of thioredoxin overexpression on Mn2+-mediated JNK phosphorylation. 
Cells were transfected with thioredoxin for 18 hr before treatment with Mn2+ (0.25 mM) for 12 hr.  (A) 
Representative western blot showing the effect of DNA dose-dependent overexpression of thioredoxin 
on Mn2+-mediated JNK activation. (B) Representative western blot with accompanying bar chart 
showing the effect of thioredoxin on Mn2+-treated cells in the presence of lysosomal inhibition. Error 
bars represent standard error (S.E.) with *, p<0.05 and **, p<0.01. (C) Representative western blot 
showing the effect of thioredoxin on Mn2+-treated cells in the presence of lysosomal inhibitor, 
chloroquine (CQ).   





FIGURE 3.20. Effect of thioredoxin overexpression on Mn2+-treated N2A cholinergic cells and 
cell viability of Mn2+-treated S-DMT1 cells. (A) Representative western blot and accompanying bar 
chart showing the effect of thioredoxin overexpression of Mn2+-mediated JNK activation in murine 
cholinergic N2A cell line. Cells were transfected with thioredoxin for 18 hr before treatment with 0.25 
mM Mn2+ for 12 hr. Experiments were repeated three times with error bars representing standard error 
(S.E.) and *, p<0.05 and **, p<0.01. (B) Cell viability of S-DMT1 cells treated with Mn2+ or Mn2+ in 
the presence of NH4Cl, both in vector plasmid and thioredoxin overexpressed cells. Similarly, cells 
were transfected with thioredoxin for 18 hr before treatment with 0.25mM Mn2+ for 12 hr before the 
addition of MTT. Cell viability assay was repeated five times in duplicates with *, p<0.05, **, p<0.01. 
Error bars represent standard error (S.E.).  
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PART TWO  
3.3 Characterization of Transgenic Mouse Model of  Divalent Metal Transporter 
1 (DMT1)  
3.3.1 Generation of MoPrP-DMT1B-myc transgene and transgenic founder  
The initial generation of the DMT1 transgenic mice was done by Dr. Philip Tsang. 
The DMT1B (NRAMP2) isoform without iron response element (DMT1B/-IRE) of 
the Macaca fascicularis (GenBank: AF153279.1) was cloned with a myc-tag at the c-
terminal end of the open reading frame, but excluding the stop codon. The DMT1B-
myc transgene was inserted into the MoPrP.Xho (previously called pPrPpE1/E2,3sal) 
expression vector which is known to drive high expressions of the transgene in the 
brain (Borchelt, Davis et al. 1996).  
The DMT1B-myc was inserted between exon 2 and exon 3 of the MoPrP.Xho (Figure 
3.21A). The founder mouse was generated in the C3HeJ with C57BL/6J founder one 
(F1) mating. After the initial screening of the founder mice which showed comparable 
DMT1B-myc protein expression previously done by Dr. Ang Eng-Tat, one line was 
chosen for further characterization by me. The presence of the transgene in the mice 
was determined using two PCR primer pairs flanking (i) exon 2 and DMT1-myc and 
(ii) exon 2 and exon 3, producing two PCR products of approximately 400bp and 
2kbp, respectively (Figure 3.21B). The founder mice were back-crossed with 
C57BL/6J up to the 6th generation. The protein expression of DMT1B-myc was 
determined using a DMT1B-specific monoclonal antibody which detected the protein 
at approximately 65kDa using SDS lysis buffer.  




Figure 3.21. Genotyping strategy and expression of DMT1B-myc. (A) Plasmid map of the 
MoPrP.Xho-DMT1B-myc with genotyping strategy using two primer pairs, (i) DMT1B forward primer 
and (ii) PrP Exon 2 forward primer. PrP Exon 3 reverse primer was used as a common primer for the 
forward primers, producing a short and a long PCR product. (B) Representative genomic DNA 
genotyping analysis showing 400bp and 2kbp positive bands in transgenic mice using primer pairs 
mentioned above. TG1 and TG2 were two independent representative transgenic mice while non-
transgenic was denoted as +Ve. Water control has the complete PCR mix except the genomic DNA 
while template control has everything except DNA polymerase. (C) Western blot analysis of DMT1B-
myc expression in the brain using DMT1B-specific monoclonal antibody.  
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3.3.2 Brain expression of DMT1B-myc.  
The mouse prion promoter is known to target high expression of the transgene into 
both glial cells and neurons (Borchelt, Davis et al. 1996, Maskri, Zhu et al. 2004). To 
verify that the DMT1B-myc under the prion promoter drove the transgene into 
different regions of the brain, we examined the expression of the transgene on the 
coronal plane of the mouse brain. Cryo-sections of 20 μM were prepared and stained 
with DMT1B antibody using DAB immunohistochemical method. Six regions of the 
brain which are commonly associated with motor and non-motor neurological 
disorders were chosen and represented in Figure 3.22A. By viewing under the light 
microscope, all six brain regions (olfactory bulb, hippocampus, substantia nigra, 
striatum, cortex and cerebellum) showed marked increase in DMT1B 
immunoreactivity, suggesting a widespread expression of DMT1 in the brain of the 
DMT1_Tg. To further validate the extensive expression of the transgene in the brain, 
regional dissection involving the six regions were performed. Indeed, by using SDS 
lysis and normalization of protein using BSA method, consistent DMT1 expression 
was found to be present in the brain of the DMT1_Tg using antibody against DMT1B 
(Figure 3.22B). Following the normalization with loading control actin, it was 
discovered that the expression levels of the transgene driven by the mouse prion 
promoter showed subtle regional differences. Regional expression differences were 
also reported in another prion promoter mouse model driving the expression of α-
synuclein, suggesting that the mouse prion promoter may have inconsistent 
integration process. Nonetheless, in our transgenic model, the DMT1B-myc transgene 
was observed to be extensively expressed in the brain of the DMT1_Tg, including the 
substantia nigra and striatum (Maskri, Zhu et al. 2004).  




FIGURE 3.22. Brain regional expression of the transgene. (A) Immunohistochemical analysis (10X 
objective) of DMT1B expression in different regions of the brain in non-transgenic and transgenic 
mice, using DMT1B-specific monoclonal antibody. DMT1_Tg showed marked increase in DAB 
brown staining as compared to non-Tg. (B) Western analysis of regional brain lysates of DMT1_Tg. 
Accompanying bar chart shows the relative protein levels of DMT1B-myc in the DMT1_Tg. 
Experiments were repeated at least three times with error bars representing standard error (S.E.).  
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As that the DMT1_Tg was expressing high levels of the transgene in the brain, we 
next determine whether the increase in expression of DMT1 would facilitate more 
iron entry into the brain. Iron-enriched diet has previously been used on weanling (21 
days) C57/BL6J normal mice for 30 days. The total concentration of carbonyl iron 
used was 25,000 mg/kg feed (Lan and Jiang 1997). Striatal iron content measured 
using atomic absorption and emission spectroscopy was found to be significantly 
increased as compared to control mice on normal diet. In another separate study, 
C3H/HeNCrl male mice (5 weeks old) were given iron-enriched diet (1000 mg/kg 
feed) up to 26 weeks. While hematologic parameters of iron, such as transferrin 
saturation, haemoglobin and hematocrit count, and serum iron were not significantly 
changed, nonetheless liver and spleen iron content was substantially altered. Liver and 
spleen iron content were increased by an average of 2.4 and 1.6 folds after 6-months 
of iron-supplementation, respectively (Jiao, Wilkinson et al. 2009). While these 
experiments were performed on mice of relatively younger age from 2 to 5 weeks old, 
these mice might not be sufficiently mature for the study of iron- and age-related 
neurodegenerative process.  
Hence, as an initial optimization on how age and dietary manipulation would affect 
iron loading into the brain of mice, male adult non-Tg and DMT1_Tg mice were 
given iron-enriched diet for a stipulated time before the determination of iron 
deposition. To do this, the study design involved 2 groups of mice. In group one; non-
Tg and DMT1_Tg male mice of 9 months of age were given iron-enriched diet. 
Carbonyl-iron was supplemented into AIN93M background feed to reach a total iron 
content of 1000 mg/kg feed. AIN93M was chosen as it is an improved version of the 
previous AIN76A, with reduced fat and protein for the maintenance of adult mice 
(Reeves, Nielsen et al. 1993, Reeves 1997). As a control, group two consisted of age-
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matched non-Tg and DMT1_Tg mice and were given normal AIN93M feed which 
contained 39 ppm (equivalent to 39 mg/kg feed) trace iron. Hence, the mice on iron-
enriched feed were given with approximately 25 times more iron than normal diet. 
The mice were fed ad-libitum for another 9 months prior to further experimentation. 
The mice were sacrificed at 18 months of age for analysis.  
3.3.3 Brain iron content in DMT1_Tg measured using T2-weighted magnetic 
resonance imaging (T2-MRI) 
The diagnostics for the detection of iron accumulation in patients with suspected brain 
iron accumulation heavily rely on scanning methods. The magnetic resonance 
imaging (MRI) is a non-invasive scanning method frequently used for detection of 
iron accumulation in the brain (McNeill, Birchall et al. 2008). Unlike iron 
accumulation in other systemic organs such as the liver and heart, haematological as 
well as tissue biopsies are unlikely to assist in the diagnosis of brain iron 
accumulation. As iron is paramagnetic, abnormal deposition of iron in the brain alters 
the homogeneity of the magnetic field and consequently enhancing tissue T2 
relaxation. Based on this characteristic, changes in T2 relaxation (or T2 shortening) 
using MRI is usually associated with iron accumulation in the brain, which displays a 
decrease to the signal intensity of T2-weighted images, and hence called T2 
hypointensity (Chen, Hardy et al. 1993, Vymazal, Righini et al. 1999).  
In collaboration with the Singapore BioImaging Consortium (SBIC), Agency for 
Science, Technology and Research (A*STAR), T2-weighted MRI images of non-Tg 
and DMT1_Tg mice under iron-enriched diet were obtained. By investigating iron 
accumulation in the cortical and midbrain region of DMT1_Tg, the brains were 
scanned at the coronal plane. As shown in Figure 3.23 (A-C), the reference regions of 
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interest are highlighted in green, with images taken from Allen Institute for Brain 
Science.   
 
FIGURE 3.23. Magnetic resonance imaging (MRI) and iron deposition in the brain. (A) Reference 
coronal sections showing the location of the (A) cortex, (B) midbrain reticular nucleus, and (C) 
substantia nigra. Images were obtained from Brain Explorer Version 2.3. Image credit goes to Allen 
Institute for Brain Science. (D) MRI findings in DMT1_Tg. T2-weighted MRI showed marked 
hypointensity (T2 shortening) suggesting iron deposition in the substantia nigra, including the pars 
compacta and pars reticulata of the DMT1_Tg brain. Accompanying bar chart shows the densitometric 
analysis of the hypointensity of the regions in arbitrary units. T2-weighted MRI was performed in 
collaboration with Singapore BioImaging Consortium, A*STAR. Experiments were repeated with at 
least three mice per group.  
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T2 hypointenisty was specifically detected in the substantia nigra (SN), including the 
pars reticulata (SNpr) and pars compacta (SNpc) of the DMT1_Tg as compared to 
non-Tg (Figure 3.23D-E). While the transgene expression was shown to be 
widespread, nonetheless iron accumulation in other regions such as the midbrain 
reticular nucleus (Figure 3.23B) and cortex including the hippocampus (Figure 
3.23A) did not show any significant T2 shortening as compared to the SN. Thus, the 
SN profoundly shows selective iron deposition in the presence of DMT1 
overexpression, under the mouse prion promoter.  
3.3.4 Brain iron content in DMT1_Tg measured using proton-induced X-ray 
emission (PIXE) and histological Perls iron staining  
While brain MRI T2 shortening is highly associated with iron and ferritin 
accumulation, we further investigated the specific accumulation of iron in the SN by 
performing proton-induced X-ray emission spectrometry (PIXE). PIXE allows the 
determination of the elemental make-up of the tissue sample in high sensitivity. PIXE 
read-out relies on the identification of emitted electromagnetic radiation that is unique 
to individual elements. The initial proton beam generated from an ion accelerator of 
between 1 and 3 MeV energy would sufficiently energize the protons in the target 
atoms. This results in the ionization and excitation of the inner shell electrons. In the 
process of the electrons returning to the relaxed state, X-rays are being produced; and 
it is the production of these X-rays which allows the characteristic identification of a 
particular element and their relative contribution to the spectra in the samples 
analyzed (Kemp and Danscher 1979, Temlett, Landsberg et al. 1994).  
Thus, freeze-dried non-Tg and DMT1_Tg coronal brain slices containing the SN were 
subjected to PIXE analysis. The microprobe was carefully place in the SN region and 
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energized with a 2MeV protons. As shown in Figure 3.24A, typical elemental spectres 
of non-Tg and DMT1_Tg were generated. In the PIXE spectra, elemental iron is 
usually presented as two peaks among other peaks for other elements. Indeed, the X-
ray intensity counts for both iron peaks were higher in the DMT1_Tg than non-Tg, 
suggesting an increase in iron content in the SN region. On average of three 
DMT1_Tg, iron content was found to be increased by as much as 30% as compared to 
non-Tg.   
 
FIGURE 3.24. Proton-induced X-ray emission (PIXE). (A) Representative PIXE spectrum of non-Tg 
and DMT1_Tg showing profiles of metal elements. The DMT1_Tg showed approximately 30% 
increase in total iron content (peaks for Fe2+ and Fe3+) in the SN. (B) Representative elemental density 
maps showing increase in iron density in the SN of DMT1_Tg as compared to non-Tg. The images 
were depicted in false colours, where blue spots represent iron. Images were representative SN of non-
Tg (right) and DMT1_Tg (left). At least three mice per group were used for these experiments. PIXE 
experiments were performed in collaboration with Dr. Frank Watt from Department of Physics, NUS. 
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To complement the elemental spectrum, the brain slices were also raster-scanned 
(sequence of horizontal stripes) using the ion accelerator microprobe at 2MeV protons 
to generate an iron distribution map of the SN region. The iron distribution map is 
based on the Rutherford backscattering analysis (RBS) or more commonly known as 
nuclear magnetic resonance imaging. RBS measures the backscattered proton beam 
that was initially impinged onto the samples. The backscattered beams allow the 
reconstruction of density maps of elements, including iron (Ren, Ong et al. 2003). The 
SN region of the DMT1_Tg showed increased counts of blue spots as compared to 
non-Tg, indeed indicating an increase in elemental iron in the samples (Figure 3.24B).  
 
FIGURE 3.25. Histological Perls Prussian blue iron staining. Perls iron staining of hippocampus and 
SN of non-Tg and DMT1_Tg mice. 40X objective light microscope images of the SN neurons with 
dense blue iron staining. (D) Accompanying bar chart is the quantification of the density of blue 
staining in the SN. The density of at least 10 spots was analyzed per section. At least two mice per 
group were analyzed for this experiment with error bars representing standard deviation (S.D.). 
 
In addition, Perls Prussian blue iron staining (Perls) was also performed on the slices 
to detect for iron. Perls is based on the chemical reaction between ferric ions (Fe3+) 
and acidic potassium ferrocyanide to form insoluble ferric ferrocyanide. As Fe3+ is 
usually found within ferritin, the acidic solution is required to dissociate the iron from 
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ferritin nanocage and rapidly have the iron reacted with potassium ferrocyanide to 
form blue granules (Meguro, Asano et al. 2008). Thus, under the light microscope, the 
SN region of the DMT1_Tg was observed to contain more neurons with denser blue 
staining as compared to non-Tg, although the number of blue-stained neurons was 
almost equal in both non-Tg and DMT1_Tg sections (Figure 3.25). The hippocampus 
was also examined but did not show any observable Perls staining in both non-Tg and 
DMT1_Tg. Taken together, we confirmed that the DMT1_Tg showed iron 
accumulation in the brain, particularly detected in the SN. To verify that the MRI T2 
hypointensity in the SN was due to iron deposition, the PIXE spectra as well as 
nuclear magnetic resonance iron density map supported this finding. In addition, the 
conservative method of using Perls staining to detect for ferritin-bound iron also 
confirmed the increase in iron content in the SN of DMT1_Tg as compared to non-
Tg.  
3.3.5 DMT1 and iron-mediated microglial activation 
As we have observed substantial iron accumulation in the SN of the DMT1_Tg, we 
sought evidence whether the accumulation of iron resulted in the loss of TH neurons. 
Coronal cryo-sections of the SN were prepared and stained with TH antibody. The 
sections were viewed under confocal microscopy. However, we did not discover any 
major loss of TH neurons in SN of the DMT1_Tg (Figure 3.26A). To further 
corroborate that there was no significant loss of TH neurons, regional SN was isolated 
from the DMT1_Tg and non-Tg for western analysis. By staining for TH, we did not 
observe any significant change to TH immunoreactivity, with actin as loading control 
(Figure 3.26B). This observation was not surprising, as prior to TH staining we did 
not observed any motor-associated deficits in the DMT1_Tg as determined using 
rotarod performance test (Figure 3.26C).  




FIGURE 3.26. TH neurons and microglial activation. (A) Immunofluorescence of TH-containing 
neurons using TH antibody in the SN of non-Tg and DMT1_Tg. No major loss to TH neurons was 
observed. (B) Representative western blot showing the expression of TH in the SN. Accompanying bar 
chart is the protein density of TH, normalized to actin. (C) Rotarod performance of DMT1_Tg was 
determined by averaging the latency to fall by mice after three 240 sec trials. (D) Detection for 
microglial activation using CD11B in the SN of the non-Tg and DMT1_Tg. Marked microglial 
activation in the SN of DMT1_Tg. Microglial activation was characterized by increase in CD11B 
immunoreactivity and morphological change of cells to assume a more amoeboid-like structure. 
Experiments were performed at least three times, with error bars representing standard error (S.E.). 
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While TH neurons were not significantly affected, we questioned whether non-
neuronal cells were affected by iron deposition. Increased iron deposition in the SN 
could possibly initiate neuroinflammatory events facilitating the degeneration process 
(Ong and Farooqui 2005). Hence, we determined whether there was any sign of 
neuroinflammation by examining the microglial cells in the SN of the DMT1_Tg. 
CD11B is a specific cell surface marker for macrophages, which is part of the innate 
immunity. During development, a fraction of these macrophages reside in the brain 
and mature to become resident macrophages called microglial cells. Resting 
microglial cells usually assume a ramified structure with a small cell body. Activated 
microglial cells are associated with enlarged cell body and retracted ramifications 
(Roy, Jana et al. 2008). To examine the presence of neuroinflammation in the 
DMT1_Tg, brain cryo-sections containing the SN were stained with CD11B and 
developed using DAB. As shown in Figure 3.26D, the SN of DMT1_Tg was found 
with marked increase in CD11B immunoreactivity (40X objective). At closer 
examination (100X objective), the microglial cells were found to be activated, 
typified by enlarged cell bodies. As microglial activation is generally associated with 
inducible nitric oxide synthase (iNOS) upregulation (Roy, Jana et al. 2008), we 
further verified the expression of iNOS in these cells. To test this, the brain sections 
were co-stained with CD11B and iNOS antibody, and subsequently conjugated with 
red and green fluorescence, respectively. As shown in Figure 3.27A, the SN of 
DMT1_Tg was observed with increased immunoreactivity for CD11B, shown in red. 
In addition, iNOS (green) immunoreactivity was also observed in the DMT1_Tg, 
which co-localized with CD11B. This suggests that microglial activation in the SN of 
DMT1_Tg is associated with the increased expression of iNOS, which was not 
observed in the SN of non-Tg.  





FIGURE 3.27. Microglial activation associated with nitrosative stress. (A) Co-localization of 
CD11B (red) and iNOS (green) in the SN of DMT1_Tg using immunofluorescence analysis. (B)  
Representative images of immunohistochemical method for the detection of nitrated proteins using 
nitrotyrosine antibody (3-NT). Marked increase in brown DAB staining were observed in the SN of 
DMT1_Tg. Accompanying bar chart showing the average density of nitrotyrosine residue of each cell. 
At least 25 cells were analyzed per section with error bars representing standard deviation (S.D.).  
 
 The upregulation of iNOS is known to increase the production of uncontrolled nitric 
oxide (NO), which is a free radical species. Excessive release of NO could lead to the 
formation of peroxynitrite through its reaction with superoxide anion (·O2− + ·NO → 
ONOO−). Peroxynitrite is a strong nitrating agent which may result in the formation 
of nitrotyrosine residues in proteins (Tsang and Chung 2009). As we observed 
increased expression of iNOS in the microglial cells of the SN in the DMT1_Tg, we 
sought evidence whether the increase in iNOS was associated with nitration of 
proteins. Indeed, using a specific antibody, 3-nitrotyrosine (3-NT) for the detection of 
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nitrated proteins, we found that the SN of DMT1_Tg has increased immunoreactivity 
for 3-NT (Figure 3.27B) using DAB immunohistochemical method. By quantifying 
the brown density of each cell in the SN, we determined the density of 3-NT staining 
in the DMT1_Tg as compared to non-Tg. The SN neurons of the DMT1_Tg were 
found to have an average of 2-fold increase in 3-NT immunoreactivity as compared to 
non-Tg. Taken together, the DMT1_Tg mice showed selective iron deposition in the 
SN upon dietary supplementation with carbonyl iron for 9 months. Even though there 
was no obvious reduction in TH neurons or SN-related motor deficits tested using 
rotarod, the increase in iron was associated with neuroinflammation characterized by 
microglial activation and nitrosative stress. We reasoned that if the mice were aged 
beyond 9 months upon iron-feeding, likely a significant phenotype could be observed.  
  




3.4 The Role of Nitric Oxide (NO) on DMT1 Function 
The selective deposition of iron in the SNpc of PD remains elusive. DMT1 expression 
has been reported to be upregulated in a mouse model of PD intoxicated with MPTP. 
In addition, the DMT1/+IRE was found to be significantly increased in the SNpc of 
PD patients with microglial cells activation. Numerous microglial cells (CD68) co-
stained with DMT1 were observed in the SNpc, suggesting a possible association 
between DMT1 expression and microglial activation. As microglial activation is 
associated with iNOS-derived NO production, we questioned whether the NO 
produced by iNOS could modulate the function of DMT1. This could potentially be a 
link for the selective iron deposition in the SN and the selective vulnerability of the 
SN to cell death in PD.  
3.4.1 NO increases DMT1-mediated Fe2+ influx 
To investigate the role of NO in modulating DMT1 function, several nitric oxide 
donors were chosen for this purpose. SIN-1 and SNAP are short-lived spontaneous 
NO donors while NOC-18 is a long-lived spontaneous NO donor. NOC-18 is 
considered a long-lived donor due to its spontaneous rate-controlled release of NO. S-
DMT1 cells were treated with 500 μM of nitric oxide donors (SIN-1, SNAP and 
NOC-18) for 3 hr and thereafter incubated with Fe55 (100 μM) for 30 min at pH 5.5. 
As a control, cells were also treated with GSH which is an inactive NO donor. As 
shown in Figure 3.28, all three NO donors mediated a significant influx of iron into 
the cells measured using a scintillation counter. As 500 μM of NOC-18 was observed 
to significantly (p<0.01) increase the uptake of iron, NOC-18 was chosen for 
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subsequent experiments. This portion of the experiment was performed by a colleague 
who is certified to handle radioactive isotope. 
 
FIGURE 3.28. Nitric oxide increases DMT1-mediated iron uptake. Both short and long-lived nitric 
oxide donors were shown to mediate the uptake of Fe2+ into cells overexpressing DMT1. NOC-18, 
which is a long-lived donor showed robust uptake of cells. Iron uptake assay was performed at least 
three times with error bars representing standard error (S.E.) with *, p<0.01.  
 
3.4.2 NO-mediated S-nitrosylation of DMT1 
The indirect effect of nNOS-derived NO on DMT1 function has previously been 
reported. As the activation of glutamate-NMDA receptors stimulates nNOS activation 
through Ca2+ signalling, this leads to the S-nitrosylation of Dexras1. The interaction 
between S-nitrosylated Dexras1, PAP7 and DMT1 enhances iron uptake (Cheah, Kim 
et al. 2006). While the S-nitrosylation of Dexras1 could affect DMT1 function, we 
wondered whether there was a direct effect of NO on DMT1 function. Notably, we 
have shown that cells overexpressing DMT1 was observed to uptake more Fe2+ in the 
presence of NO donors. Figure 3.29A shows the putative topology of the DMT1 with 
possible cysteine residues available for S-nitrosylation. To test this hypothesis, we 
performed the biotin-switch assay on the protein lysates of SH-SY5Y cells stably 
overexpressing DMT1. The biotin-switch protocol was kindly given to us by Dr. 
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Viktor Korolchuk, Newcastle University, which was originally from Professor 
Solomon Snyder’s laboratory, Johns Hopkins University. The optimization of the 
biotin-switch protocol was performed by Bryce Tan, a year-one NUS medical student 
under our supervision. Prior to the treatment of the protein lysates with NOC-18 (200 
μM) for 1 hr, the cells were lysed using a non-SDS (non-reducing) buffer to preserve 
the native structure of the proteins. This was important as we wanted to only 
determine physiological cysteine residues susceptible to S-nitrosylation. The S-
nitrosylated protein was then tagged with biotin and pulled down using avidin beads. 
Parkin is known to be S-nitrosylated (Chung, Thomas et al. 2004). Therefore, parkin 
protein lysates acquired from SH-SY5Y cells overexpressing parkin from our 
laboratory was used as a positive control in the biotin-switch assay. As shown in 
Figure 3.29B, in the presence of biotin, parkin and NOC-18, parkin was found to be 
pulled down by avidin beads (lane 4), confirming that parkin was S-nitrosylated. 
Using the same conditions for parkin, DMT1 was discovered to be S-nitrosylated 
(lane 3). To rule out any possibility of unspecific pull down, lysates with (i) DMT1 
and NOC-18, without biotin (lane 1) or (ii) DMT1 and biotin, without NOC-18 (lane 
2) were not pulled down with avidin beads as shown in the absence of DMT1 
immunoreactivity in the pull down panel as compared to the input panel (lane 5, 6, 
and 7). Taken together, we have found a novel mechanism of NO in affecting DMT1 
function through S-nitrosylation. The S-nitrosylation of DMT1 was confirmed to 
enhance the uptake of Fe2+ and may suggest a possible link between nitrosative stress 
and iron accumulation in neurodegenerative diseases. The 12 individual cysteine 
residues of the DMT1 has been systematically mutated to alanine using site-directed 
mutagenesis and further investigation is currently in progress to determine which 
cysteine residue(s) are important for S-nitrosylation.    





FIGURE 3.29. S-nitrosylation of DMT1. (A) Putative topology of DMT1B. Black dots show potential 
cysteine residue(s) susceptible to S-nitrosylation. (B) Biotin-switch assay. Protein lysates from cells 
overexpressing DMT1 or parkin were treated with NOC-18 for 3 hr before proceeding with biotin-
switch assay. Parkin was used as a positive control for S-nitrosylated protein. GSH was used as an 
inactive NO donor. Both DMT1 and parkin were shown to be S-nitrosylated in the presence of NOC-
18 and biotin, but not in the GSH and biotin pull down fractions.  
  




 DISCUSSION AND CONCLUSIONS  
The overall objectives of this thesis are (i) to understand the cellular interactions 
between Mn2+ and Fe2+ via DMT1; (ii) to characterize the novel transgenic mouse 
model of DMT1 overexpression and (iii) to examine the role of nitric oxide on DMT1 
function. On the completion of the project, I have made several important discoveries 
that have helped refine our knowledge on the role of DMT1 and cellular Fe2+ and 
Mn2+ interaction. In the first part of the thesis, I have attempted to compare and 
contrast the cytotoxic effects of Fe2+ and Mn2+ on cell viability and MAP kinase 
pathway in SH-SY5Y cells overexpressing DMT1. The results in this thesis reveal 
that in addition to Mn2+ cytoxicity per se, Mn2+ overexposure could mediate 
disturbance to intracellular iron homeostasis. This is due to the preferential 
accumulation of Mn2+ in the cytoplasm thus disrupting labile iron pool. In addition, I 
have uncovered that the robust activation of autophagy upon Mn2+ exposure was 
important for the maintenance of iron homeostasis, through the degradation of ferritin. 
The activation of autophagy was independent of JNK phosphorylation, which appears 
to be the major MAP kinase responsible for arbitrating the cytotoxic effect of Mn2+. 
However, unlike the conventional ROS-dependent activation of JNK and autophagy, 
Mn2+ exposure was not associated with the increase in intracellular ROS. 
Nonetheless, JNK activation upon Mn2+ exposure was revealed to be associated with 
iron depletion as inhibition to ferritin degradation via lysosomal or autophagy 
inhibition further enhanced JNK activation. In addition, pre-treatment of cells with 
Fe2+ was found to partially suppress JNK phosphorylation mediated by Mn2+ 
exposure. As a concluding study to part of one of the thesis, thioredoxin (TRX) 
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overexpression showed that Mn2+-mediated JNK activation proceeds via the TRX-
ASK1-JNK pathway.  
In part two of this thesis, I have characterized the transgenic model of brain DMT1 
overexpression for the investigation of iron and manganese neurotoxicity studies. 
While the DMT1 transgene driven by the mouse prion promoter was widespread in 
the brain, T2-weighted MRI, PIXE and Perls Prussian blue staining have 
demonstrated selective iron deposition in the substantia nigra (SN) region. DMT1-
mediated iron deposition in the SN was shown to be associated with microglial 
activation, increase in iNOS-derived NO and nitrated proteins. Finally, to investigate 
the relevance of the NO and DMT1 function, in part three of the thesis, S-
nitrosylation studies demonstrated that NO indeed could enhance iron uptake into 
cells through the direct S-nitrosylation of DMT1. This result indicates a likely 
interplay between neuroinflammation and selective iron deposition in 
neurodegenerative diseases. Taken together, the findings in this thesis have clarified 
the fundamental aspects underlying Mn2+ cytotoxicity and revealed a novel 
pathomechanism behind iron accumulation via DMT1. In this concluding chapter, I 
shall discuss these results in perspective.  
4. 1 Part One  
The involvement of DMT1 in mediating cellular Mn2+ toxicity has not been 
comprehensively investigated. We have identified the intracellular interplay between 
Fe2+ and Mn2+ in mediating Mn2+ toxicity (Figure 4.1). In our study, the 
overexpression of DMT1 facilitated a concentration-dependent uptake of Mn2+ into 
the cytoplasm of the cell. Indeed, cytoplasmic accumulation of labile Mn2+, measured 
using Calcein-AM, contributed substantially to the loss in cell viability as there is no 
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known manganese storage protein. Unlike iron, the lack of specialized proteins to 
scavenge manganese ions is likely due to the minimal cellular requirement for 
manganese. In fact, most of the manganese ions are mostly bound to saturable 
metalloproteins such as glutamine synthetase and arginase, which are abundantly 
found in the brain especially in astrocytes (Carl, Blackwell et al. 1993, Takeda 2003).  
 
Figure 4.1. A proposed model of cellular Mn2+ toxicity via DMT1. (A)  Under normal conditions, 
cells acquire adequate amounts of Fe2+ through cellular uptake via DMT1 and degradation of ferritin to 
maintain LIP and metabolic processes. (B) However, Mn2+ overexposure competes with Fe2+ for 
DMT1. In addition, the accumulation of Mn2+ in the cytoplasm disrupts LIP, resulting in the enhanced 
autophagy to degrade ferritin for Fe2+ mobilization. Mn2+-mediated cellular iron depletion also results 
in the activation of JNK via the TRX-ASK1 pathway, leading to reduction in cell viability and death.   
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Therefore, apart from Mn2+ cellular uptake, it is likely that the requirement for 
physiological Mn2+ is met via the proteolysis of metalloproteins and the recycling of 
the ions. While we initially predicted similar accumulation of cytoplasmic chelatable 
Fe2+ pool, however it was not supported in our data. Interestingly, Fe2+ treatment only 
resulted in a 25% expansion in labile iron pool (LIP) which did not drastically affect 
cell viability. The upregulation of ferritin upon Fe2+ treatment protected the cells 
against Fe2+-mediated cytotoxicity. This is similarly supported by another study that 
demonstrated the protection against iron-containing heme through exogenous 
overexpression of ferritin heavy chain, which converted the reactive Fe2+ into the non-
reactive Fe3+ (Regan, Kumar et al. 2002). Additionally, Mn2+-mediated cell viability 
reduction could be partially restored with Fe2+ co-treatment, suggestive of the 
competition between Fe2+ and Mn2+ at the DMT1 entry level. This is in agreement 
with a  recent electrophysiological study which demonstrated Mn2+ being a substrate 
competitor of Fe2+ for DMT1 (Illing, Shawki et al. 2012).  
The mechanism of cell death mediated by Mn2+ remains controversial and may 
involve multiple forms of cell death (Chun, Lee et al. 2001, Roth, Horbinski et al. 
2002, Afeseh Ngwa, Kanthasamy et al. 2011, Costa, Zito et al. 2011). While many 
studies demonstrated the involvement of apoptosis in Mn2+-mediated cell death, 
however the exact mechanism leading to apoptosis remains elusive. Our current study 
demonstrated that the JNK signalling pathway played the important role in mediating 
cell viability reduction in the presence of Mn2+. The rescue through JNK inhibition 
(SP600125) indeed showed the prominence of this pathway in Mn2+ cytotoxicity. 
While Mn2+ cytotoxicity in SH-SY5Y neuroblastoma cells were found to be mediated 
via JNK pathway, another study using lymphoma B-cells confirmed the importance of 
p38 MAP kinase pathway (El Mchichi, Hadji et al. 2007). Therefore, the unresolved 
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controversy in Mn2+-mediated cell death is likely to be due to cell variation and the 
involvement of different signalling pathways (Schrantz, Blanchard et al. 1999, Roth, 
Feng et al. 2000, Oubrahim, Chock et al. 2002, Anantharam, Kitazawa et al. 2004, El 
Mchichi, Hadji et al. 2007).  
Discussing further into the relevance of JNK activation in Mn2+ cytotoxicity, it is 
known to mediate both type I (apoptosis) and type II (autophagic cell death) 
programmed cell death (Wong, Iskandar et al. 2010, Liang, Nagai et al. 2011). As the 
effect of Mn2+ on apoptosis has been reported, the relevance of autophagy remains 
unexplored. We questioned whether autophagy would be affected as there was 
heightened JNK phosphorylation upon Mn2+ exposure. Autophagy is considered as a 
pro-survival response upon exposures to toxicants, invading pathogens, starvation and 
during intrinsic cellular stress (Dalby, Tekedereli et al. 2010, Amelio, Melino et al. 
2011). However, unregulated or excessive stimulation of autophagy may be 
detrimental, especially to post-mitotic cells such as neurons (Huang and Klionsky 
2007, Mizushima, Levine et al. 2008). Indeed, such pro-death role of enhanced 
autophagy has been reported in our previous finding illustrating an example of 
intrinsic cellular stress from mutant α-synuclein overexpression and chronic Fe2+ 
overload (Chew, Ang et al. 2011).  
For the first time, my current work reports the robust activation of autophagy with 
Mn2+ treatment. We were initially optimistic that Mn2+ could potentially stimulate 
autophagy towards pro-death as it has been shown that preceding JNK activation 
could lead to autophagic cell death via the phosphorylation of Bcl-2, the negative 
regulator of autophagy (Shimizu, Konishi et al.). Even though Mn2+ treatment in our 
experiments showed significant stimulation of JNK in a time- and concentration-
dependent manner, however, our data did not support the role of autophagy in 
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mediating cell death for several reasons. We showed that chemical inhibition of JNK 
phosphorylation did not correspondingly decrease autophagy, thus clarifying that 
autophagy stimulation provoked by Mn2+ is independent of JNK phosphorylation. 
Instead, we found that stimulation of autophagy during Mn2+ exposure played a pro-
survival role. At the outset, we tried using chemical inhibitors to autophagy to 
substantiate its pro-survival role. When cells were treated with unspecific PI3K Class 
III inhibitors (3-MA and WM) at optimized concentrations used in our laboratory, the 
cells did show any significant reduction in cell viability when treated with Mn2+. We 
reasoned that perhaps the unspecific inhibitory effect on both PI3K Class I and Class 
III might have produced antagonistic effects. While the inhibition of PI3K Class III is 
associated with autophagy suppression, the inhibition of PI3K Class I stimulates 
autophagy. Indeed, it was reported that when 3-MA was used in nutrient-rich cultures, 
autophagy was stimulated due to PI3K Class I inhibition. It was then followed by 
autophagy inhibition when nutrients were low through the inhibition of PI3K Class III 
(Wu, Tan et al. 2010). Therefore, the nutrient-dependent effect of these inhibitors 
likely explains the failure to produce the expected results with Mn2+ on MTT cell 
viability assay. Nonetheless, the pro-survival role of autophagy was indeed confirmed 
in autophagy-deficient MEF cells as they were more sensitive towards Mn2+ toxicity 
as compared to WT cells.  
Unlike the pro-death role of autophagy in the presence of Fe2+ and mutant α-synuclein 
(Chew, Ang et al. 2011), we discovered that autophagy upon Mn2+ exposure is crucial 
for the maintenance of iron homeostasis. Indeed, several studies have shown the 
importance of autophagy in targeting ferritin towards lysosomes for terminal 
degradation and iron mobilization (Radisky and Kaplan 1998, De Domenico, Vaughn 
et al. 2006, Zhang, Mikhael et al. 2010). Prior to this, we initially questioned whether 
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the loss of ferritin upon Mn2+ exposure was a process of protein aggregation. 
Importantly, the mutant form of the ferritin light chain, mp.Phe167SerfsX26 (MT-
FTL) associated with hereditary ferritinopathy has been shown to have a higher 
propensity towards misfolding in the presence of iron overload (Baraibar, Barbeito et 
al. 2008). Even as the aggregation of wild-type ferritin heavy chain has not been 
reported, this gave me the impetus to examine the effect of Mn2+ on ferritin 
aggregation. And it was revealed in my study that even in high amounts of ferritin 
protein after Fe2+ induction, Mn2+ did not result in ferritin aggregation but the 
proteolysis of it. While one study suggested that Mn2+ could directly interfere with 
IRPs (especially IRP2) and thus promoting the binding of IRPs to IRE to reduce 
ferritin synthesis (Crooks, Ghosh et al. 2007), my study provided evidence that Mn2+ 
resulted in the proteolysis of ferritin with heightened autophagy.  
Even as the putative proteins responsible for the degradation of ferritin mediated by 
Mn2+ are currently unknown, nonetheless we also tested whether it could be Mn2+-
mediated JNK phosphorylation which targeted ferritin for degradation. Unlike a study 
involving TNF-α which reported the degradation of ferritin via JNK activation 
(Antosiewicz, Ziolkowski et al. 2007), it is not so for Mn2+ as we showed that ferritin 
degradation is independent of JNK. The breakdown of ferritin by TNF-α was 
followed by the increase in labile iron and ROS. And iron-catalyzed ROS was 
proposed for the stimulation of JNK. However, unlike TNF-α, Mn2+ is not associated 
with the increase in intracellular ROS. Additionally, we also ruled out the 
involvement of Fe2+ in mediating JNK activation by overexpressing ferritin heavy 
chain to scavenge Fe2+. Ferritin overexpression did not halt the activation of JNK 
provoked by Mn2+. Paradoxically, JNK activation mediated by Mn2+ does not proceed 
via ROS or Fe2+. Indeed, it was suggested that Mn2+ does not readily participate in the 
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Fenton chemistry to generate ROS but may act as an antioxidant (Kurz and Brunk 
2009, De Domenico, Ward et al. 2010, Castino, Fiorentino et al. 2011). While 
manganese is generally associated with mitochondrial SOD (SOD2) as an antioxidant, 
the existence of non-proteinaceous manganese complexes (non-SOD Mn2+) carrying 
antioxidant capabilities is barely discussed. These non-SOD Mn2+ were initially found 
in Lactobaccilus plantarum that lacks SOD yet resistant to O2·-  (Daly 2009). L. 
plantarum accumulated high amounts of non-SOD Mn2+ which have superoxide 
scavenging effect. In addition, the effect of these non-SOD Mn2+ was also established 
in both unicellular and multicellular organisms genetically-modified to be deficient in 
MnSOD, including in strains of Escherichia coli, Neisseria, Baccillus and yeast 
Saccharomyces Cerevisiae (Aguirre and Culotta 2012). The higher organism 
Caenorhabditis elegans fed with manganese supplementation similarly exhibited 
resistance towards oxidative stress. While the mechanism on how non-SOD Mn2+ 
scavenges superoxide is not known, it likely explains the reduction in superoxide 
levels observed in my study. Nevertheless, even though Mn2+ may act as an 
antioxidant, its overexposure out-competes Fe2+ for DMT1 and intracellular 
signalling, which eventually compromises cell viability through iron starvation.  
Additionally, autophagy-lysosomal deficiency and the presence of Mn2+ overexposure 
could result in the aggravation of cell viability due to reduction in ferritin degradation 
and iron mobilization. Indeed, cellular iron starvation has been associated with cell 
cycle arrest, DNA damage and apoptosis. The effect of iron starvation was previously 
reported to be mediated via the upregulation of the growth arrest and DNA damage 
45alpha protein, GADD45alpha (Saletta, Suryo Rahmanto et al. 2011). However, 
whether GADD45alpha is implicated in Mn2+ -mediated iron depletion remains to be 
explored.  
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In addition, there is a delicate interplay between intracellular Fe2+ and Mn2+ on the 
JNK pathway. Since our hypothesis predicts that Mn2+ affects cellular iron 
homeostasis and result in JNK activation, one study by Yu et al. similarly showed the 
activation of JNK via iron chelation. In particular, Yu et al. demonstrated that cellular 
iron depletion is associated with the ASK1-TRX-JNK pathway (Yu and Richardson 
2011). ASK1 (apoptosis signal-regulating kinase 1) is one of the upstream kinases 
responsible for the activation of JNK. Even as TRX (thioredoxin) is a redox sensor 
bound to ASK1, the oxidation of TRX dissociates itself from ASK1, thus revealing 
the active catalytic site followed by the phosphorylation of JNK (Liu, Nishitoh et al. 
2000, Liu and Min 2002). Together, my work involving Mn2+ toxicity (Chapter 1, part 
one) and iron chelation (Yu and Richardson 2011) firmly established the involvement 
of the ASK1-TRX-JNK pathway in cellular iron depletion.  
Nonetheless, one unresolved controversy is left to be answered. While we found that 
TRX overexpression in my study indeed suppressed JNK phosphorylation provoked 
by Mn2+, the question remains as to what is the initial trigger for the oxidation and 
dissociation of TRX from ASK1? As intracellular ROS level is reduced with Mn2+, it 
is unlikely for the oxidation of TRX to proceed via oxidative stress.  
Nevertheless, there may be a few possible explanations. The conversion of oxidized 
TRX to reduced TRX is maintained by thioredoxin reductase (TrxR). TrxR has been 
shown to be noncompetitively inhibited by trivalent arsenic (Lin, Del Razo et al. 
2001). Thus, the deficiency in TrxR could lead to the accumulation of oxidized TRX 
which leaves ASK1 to freely phosphorylate JNK. Even though this is not proven, 
perhaps there may be a possibility of TrxR inhibition by Mn2+, or even trivalent 
manganese (Mn3+) as both were also found to be potent inhibitors of an unrelated 
aconitase protein.  
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Finally, several rodent studies found that chronic high manganese exposure affected 
the profile of several trace metals in multiple organs including the brain. Injection of 
MnCl2 (I.V.) for 30 days was associated with decrease in iron content in the 
cerebellum with reduction in lipid peroxidation, corroborating our cellular finding of 
iron disruption and reduction in ROS with Mn2+  (Chen, Yiin et al. 2002). In addition, 
another study using I.P. injection of MnCl2 for 30 days resulted in a 32% reduction in 
plasma iron. Interestingly, the CSF of the MnCl2-intoxicated rats were found with 3-
fold increase in iron content as a result of a robust (50%) increase in transferrin 
receptor mRNA and probably protein levels, which could have allowed the 
unidirectional entry of iron despite low plasma iron (Zheng, Zhao et al. 1999). Indeed, 
chronic manganese supplementation was observed to produce behavioural deficits in 
rats with existing iron deficiency, again pointing to the delicate interplay of these two 
metals physiologically (Fitsanakis, Thompson et al. 2009). 
To conclude part one of the thesis, our observations provided insights into Mn2+ 
toxicity involving cellular iron disruption. The loss in cellular ferritin protein during 
Mn2+ exposure is an indicator of iron depletion. The autophagy-lysosomal pathway is 
crucial for the degradation and extraction of iron from ferritin during Mn2+ exposure 
of which the inhibition of the lysosomes could result in enhanced JNK 
phosphorylation through the ASK1-TRX pathway. 
Part Two and Part Three 
Part two and part three of this thesis are initial characterization of the transgenic 
mouse model for iron and manganese studies. As there is significant increase in 
DMT1 in patients with iron deficiency and PD, we sought evidence on whether 
DMT1 overexpression in the brain could indeed facilitate iron and manganese 
accumulation. In particular, as the substantia nigra (SN) of PD patients is often found 
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with selective iron deposition, we wondered whether the overexpression of DMT1 
would similarly promote the selective entry of iron. The mouse prion promoter was 
chosen over other promoters such as the mouse tyrosine hydroxylase (TH) or the 
mouse β-actin promoters for several reasons. The mouse TH promoter could 
specifically drive the expression of DMT1 into TH neurons and presumably with 
accompanying iron accumulation. However, the use of this promoter does not help us 
answer whether there was indeed selective iron deposition in the SN as compared to 
other regions of the brain. Another commonly utilized promoter is the mouse β-actin 
promoter. It is known to drive the expression of transgene to both neuronal and non-
neuronal cells. However, apart from the brain, the β-actin promoter also drives the 
undesirable high expression of the transgene to other peripheral organs (Maskri, Zhu 
et al. 2004). Thus, the prion promoter was chosen and indeed, DMT1 expression was 
shown to be extensively expressed in the brain of the DMT1_Tg. Interestingly, iron 
deposition was selectively found in the substantia nigra detected using T2-weighted 
MRI. The T2 hypointensity observed in the SN was substantially higher and 
recapitulates MRI findings produced in PD patients (Gorell, Ordidge et al. 1995, 
Atasoy, Nuyan et al. 2004). As some may argue that the T2 hypointensity observed in 
DMT1_Tg fed with iron-enriched diet might not be due to iron accumulation per se, 
the validity of the iron elemental species deposited in the SN was further corroborated 
with PIXE and Perls Prussian blue staining. While the reason behind the selective 
deposition of iron in the SN of DMT1_Tg remains elusive; we hypothesize that the 
SN may potentially have a lower physiological pH than the rest of the brain. 
Consequently, the lower pH may facilitate the transport of iron via the proton-
dependent DMT1. Previously, non-invasive method that could allow the measurement 
of brain pH changes with high temporal and spatial resolution was not available. 
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However a method utilizing T1 relaxation MRI was recently discovered to be 
effective in measuring widespread brain pH changes evoked by systematic 
manipulation of carbon dioxide or bicarbonate levels (Magnotta, Heo et al. 2012). 
This method is currently being considered for the determination of pH in the SN of 
our transgenic model.  
In addition, the possibility of region-specific expression of ferric reductases may also 
play a role in influencing the selective iron deposition in the SN. Ferric reductases 
such as STEAP 2 and STEAP 3 are important endosomal membrane glycoprotein 
which mediates the conversion of Fe3+ to Fe2+ for the transport of Fe2+ out into the 
cytoplasm via DMT1 (McKie 2005, Ohgami, Campagna et al. 2005). While currently 
there is no literature to suggest the association between STEAP 2/3 and PD, 
nonetheless one interesting study proposed α-synuclein to contain ferric reductase 
activity, which indeed opens a greater link between iron, α-synuclein and PD (Davies, 
Moualla et al. 2011). And it was recently shown in another convincing study that the 
α-synuclein mRNA which contains the putative iron-response element (IRE) at the 
5’UTR, was responsive to iron treatment (Febbraro, Giorgi et al. 2012). Together, it is 
possible that the initial iron overload in the SN may aid in the upregulation of α-
synuclein, which in turn lead to the increase of Fe2+ due to its ferric reductase activity. 
While α-synuclein can be secreted to the extracellular space (Emmanouilidou, 
Melachroinou et al. 2010), these α-synuclein proteins located on the outside of the 
neuron may mediate the increase in extracellular Fe2+ and subsequently the entry into 
neuron via DMT1. As the SN in both humans and mice has been shown to be 
vulnerable to α-synuclein pathology (Tofaris, Garcia Reitbock et al. 2006, Uversky 
2008), the increase in Fe2+ ion within the cell may increase intracellular ROS and 
eventually the misfolding of α-synuclein and the formation of Lewy bodies, leading to 
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neuronal cell death. While these considerations remain highly speculative, it does 
indicate that vulnerability of the SN is likely due to inherent properties of the SN not 
found in other regions.   
Further corroborating the role of DMT1 in metal ion entry, another group proposed 
the use of DMT1 as a reporter protein in manganese-enhanced MRI (MEMRI) 
(Bartelle, Szulc et al. 2012). In the study, tumorigenic GL261 glioma cells 
overexpressing DMT1 were stereotaxically injected into the brain of C57BL/6J mice 
and a tumour was allowed to grow for 3 weeks. T1 hyperintensity (a measure of 
manganese accumulation) was greatly enhanced in the DMT1 containing tumour cells 
upon MnCl2 I.P. injection as compared to neighbouring brain regions or control cells. 
In addition, our preliminary investigation of DMT1_Tg (n=8) fed with manganese-
enriched diet (1000mg/kg feed) after 16 weeks showed significant (p<0.05) reduction 
in rotarod performance as compared to non-Tg (n=8) (Figure A2C, Appendix). The 
high dietary manganese likely affected the brain motor function of the DMT1_Tg, 
which is currently under intense investigation in our laboratory. Together, these 
suggest that the overexpression of DMT1 indeed could facilitate the entry of both iron 
and manganese to the brain.  
As there was increased nitrosative stress in the DMT1_Tg fed with iron, it is worth 
discussing its role in neurodegeneration and metal toxicity. Endogenous NO is an 
important regulator of physiological and pathological events (Choi 1993). While 
Ca2+-regulated release of NO via neuronal NOS (nNOS) and endothelial NOS (eNOS) 
is important for biological signalling, inducible release of NO via iNOS is associated 
with harm to cells. Unlike nNOS and eNOS, the release of NO by iNOS is 
unregulated and independent of Ca2+ signalling. The high output of NO radical from 
iNOS is mediated primarily by microglia and is important in destroying invading 
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pathogens. Nonetheless, uncontrolled NO production may affect the viability of 
neighbouring cells as a bystander effect (Block and Hong 2007, De Lella Ezcurra, 
Chertoff et al. 2010). Furthermore, the microglial activation and neuroinflammation 
has long been suggested as a major contributor to the neurodegeneration process (Lull 
and Block 2010). While microglial activation is usually associated with brain injury 
and invading pathogens, there are studies to suggest the involvement of transition 
metal ions as an inducer of microglial activation (Chang and Liu 1999, Filipov, 
Seegal et al. 2005, Crittenden and Filipov 2008). Importantly, DMT1/+IRE 
upregulation along with microglial activation has been observed in the SN of PD 
patients (Salazar, Mena et al. 2008). Thus, the activation of microglia in the SN of 
DMT1_Tg indeed suggest a link between DMT1-mediated iron deposition and 
neuroinflammation.  
In addition, the upregulation of iNOS in amoeboid-like activated microglia was 
observed in a rat model of neurodegeneration using LPS (Arimoto and Bing 2003). 
Interestingly, manganese has been shown in several in-vitro and in-vivo studies as a 
potent inducer of neuroinflammation. BV2 microglial cells treated with Mn2+ was 
found to stimulate the expression of iNOS and was proposed to be mediated via 
JNK/ERK and P13K/AKT signalling pathways (Bae, Jang et al. 2006). In chronic 
manganese exposure study, prominent microglial activation along with increased 
iNOS, L-ferritin and intracellular ferric iron was observed in the SN of non-human 
primates (Verina, Kiihl et al. 2011). Taken together, iron and manganese indeed has a 
prominent role in the neuroinflammatory process mediated by reactive microglia and 
production of NO.   
Discussing further, the presence of nitrated proteins in the DMT1_Tg suggests the 
increase in nitrosative stress. Proteins commonly undergo S-nitrosylation and 
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nitration in the presence of excess NO. In particular, excess NO can mediate the 
spontaneous production of peroxynitrite (ONOO−) upon reacting with superoxide 
(·O2−). Even though peroxynitrite is not a free radical, it is a very strong biological 
oxidant capable of oxidizing proteins through the formation of nitrotyrosine residues 
(Tsang and Chung 2009). Indeed, nitrosative stress has been observed in 
neurodegenerative diseases such as PD and AD (Yao, Gu et al. 2004, Gu, Nakamura 
et al. 2005). In a recent in vitro model of ageing and AD, it was found that presenilin 
1 (PS1), a catalytic component of Ɣ-secretase was nitrated in primary neuronal 
culture which consequently shifted the ratio of Aβ load towards the Aβ42 pathogenic 
species (Guix, Wahle et al. 2012). This work indicated the relevance of ageing-
associated nitrosative stress in the pathogenesis of AD. In addition, S-nitrosylation 
has also been implicated in PD. Proteins susceptible to S-nitrosylation include XIAP, 
parkin, mitochondrial complex I (MitoC1) and peroxiredoxin-2 (Prx2). XIAP and 
parkin are E3 ubiquitin ligases while MitoC1 and Prx2 are important mediators in 
ROS formation. The S-nitrosylation of XIAP and parkin was shown to impair their 
ubiquitination function while S-nitrosylation of MitoC1 and Prx2 resulted in the 
increase in ROS. Indeed, the functional consequence of NO production in the 
DMT1_Tg model was also tested in our in vitro model of DMT1. In addition to the 
work by Cheah et al. on the role of S-nitrosylation on Dexras1 and the subsequent 
association with PAP7 and DMT1, we have shown the direct potential of NO in 
affecting DMT1 function via S-nitrosylation. Together, it is tempting to speculate that 
the selective regional iron deposition observed in neurodegenerative diseases is likely 
a consequence of uncontrolled NO production from neuroinflammatory processes. 
The NO-mediated increase in DMT1 activity would promote the entry of iron and 
hence leading to its accumulation. As there are brain regional differences in the 
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density and degree of microglial activation, these may likely be the contributing 
factors for region-specific neurodegeneration. In particular, the SN has been shown to 
have the highest microglial density, observed both in C57BL/6J mice as well as in 
human brains. In a LPS model of systemic inflammation (I.P.), the microglia in the 
SN of C57BL/6J mice showed the highest activation, suggesting that the SN is the 
most vulnerable region to neurotoxins (Yang, Lin et al. 2012). In another study of 
parkinsonism involving non-human primates, persistent microglial activation was 
observed in the SN after 1-year of MPTP exposure (Barcia, Sanchez Bahillo et al. 
2004). In addition, there is prominent microglia activation (Beach, Sue et al. 2007) 
and iron deposition (Zucca, Bellei et al. 2006) in the SN of normal human brains with 
aging, which may be closely related to the slow progressive (4.7% per decade) loss of 
dopaminergic neurons in the SN. Yet, in neurodegenerative diseases such as PD, 
aggravated microglia reactivity and significant iron deposition are observed in the SN 
with a more pronounced loss of dopaminergic neurons.  Perhaps, the vulnerability of 
the SN to degeneration may be explained by chronic inflammation mediated by 
increased density of activated microglia and prolonged effect of NO on DMT1, which 
facilitates the entry and increase in iron deposition, and subsequently neuronal cell 
death.  
Taken together, the findings in my thesis have shed light on the pathomechanism 
underlying cellular Mn2+ toxicity via DMT1 which involves iron imbalance. In 
addition, I also provided evidence of the role of microglial-derived NO in mediating 
iron entry via DMT1 which may underlie the mechanism behind iron accumulation in 
PD. These findings could be further validated for the proposal of iron-
supplementation on high risk manganese occupational exposures as a prophylaxis 





There are several gaps in knowledge that I wish to address in future works to clarify 
our understanding in the pathomechanism behind Mn2+ toxicity. While in part one of 
my thesis I have addressed the role of Mn2+ in affecting iron homeostasis using SH-
SY5Y cells, this study could be extended to primary cortical and TH neuronal 
cultures using our DMT1_Tg mice. This would allow us to better appreciate the effect 
of Mn2+ on a native cell culture system. In addition, a comprehensive cell death 
mechanism of Mn2+ toxicity could be performed on these cells overexpressing DMT1.  
These include the clarification of controversies between apoptosis and the possible 
involvement of necrosis and paraptosis mediated by Mn2+ toxicity, by employing the 
use of electron microscopy and specific proteins related to these cell death 
mechanisms.  In addition, a thorough understanding on how Mn2+ could affect other 
iron-regulatory proteins, such as transferrin receptor, ferroportin, and other 
neurodegenerative disease-associated proteins such as α-synuclein, parkin and the 
recently found ATP13A2, would help us refine our understanding on the mechanism 
of Mn2+ in mediating toxicity in the brain. Additionally, the investigation of 
overexposure of Mn2+ on PD-related proteins such as α-synuclein and parkin may 
unravel interesting mechanisms underlying metal exposures and risk of developing 
PD.  
In part two of my thesis, while the DMT1 transgenic model has been characterized 
with increased iron deposition in the brain, the accumulation of manganese has yet to 
be confirmed. Thus, we would be similarly investigating the deposition of manganese 
in the brain of the DMT1_Tg mice using T1-MRI (T1 hyperintensity) and PIXE. As a 




DMT1_Tg, biochemical as well as immunohistochemical analysis would be 
performed to determine the possible loss of TH neurons in both the SN and striatum. 
In addition, signs of microglial activation and its associated nitrosative stress would 
be investigated.  
To validate the findings I found in-vitro, we would validate the observations in the 
transgenic model by examining changes in iron-regulatory proteins and JNK 
phosphorylation in the manganese-supplemented DMT1_Tg mice. Once the 
characterizations of transgenic mice on individual metal diets have been investigated, 
the effect of iron supplementation on high manganese diet would be performed to 
determine the potential of iron supplementation to protect against manganese 
neurotoxicity. In particular, as a large human population are iron-deficient, iron 
deficiency has indeed been correlated with high manganese content in the brain. 
Finally, in part three of the thesis, we showed the direct S-nitrosylation of DMT1 in 
affecting its function. As I have systematically mutated the individual 12 cysteine 
residues to alanine, biotin-switch assay would be performed on the 12 clones 
transiently-overexpressed in SH-SY5Y cells to determine the cysteine residue(s) 
important for S-nitrosylation.  
This would provide an elegant mechanistic understanding into the effect of NO on 
DMT1. In addition, we would also co-transfect iNOS or nNOS clones (obtained from 
Professor Solomon Synder’s laboratory, Johns Hopkins University) with DMT1 to 
verify the effect of NO on DMT1 in a cell-based system. This would be done using 
patch-clamp electrophysiological method to detect either Fe2+ or Mn2+ ion entry via 
DMT1, a method well-established in our laboratory. Taken together, this future work 
will shed light on the role of DMT1 in mediating iron and manganese accumulation in 




understanding to health policy makers on the use of iron-supplementation on high-risk 
occupational exposure to manganese such as welders and workers in the shipbuilding 
industries. As manganese is also a heavy environmental pollutant found in the air and 
water, our study may also have implications for iron supplementation in populations 
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Effect of Dietary Manganese and Iron on Rotarod Performance of DMT1_Tg 
A.1 Overview 
The data presented in this short chapter is an extended preliminary result of an on-
going experiment to investigate the effect of manganese and iron-enriched diet on 
DMT1_Tg. The data was included in this thesis to extend the understanding of the 
role of DMT1 in mediating possible harmful effects of manganese in affecting motor 
performance of DMT1_Tg.  
A.2 Materials and Methods  
Dietary manipulation of 1000mg/kg carbonyl iron and 1000mg/kg carbonyl 
manganese on normal feed AIN93M as shown in Figure A1 (A), was started earlier at 
3 months of age as oppose to 9 months in the initial experiment presented in Chapter 
3, part two. Feeding was started earlier to reduce the likely death to mice due to aging. 
The weight of the mice were measured fortnightly as a gross determination of general 
health. Rotarod test was performed fortnightly on an accelerating protocol. Briefly, at 
every test, mice were first acclimatised to the procedure room for 30 min at the same 
time of the day. Mice were made to move on the rotating beam at 4 rpm for 30 sec. 
Once the mice were stable without any random falls, the test was started. Acceleration 
speed was ramped up from 4 to 40 rpm in 240 sec. Mice were given three trials with 
at least 15 min rest between trials. Results were analysed as latency to fall in seconds. 
Statistics were performed using Microsoft Office Excel Student’s t-test (two-tailed 
distribution) with two-sample unequal variance.    




A.3 Results and Discussion 
Weights of both non-Tg and DMT1_Tg mice on dietary manipulation up to 22 weeks 
did not show any significant change as compared to normal feed as shown in Figure 
A1 (B) and (C). While DMT1_Tg on iron supplementation showed a borderline 
decrease in body weight as compared to normal feed, however iron supplementation 
did not impair growth in the mice, Figure A1 (C).  
 
Figure A1. Dietary manipulation strategy and weight of mice. (A) DMT1_Tg and non-Tg were 
started on normal, iron or manganese-enriched diets 90 days post-weaning for 22 weeks and beyond. 
Weight and rotarod performance were determined fortnightly. Weight of mice (in grams) over 22 
weeks are shown in (B) non-Tg (WT), (C) DMT1_Tg (DMT1), with n: representing the number of 
mice per group. No significant weight change was observed in either non-Tg or DMT1_Tg with dietary 
manipulations.  
 
Even as dietary manipulation did not affect the weight of mice, we hypothesized that 




result in motor phenotype. Thus, we closely monitored the mice using a rotarod for 
every two weeks. Motor performance of DMT1_Tg on normal diet (n=9) was not 
significantly different from non-Tg (n=8). In addition, motor performance of 
DMT1_Tg (n=7) was also similar to non-Tg (n=7) both on iron diet. Interestingly, 
DMT1_Tg was shown to be vulnerable to manganese diet (n=8) showing significant 
(p<0.05) fall latencies at week 8, 16, 20 as compared to non-Tg. The overexpression 
of DMT1 likely explained the vulnerability of DMT1_Tg to manganese as compared 
to non-Tg. However, a more convincing conclusion could only be made if there was 
significant deterioration in motor performance of DMT1_Tg at every time point as 
compared to non-Tg. This is likely limited by the small sample size for behavioural 
study. In addition, we currently have no explanation to the oscillation-like trend in 
motor performance in the DMT1_Tg under manganese diet as shown in Figure 
A.2(C). We hypothesized that metal efflux transporters might be upregulated in 
response to manganese overload to reduce metal burden in the brain. One such 
transporter could be ferroportin, which was previously shown to be upregulated upon 
manganese exposure in cultured cells (Yin, Jiang et al. 2010). This is under 
investigation in our laboratory.  
Taken together, our interim finding presented in this chapter suggests the role of 
DMT1 in brain manganese transport on top of brain iron transport (Chapter 3, part 
two). Indeed, dietary manganese overload could lead to motor disturbances with brain 
DMT1 overexpression, which may suggest the versatility of this transgenic mouse as 






Figure A2. Rotarod performance of mice under (A) normal diet, (B) iron diet (C) manganese diet, 
determined every fortnightly for up to 22 weeks. n: represents number of mice, *, p<0.05 with error 
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